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Swept it for half a year, 
Do you suppose," the Walrus said, 
"That they could get it clear?" 
"I doubt it," said the Carpenter, 
And shed a bitter tear. 
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Symbols and abbreviations 
ADHl 
P-gal 
cAMP 
CAK 
Cdc 
Cdk 
Cdki 
cDNA 
CKS 
CLN 
CLB 
DMEM 
DTT 
EDTA 
EGF 
EGTA 
FBS 
Go 
G, 
G2 
GSK 
GST 
HA 
HBS 
Hepes 
IC50 
IL-2 
M 
MAP 
MOI 
alcohol dehydrogenase 
(J-galactosidase 
cyclic AMP 
Cdk-activating kinase 
cell division cycle gene 
cyclin-dependent kinase 
Cdk inhibitor protein 
complementary DNA 
cyclin-dependent kinase regulatory subunit 
yeast cyclin 
yeast cyclin B 
Dulbecco's Modified Eagle Medium 
dithiothreitol 
ethylene-diamine tetraacetic acid 
epidermal growth factor 
bis-(aminoethyl)-glycolether-N,N,N',N'-tetraaceticacid 
fetal bovine serum 
quiescent state cells enter the cell cycle 
first gap phase of the cell cycle 
second gap phase of the cell cycle 
glycogen synthase kinase 
gluthathione-S-transferase 
human hemaglutinin antigen 
Hepes buffered saline 
4-[2-hydroxyethyl]-l-piperazineethane sulphonic acid 
50% inhibitory concentration 
interleukin-2 
mitosis 
mitogen-activated protein 
multiplicity of infection 
NF 
NF-L, -M and -H 
NP-40 
p35 
PBS 
PCNA 
PHF 
PMSF 
p-NPP 
pol 8 
pRb 
R 
S 
TGF-p 
TPK 
Tris 
tRNA 
wt 
X-gal 
neurofilament 
NF of low, medium and high molecular mass respectively 
Nonidet P-40 
35 kDa protein which activates Cdk5 
phosphate buffered saline 
proliferating cell nuclear antigen 
paired helical filaments 
phenylmethanesulfonylfluoride 
4-nitrophenyl phosphate disodium salt 
DNA polymerase 8 
retinoblastoma protein 
restriction point 
synthesis 
transforming growth factor p 
tau protein kinase 
2-amino-2-hydroxymethylpropane-1,3-diol 
transfer RNA 
wildtype 
5-bromo-4-chloro-3-indolyl-P-D-galactopyranoside 
1. General introduction 
1.1 The Cell Cycle 
Completion of the cell cycle requires coordination of a variety of macromolecular 
syntheses, assemblies, and movements. The chromosomes must be replicated, 
condensed, segregated, and decondensed. The spindle poles must duplicate, separate, 
and migrate to opposite ends of the nucleus. In metazoans, the nuclear membrane is 
disassembled and reassembled, the spindle is assembled and disassembled, and the cell 
membranes invaginate to complete cytokinesis. Coordination of these complex 
processes is thought to be achieved by a series of changes (phase transitions) in the cell 
cycle (1,2). 
Cdk4 
Cdk6 
Cdkl-cyclin A 
yclin B 
Figure 1. The Cell Cycle in higher eukaryotes 
G,: first gap, S: DNA replication phase, G2: second gap, M: mitosis, G0: quiescent 
state, R: restriction point, RB: retinoblastoma protein. Horizontal lines illustrate G,/S 
and G2/M phase transitions. Filled-in arrows indicate kinases active at phase 
transitions. 
The cell cycle, divided into phases designated G, (first gap), S (synthesis), G2 (second 
gap) and M (mitosis), is regulated at two major decision points: prior to the G,/S 
transition (designated "START" in yeast and "restriction point" (R) in mammalian 
cells) and the G2/M transition (3). G0 is described as the quiescent state of the cells. In 
this phase cells are in a dormant state (Fig. 1). In multicellular eukaryotes, the cell 
cycle is driven by the complex interplay of regulatory cyclin proteins-cyclins A, B, C, 
D, E and H-with protein serine/threonine kinases, designated Cdc (cell division cycle 
gene) 2, and Cdk (cyclin-dependent kinase) 2,3,4,5,6,7 and 8 (Table 1). Cdc2 is also 
known as Cdkl. In unicellular eukaryotes such as budding (Saccharomyces cerevisiae) 
and fission (Schizosaccharomyces pombe) yeast, a single protein kinase (CDC28 or 
cdc2+, respectively) fulfills the function of the family of proteins found in multicellular 
organisms. At distinct stages of the cell cycle different yeast cyclins activate the 
protein kinase: CLN1, 2 and 3 at START, CLB5 and 6 in S phase and CLB1 and 2 at 
mitosis (the roles of CLB3 and 4 are less well defined) (4-8). 
Table 1. Cdk-s and their cyclin partners 
Cdk 
Cdkl 
Cdk2 
Cdk3 
Cdk4 
Cdk5 
Cdk6 
Cdk7 
Cdk8 
cyclin 
cyclin A,B 
cyclin A,E 
unknown 
cyclin D 
cyclin D,E 
cyclin D 
cyclin H 
cyclin C 
The cell cycle stage is determined by the constellation of proteins activated or 
inactivated by phosphorylation as a result of the activity of the Cdk-s during that stage. 
The passage of cells from one stage of the cell cycle to another is tightly regulated by a 
wealth of controls that act on the transcription of cyclin genes, the degradation of 
cyclin proteins, and the modification of the kinase subunits by phosphorylation. A 
number of positive and negative feedback loops also contribute to cell cycle 
progression (1). 
1.2 Cdk activity regulation 
Figure 2. Principles of Cdk regulation (6) 
At center right lies the active Thrl60/161-phosphorylated Cdk-cyclin complex. 
Moving outward along any of the four pathways results in inactivation; moving inward 
leads to activation. This is a highly simplified scheme from which many pathways and 
alternative states have been omitted. 
Presumably, the larger number of Cdk-s in higher eukaryotes reflects the increased 
regulatory capacity required to execute the complex instructions of development. 
These Cdk-s are closely related in size (~33 kDa) and sequence (> 40% identity). 
Specific cyclins, with their Cdk partners, have been shown to promote the 
advancement of different phases of the cell cycle (4,9). Thus, G, active cyclins A, C, 
Dl, D2, D3, and E have been shown to mediate the progression through G,/S (10-13), 
while G2 cyclins A, Bl, B2 and B3 usher the cell through G2/M (14). Cellular Cdk 
levels tend to remain in constant excess throughout the normal cell cycle, and 
regulation of catalytic activity is primarily post-translational. The activity of the Cdk 
enzymes is controlled both by their association with cyclins and by phosphorylation of 
a threonine residue (Thrl61 in Cdkl and Thrl60 in Cdk2) of the Cdk polypeptide 
itself which obscures the substrate-binding site in its inactivated state. Cdk-s and their 
regulators are found in specific locations, but little is known about the mechanisms 
responsible or whether localization is regulated. One of the enduring mysteries of Cdk 
regulation is the role of the S. pombe protein, pl3sucl, and its homologues, the CKS 
proteins, in S. cerevisiae and vertebrates. These small proteins, which are essential for 
cell-cycle progress in yeast, have long been known to bind tightly to certain Cdk-s in 
vivo. They do not, however, have any distinct effect on Cdk function in vitro. The 
crystal structure of one family member, CksHs2, suggests that these proteins may be 
involved in Cdk oligomerization in the cell. Figure 2 shows the principles of Cdk 
regulation (4,6-8). 
1.2.1 Cyclins 
The cyclins possess a short life span. The persistence of the gene expression or 
stability of the protein may determine the length of the cell cycle phase in which the 
cyclin is expressed. Constant synthesis during the cell cycle results in a roughly linear 
increase in cyclin concentration, until at mitosis cyclin degradation abruptly increases, 
producing a rapid decline in cyclin levels. Mitotic cyclin degradation involves the 
ubiquitin-dependent proteolytic machinery, and requires a small sequence motif (the 
destruction box) near the amino terminus of mitotic cyclins. The trigger for destruction 
may be the increased Cdkl activity at mitosis and the activation of components of the 
ubiquitin system by Cdkl. In S. cerevisiae activation of CDC28 by the G, cyclins 
(CLN-s) leads to activation of CLN1 and CLN2 transcription in a positive feedback 
loop. Activation of CDC28 by CLNs also inactivates the machinery responsible for the 
degradation of the CLB mitotic cyclins, allowing CLB levels to rise after G,. CLB 
proteins then help to repress CLN transcription, while at the same time stimulating 
their own transcription in another positive feedback loop. The resulting increase in 
CLB levels leads to mitotic activation of CDC28, which then triggers CLB 
destruction. Cyclins are thought to contain regions that target the Cdk to specific 
substrates or subcellular locations. In addition to simply activating the associated Cdk, 
they can thus promote activity toward specific substrates. The enhanced activity of 
certain complexes is probably due to positive interactions between the cyclin and the 
substrate (6-9). 
1.2.2 CAK 
The activation of Cdk-s via phosphorylation of Thrl60/161 is mediated by an enzyme 
complex termed Cdk-activating kinase (CAK), which itself is composed of a Cdk 
(termed variously MO 15 or Cdk7), a cyclin (cyclin H) and a RING finger protein 
subunit MAT1 (15-20). This Cdk activation is reversed by a specific phosphatase (21). 
Since Cdk7 is also dependent upon an activating phosphorylation event (Thrl70 in 
human Cdk7) by yet another kinase, this suggests the possibility of positive control by 
an extended kinase cascade, a notion that at present lacks direct experimental support. 
During the normal vertebrate cell cycle, phosphorylation of Thrl60/161 tends to rise 
and fall in parallel with cyclin binding. Changes in phosphorylation are probably not 
due to changes in CAK activity, which does not change during the cell cycle, but 
appear to reflect the ability of cyclin binding to stimulate Cdk phosphorylation (4,6-8). 
1.2.3 Weel, Mytl and Cdc25 
Negative regulation of Cdk activity occurs via inhibitory phosphorylation of Tyrl5 
and Thrl4 close to the ATP-binding region through Weel (22,23) and the dual-
specificity kinase Mytl (24) respectively. This inhibition is part of a negative-feedback 
pathway that prevents cells from entering mitosis with damaged or incompletely 
replicated DNA. Cdkl-cyclin B complexes are maintained in an inactive state, until 
Thrl4-Tyrl5 dephosphorylation at the end of G2 activates Cdkl. This abrupt 
dephosphorylation is brought about by coordinated changes in the activities of kinases 
and phosphatases acting at these sites. Weel activity declines during mitosis, 
contributing to the fall in inhibitory phosphorylation at this stage. Decreased kinetic 
activity during mitosis is due to phosphorylation of Weel. In S. pombe, the protein 
kinase Niml inhibits Weel by phosphorylating its C-terminal catalytic domain. Thrl4 
and Tyrl5 are both dephosphorylated by the dual-specificity phosphatase termed 
Cdc25 (25-28). Cdc25 activity increases during mitosis, largely because of increased 
phosphorylation in its N-terminal half. During mitosis, the kinase responsible for this 
phosphorylation is activated and the corresponding phosphatase is inhibited. The 
Cdc25-stimulatory kinase is Cdkl itself, forming the basis of an elegant positive-
feedback system that induces the abrupt mitotic dephosphorylation of Cdkl. Positive 
feedback is also achieved by coordinated effects on other components: Cdkl 
phosphorylates and inactivates Weel and may inhibit the phosphatase(s) that 
inactivates Cdc25 and activates Weel (4-8). 
1.2.4 Cdk inhibitors 
Different Cdk inhibitor proteins (Cdki) could form barriers at different control points 
in the cell cycle, for example G, and G2 phases. Thus as cyclins are synthesized, they 
will bind a Cdk partner and a Cdki, such that the cyclin-Cdk complexes will remain 
inactive until the amount of cyclin-Cdk complex exceeds the amount of Cdki. At this 
point there will be insufficient Cdki to bind all the complexes, leaving active cyclin-
Cdk-s to promote the next phase of the cell cycle (7,29). 
Negative growth signals mobilize Cdki-s that associate either with a Cdk or with a 
cyclin-Cdk complex and block their function. The universality of negative cell cycle 
control via Cdk inhibitors is indicated by the identification of inhibitors in budding 
and fission yeast, as well as in mammalian cells (4,8,29,30). 
One of the inhibitors known to be expressed in yeast is FAR1, found in S. cerevisiae, 
which inhibits CLN-CDC28 activity and blocks the cell cycle in G, in response to the 
pheromone cc-factor. The pheromone-response pathway stimulates a mitogen-activated 
protein (MAP) kinase cascade that then activates a transcription factor, Stel2, to 
induce transcription of several genes such as the FAR1 gene. After expression FAR1 is 
rapidly phosphorylated by the MAP kinase FUS3. The antimitogen oc-factor thus 
appears to amplify FAR1 activity by two mechanisms, one transcriptional and the 
other posttranslational. SIC1 (p40) which is found in the same organism regulates 
entry into S phase by inhibiting CLB5.6-CDC28 kinase activity. Synthesis of FAR1 
and SIC1 is under cell cycle control such that their levels peak in Gl. This pattern 
results from transcriptional activation in a periodic manner and specific degradation 
after the Gl/S transition. The temporal appearance ensures that these Cdki-s will 
inhibit only the kinases that are present during this time period. The Cdki-s are 
degraded by the ubiquitin-dependent proteolysis machinery. Studies indicate that SIC1 
reduces both the V ^ and the K^ of CDC28 for protein substrate. The inhibitor ruml+ 
is expressed in S. pombe and has the same function as SIC1 by inhibiting cdcl3-cdc2 
(31,32). Cdk-s are now known to participate in more than just cell cycle regulation. 
The Cdk PHO85-PHO80 expressed in S. cerevisiae regulates transcription of the acid 
phosphatase gene PH05. Genetic analysis identified the PH081 gene, coding for a 
protein with homology to pi6™", which functions upstream of PHO85-PHO80. 
PH081 has recently been shown to inhibit PHO85-PHO80 activity in vitro by 
functioning as a Cdki (4,8,29,30). 
In higher eukaryotes the CIP/KIP inhibitor family (p21CIP1/WAF1, p27ia?1, pS?™2) (33-
38) are known to inhibit all Cdk-s by binding to the cyclin-Cdk complex whereas the 
INK4 inhibitor family (pM1*46, plS1™48, pie™4*, pl8™*c, p l ^ 4 0 ) (39,40) 
specifically inhibit Cdk4 and Cdk6 by competitively preventing binding of cyclin D to 
the Cdk. Cdki-s are phosphorylated by their Cdk target suggesting an interaction with 
the protein substrate binding site. The stoichiometry of Cdki-Cdk binding is unclear 
(4,6,8,29,30,41-43). 
1.2.4.1
 P 2 1 C I P , / W A F 1 
Radiation and other DNA-damaging agents block pRb phosphorylation through use of 
the Cdki named p2icn>1/WAF1. Steady-state levels of p53 increase rapidly upon DNA 
damage. p53 is a transcription factor that is involved in at least three functions: cell 
cycle arrest in G, in response to DNA damage; transcriptional activation of genes 
responding to DNA damage; and regulation of 'programmed cell death', apoptosis. 
p53 activates expression of p21CIP1/WAF', GADD45 and MDM2. Once DNA lesions are 
erased, the pRb-imposed block may be lifted and the cell permitted to advance into S 
and replicate its now-restored genome. Alternatively, in the face of irreparable lesions, 
the cell may choose to commit itself to an apoptotic death. Normal diploid fibroblasts 
differ from transformed cells in that many Cdk-cyclin complexes contain proliferating 
cell nuclear antigen (PCNA) in addition to p21CIP1/WAF1. PCNA plays a positive role in 
cell proliferation in that it is required for processive DNA replication carried out by 
DNA polymerase 8 (pol 8).
 p21cnM/WAF1 inhibits PCNA function by directly binding to 
the protein. Although not yet verified in vivo, these data suggest that p21clP1/WAF1 plays 
a dual role in the DNA-damage checkpoint by both arresting the cell cycle through 
inhibition of Cdk-s and blocking DNA replication. Levels of mRNA encoding 
p2 jCipi/wAFi ^ gg io-20-fold when cells become senescent, and also rise as cells become 
quiescent (4,8,29,30). Normal human fibroblasts do not express telomerase, the 
enzyme that replicates the repeated sequences at the ends of chromosomes; thus, 
telomere length decreases as cells proliferate. It has been suggested that chromosome 
ends with shortened telomeres may activate a checkpoint pathway that inhibits cell 
proliferation and that senescence occurs as a result of the loss of telomeric sequences. 
One gene thought to be necessary for the arrest of proliferation in senescent cells is 
P21CIP./WAFI
 (1) A s s o c i a t i o n 0f p21cn>"WAF1 with Cdk-s is greatly enhanced by cyclin 
binding. This property is shared by the structurally related inhibitor p27iapl, suggesting 
a common biochemical mechanism for inhibition. With respect to Cdk2 and Cdk4 
complexes, p27KIP1 shares the inhibitory potency of
 p21CIP1/WAF1 but has slightly 
different kinase specificities. In normal diploid fibroblasts, the vast majority of active 
Cdk2 is associated with p2lCIP1/WAF1; but this active kinase can be fully inhibited by 
addition of exogenous p21CIP'/WAF1. Reconstruction experiments using purified 
components indicate that multiple molecules of p21CIPI/WAFI can associate with 
Cdk/cyclin complexes and inactive complexes contain more than one molecule 
P21CIPIAVAFI
 T o g e t h e r ) t h e s e d a t a suggest a model whereby p21c,pl/WAF1 functions as an 
inhibitory buffer whose levels determine the threshold kinase activity required for cell 
cycle progression (34). 
1.2.4.2
 P27K1P' 
At least three molecular mechanisms have been proposed to explain the ability of the 
extracellular signal protein, transforming growth factor (TGF)-P, to obstruct pRb 
phosphorylation. The first of these involves p27iapi, a Cdki that interacts with Cdk2, 
Cdk4 and Cdk6 and prevents their functional activation at the hands of CAK. The total 
amount of p27KIP1, however, is unaffected by TGF-p treatment or during the cell cycle. 
Rather, p27K1PI appears to be sequestered in a heat-labile compartment, from which it is 
released upon TGF-p treatment. Contact inhibition and cAMP also act through their 
ability to mobilize p27KIP1 (37). TGF-p also acts via p53 to dramatically reduce the 
translational level of Cdk4 (44-46) leading to a reduction in Cdk4-cyclin D complexes 
that harbor the majority of p27KIP1 in cycling cells and potentially freeing p27KU>1 to 
inhibit other Cdk-s (e.g. Cdk2; 44,45,47). Alterations in the balance of active Cdk-
cyclin complexes through redistribution of inhibitors may be a common theme in 
cellular growth control. p27iapi is inactivated by the mitogen interleukin-2 (IL-2) 
(4,8,29,30). Cyclin A mRNA induction by Myc in fibroblasts is inhibited by 
P2JCIPIAVAFI
 an^ p27KIP' whereas Myc-induced apoptosis is insensitive to these Cdk 
inhibitors (48). 
1.2.4.3 pl5,NK4B and pl6,NK4A 
An alternative mechanism is suggested by the recent discovery that TGF-P can induce 
expression of plS™48 (49), another Cdki. plS^43 targets Cdk4/Cdk6, competing with 
10 
D cyclins for binding to Cdk4/Cdk6. In normal cells, Cdk4 is associated with a D-type 
cyclin, PCNA and p2lCIPl/WAF1. In some transformed cells, however, Cdk4 is found 
associated with•pl6mK4A and these complexes lack a cyclin and PCNA. Binding of 
p16iNK4A t Q C d k 4 b l o c k s a n d disrupts cyclin D association (4,8,30,50,51). 
1.3 Structure of the Cdk-cyclin complex 
Cyclin dependent kinases are a member of the highly conserved protein-
serine/threonine kinase family (52). The typical Cdk catalytic subunit contains a 300 
amino acid catalytic core that is completely inactive when monomeric and 
unphosphorylated. The crystal structure of the human Cdk2 apoenzyme shows that it is 
held in an inactive state by at least two major structural restraints: first, the substrate 
binding site is blocked by an extended loop termed the T-loop; and second, side chains 
in the ATP-binding site are oriented so that the ATP phosphates are poorly positioned 
for efficient phospho-transfer (53). Cyclin A binds to one side of Cdk2's catalytic 
cleft, inducing large conformational changes in its PSTAIRE helix and T-loop. These 
changes activate the kinase by realigning active site residues and relieving the steric 
blockade at the entrance of the catalytic cleft (54, 55). Homology among cyclins is 
often limited to a relatively conserved domain of about 100 amino acids, the cyclin 
box, which is responsible for Cdk binding and activation. In Cdk2, Thrl60 lies in the 
T loop; its side chain is inaccessible to solvent. Upon phosphorylation the T-loop 
moves by as much as 7 A, and this affects the putative substrate binding site as well as 
resulting in additional cyclin contacts (56). Phosphorylation thus affects the cyclin 
binding site and it enhances the binding of some Cdk-cyclin pairs; conversely, cyclin 
binding may enhance phosphorylation. In Cdk2, the side chains of the Thrl4 and 
Tyrl5 residues hang from the ceiling of the ATP-binding site and are certainly in a 
position to affect kinase activity when phosphorylated. The mechanism of inhibition is 
unknown, but phosphorylation of Tyrl5 does not appear to inhibit ATP binding. Both 
residues are buried beneath the T loop and are inaccessible to solvent, suggesting that 
the T loop must be moved to allow phosphorylation. This may be accomplished by 
cyclin binding, as phosphorylation is thought to be cyclin-dependent (6). 
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1.4 Substrate specificity of cyclin-dependent kinases 
Cyclin-dependent kinases are specifically phosphorylating serine/threonine residues 
preceding a proline residue. Such a substrate determinant has been found in other 
protein kinases and was termed proline-directed phosphorylation specificity. The Cdk 
phosphorylation site consensus sequence as deduced from substrate sequences is: -X-
S/T-P-X-K/R-X- (57). In addition to the carboxyl-terminal proline, a basic amino 
acid, lysine or arginine, at the third position carboxyl-terminal to the phosphorylation 
target residue also appears to be an important substrate determinant. The proto-
oncogene c-Src was among the earliest indentified Cdk substrates (58). 
1.5 G,/S transition 
1.5.1 The Rb protein 
pRb, the product of the retinoblastoma tumour suppressor gene, operates at the 
restriction point (R) of the cell cycle. Its main role is to act as a signal transducer 
connecting the cell cycle with the transcriptional machinery (59). The protein becomes 
hyperphosphorylated during the G, phase and maintains this configuration until the 
emergence from M. As cells enter anaphase, pRb dephosphorylation begins and 
continues, stepwise, until G, when pRb is once again hypophosphorylated. G, cyclins, 
serving as regulatory subunits of their partner Cdk-s, direct these enzymes to the pRb 
substrate, resulting in its phosphorylation. Cyclins of the D class (Dl, D2 and D3) are 
most prominently implicated in the phosphorylation of pRb early in G, (60-63). These 
cyclins serve as activators of the Cdk4 and Cdk6 kinases. At the end of G, Cdk2 which 
complexes with cyclin E and cyclin A phosphorylates pRb at different sites driving the 
cell into the S phase. Without functional pRb, certain cell types are susceptible to 
apoptosis. This apoptosis depends upon the p53 protein. In this way pRb plays an 
important role in the decision whether a cell should proliferate, differentiate (64), 
undergo senescence or even apoptosis. Finally, in addition to a major role in the G,/S 
transition, pRb may act at other stages in the cell cycle. For example, it has been 
shown that overexpression of pRb during S phase of the cell cycle may result in G2 
arrest (8,30). 
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1.5.2 The E2F transcription factor 
When pRb is hypophosphorylated, it is bound to the E2F transcription factor. The term 
E2F subsumes a group of at least five distinct, closely related transcription factors that 
are all targeted to variations of the consensus nucleotide sequence TTTCGCGC. E2F-1 
(65,66), E2F-2 (66,67) and E2F-3 (66) are under the direct control of pRb. E2F-4 and 
E2F-5 are under the control of pi07 which is a pRb family member (68). 
Phosphorylation of pRb causes it to lose its grip on E2F, enabling the latter to proceed 
with the activation of a cohort of genes whose transcription it controls. The genes 
which are under the control of E2F include c-myc, B-myb, cyclin E, cyclin A, Cdkl, 
dihydrofolate reductase, thymidylate synthetase, ribonucleotide reductase, thymidine 
kinase and the E2F-1 gene itself. Activation of these genes drives the cell into the S 
phase where DNA replication takes place. pRb binds to other proteins as well, such as 
Elf-1, MyoD, PU.l, ATF-2, and c-Abl proteins. Most intriguing of these is the nuclear 
tyrosine kinase encoded by the cellular abl proto-oncogene. Hypophosphorylated pRb 
is reported to bind directly to the active catalytic domain of the c-Abl kinase blocking 
its function. As expected, hyperphosphorylated pRb loses this binding ability. By 
binding multiple effectors such as E2Fs and Abl, pRb may be able to modulate 
simultaneously the activity of a number of downstream growth-controlling pathways. 
Physiological signals that favour cell proliferation should encourage pRb 
phosphorylation. Most of these signals originate with mitogens that impinge on cell 
surface receptors and in turn activate cytoplasmic signal transduction pathways that 
convey growth stimulatory signals to the nucleus (1,8). Despite an inability to bind to 
E2F, pRb mutants associated with a low risk of retinoblastoma, unlike high-risk 
mutants, retained the ability to activate transcription and promote differentiation. Thus, 
the pRb pocket participates in dual tumour suppressor functions, one linked to cell 
cycle progression and the other to differentiation control, and these functions can be 
genetically and mechanistically dissociated (69). 
1.6 G;/M transition 
The G2/M transition is prevented by DNA damage and by incompletely replicated 
DNA. This checkpoint prevents chromosome segregation if the chromosome is not 
intact. Genetic studies in S. cerevisiae and S. pombe have identified a number of genes 
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necessary for this control. In S. cerevisiae, the RAD9, RAD 17, RAD24, MEC1, MEC2, 
and MEC3 genes prevent mitosis in the presence of DNA damage or if replication is 
blocked in late S phase. The MEC1 and MEC2 genes also prevent mitosis if replication 
is blocked in the early S phase. One double-strand break in the DNA will activate this 
checkpoint and prevent the cell from undergoing mitosis. Some of the S. cerevisiae 
genes show sequence homology to the S. pombe genes, which indicates that this 
pathway evolved early and is likely to be present in human cells as well. Few gene 
products that control the G2/M transition have been identified in mammalian cells. S. 
cerevisiae encodes at least six genes that prevent the cell from initiating a new cell 
cycle in the presence of microtubule poisons: MAD1, MAD2, MAD3, BUB1, BUB2, 
and5Lft3(l). 
1.7 Tumours 
Perhaps the single most defining feature of cancer cells is uncontrolled growth. 
Tumours expand and invade with impunity, ignoring the mechanisms that maintain the 
integrity of normal tissue. They take over the body like a parasite, proliferating until 
life is sapped from the host. Cells from many advanced cancers traverse the cell cycle 
at breakneck speed. Furthermore, cells that would normally arrest their growth in 
response to specific environmental cues (such as contact with neighboring cells) 
disregard these stimuli when transformed into the cancerous state. To prevent loss of 
growth control, multiple pathways are probably involved. Some of these pathways 
may be quite general, functioning in many tissues, while others may be much more 
specific, operating in only few cell types. The increased evidence of cancer as a 
function of age has long been interpreted to suggest that multiple genetic changes are 
required for tumourigenesis, an interpretation borne out by recent systematic analysis 
of genetic changes during the evolution of colon cancer cells (1). 
As cancer is a disease characterized by loss of cellular growth control, it is not 
surprising that the molecular machinery of the cell cycle is involved in tumourigenesis. 
In addition, surveillance of telomeric sequences as they are lost during senescence may 
be important in signalling somatic cells to stop proliferation. Senescing cells exhibit an 
increased number of chromosomal aberrations, many of which appear to involve 
telomere-telomere associations. Thus, the normal senescent program may generate 
14 
chromosome instability (1). Recent discoveries have brought several cell-cycle 
regulators into sharp focus as factors in human cancer. Among the most conspicuous 
types of molecules to emerge from ongoing studies in this field are the cyclin-
dependent kinase inhibitors such as pl6INK4A. These molecules have several hallmarks 
of tumour suppressors and are perfectly positioned to regulate critical decisions in cell 
growth. Thepl6mK4A gene appears to be a particularly significant target for mutation in 
sporadic tumours and in at least one form of hereditary cancer (51,70). As many as 
70% of tumour cell lines and primary tumours from various tumour types and familial 
melanomas contain homozygous deletions or point mutations of the pl6INK4A (pi 6, 
MTS1 or CDKN2) locus. plS1™"8 may be deleted or present in a mutant form in 
carcinomas. The majority of homozygous deletions that remove pie"^4* in tumour 
cell lines also remove plS"*48. It is unclear whether inactivation of plS"""8 in tumour 
cell lines is causal or merely a bystander effect of its proximity to pl6mK4A 
(4,6,8,29,70). Many human tumour cell genomes have been found to have lost pRb 
function through chromosomal gene mutation (71). In other tumours the cyclin D gene 
(72-74) and/or the Cdk4 gene (75,76) is amplified. Abnormal expression of cyclins A, 
B and E and Cdkl have been reported (1,77). The fact that p53 is one of the most 
commonly mutated genes in human cancer points to the potential importance of 
p21cipi/wAFi i n n e g a t ; v e g rowth control (1,4,6,8,29,78-80). Alterations in expression of 
the p53 binding protein MDM2 can result in adaptation of the G,/S checkpoint (75,76). 
MDM2 is an endogenous inhibitor of p53 function (81,82). The c-mos proto-oncogene, 
a regulator of meiotic metaphase, produces polyploidy when it is expressed 
abnormally in mitotic cells, as it is during tumourigenesis (1). 
The frequent deregulation of Cdk proteins and their regulators in cancer and the 
therapeutic potential of natural inhibitors has stimulated an active search for chemical 
Cdk inhibitors (83). Seven chemical inhibitors which are specifically inhibiting Cdk-s 
have been described so far: butyrolactone (84), flavopiridol, 9-hydroxy-ellipticine, 
olomoucine (85,86), roscovitine, staurosporine (87,88) and suramin (5,89,90). The 
IC50 values (50% inhibitory concentration) of these inhibitors with respect to the 
different Cdk-s are shown in Table 2. Figure 3 shows the structure of flavopiridol and 
staurosporine which both have been used in the experiments depicted in this thesis. 
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Table 2. Specificity of known chemical Cdk inhibitors towards different Cdk-s* 
Inhibitor 
butyrolactone 
fiavopiridol 
9-hydroxy-ellipticine 
olomoucine 
roscovitine 
staurosporine 
suramin 
Cdkl 
0.60 
0.40 
1 
7 
0.65 
0.003-0.009 
4 
Cdk2 
1.50 
0.40 
ND 
7 
0.70 
0.007 
ND 
Cdk4 
no effect 
0.40 
ND 
>1,000 
>100 
0.020 
ND 
CdkS 
ND 
ND 
ND 
3-8 
0.20 
0.039 
ND 
*IC50 values (|xM) of inhibitors tested against the specific Cdk-s; ND, not determined. 
Fiavopiridol Staurosporine 
Figure 3. Molecular structure of fiavopiridol and staurosporine 
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1.8 Cdk5 and its role in differentiation 
It has become clear that not all cyclins and Cdk-s function in cell cycle control. 
Examples of cyclins and Cdk-s that function in non-cell cycle regulating events are 
mounting; for instance, Cdk7-cyclin H and Cdk8-cyclin C in the TFIIH subunit of the 
RNA polymerase II holoenzyme have possible roles in phosporylating the C-terminal 
domain of RNA polymerase II (19,91,92). In the next paragraphs the role of Cdk5 will 
be discussed. Cdk5 has been found to play a role in differentiation of nerve and muscle 
cells. Malignant function of Cdk5 may lead to Alzheimer's or Lewy body diseases. 
1.8.1 Neuronal development 
The differentiation of a nerve cell is a process that begins early in embryonic 
development and continues through subsequent cell divisions, migrations, and 
maturations. It culminates in the acquisition of the form and function that define each 
specific adult cell type. Neurons are an exceptional class of cells that both attain 
mature morphology only after cessation of mitotic activity and persist in the fully 
differentiated state for the lifetime of the organism. The cell cycle arrest is one of the 
earliest events in the neuronal maturation process, although the expression of pattern 
formation genes as well as certain differentiation markers can precede it. The 
molecular events that accomplish this seemingly irreversible transition into the 
postmitotic state and formation of neuronal morphology are as yet largely unknown 
(9,30). 
It has been observed that the duration of the cell cycle in the developing nervous 
system progressively lengthens during differentiation. This has been attributed to, 
predominantly, increases in the length of G, (9). In differentiating cells in general it has 
been shown that pRb protein levels increase whereas Cdk4 and cyclin D levels drop. 
pjgiNK4c ^ ^ pj<jiNK4D j^yg b e e n reported to be expressed during mouse brain 
development (93). Stopping cells in mid-to-late G, appears to be a prerequisite to their 
subsequent egress from the cell cycle into a more differentiated state (8). Several cell 
cycle regulators, including tumour suppressor protein pRb (30,64,94), transcription 
factor E2F-1 (95), c-Src (96), cyclins Dl (97,98), D2 (9) and E (99), cyclin dependent 
kinase Cdk5 and p35 (100-102), have been reported to be expressed in immature 
postmitotic and adult neurons whereas the expression of Cdkl, Cdk2, cyclins A and B 
is dramatically downregulated upon terminal differentiation of neurons in vivo (101-
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103). p53 mRNA expression is also downregulated but to a lesser extend (103). In pRb 
deficient mutants expression patterns of certain neurotrophin receptors are low 
compared to the wildtype. Neurotrophins form a family of closely related proteins that 
play important roles in the development and maintenance of the nervous system. This 
provides support for the possibility that certain cell cycle proteins may well be 
involved at this critical juncture between proliferation and acquisition of mature 
morphology in the differentiation of specific neurons within the central nervous 
system (30,104). 
1.8.2 CdkS 
Cdk5 was identified as a Cdk-related protein PSSALRE and shows about 60% amino 
acid sequence identity to both Cdkl and Cdk2 (105). Tyrl5 and Thrl4 are conserved 
in Cdk5 and the amino acid residue of Cdk5 corresponding to Thrl61 of Cdkl is 
conservatively substituted by a serine residue (Serl59) (Fig. 4; 106). Both human and 
mouse cdk5 genes have been localized on chromosome 5 at 7q36 and the centromeric 
region, respectively (107,108). While the location, 12ql3, for human cdk2 and cdk4 
genes is known to be associated with chromosome alteration in solid tumours, the 
location for human cdk5 gene, 7q36, is not a major site of chromosome alteration in 
tumours (107). The cdk5 gene, unlike cdkl, cdk2 and cdk3 genes, is incapable of 
complementing CDC28 mutants of S. cerevisiae. While Cdkl and Cdk2 undergo high 
affinity association with the protein product of the sucl gene, Cdk5 shows no specific 
interaction with pl3sucl (109). Instead, Cdk5 has been found to interact with an 
analogous protein of 15 kDa from starfish, pl5cdkBP, which also binds to Cdk4 (110). 
Cdk5 is the first example of a cyclin dependent kinase with neuronal function. Cdk5 is 
found to be expressed relatively equally in all human tissues with the exception of the 
central nervous system and peripheral nervous system, in which expression is several-
fold greater in both nucleus and cytoplasm (100,102,109,111-114). During maturation 
of neurons the expression of Cdk5 increases and reaches highest levels in adult 
cerebral cortex and spinal cord (99,101,115). p35 which is expressed exclusively in the 
central nervous system is the only activator of Cdk5 known thusfar (113,116-118). 
This protein has first been isolated as a smaller proteolytic product p25 (113,118-120). 
Several truncated forms of p35, including p25 and two further truncated forms p23 and 
18 
p21, were expressed as GST-fusion proteins in Escherichia coli and found to activate 
bacterially expressed Cdk5 (121). 
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>Serl59-P 
Active I * 
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Other functions Cytoskeletal dynamics Other functions 
Figure 4. Regulation and function of Cdkl-cyclin B in the cell cycle of higher 
eukaryotes and Cdk5-p35 in neurons (106). 
The active form of Cdk5 is a heterodimer, consisting of a catalytic subunit 
corresponding to Cdk5 and a neuron-specific regulatory protein, p35. In vitro, p35 
alone can activate Cdk5, resulting in full kinase activity. However, it is unclear 
whether or not Cdk5-p35 regulation in vivo involves phosphorylation. As with Cdkl-
cyclin B, one possibility may involve the phosphorylation of Cdk5 at Serl59 and the 
subsequent phosphorylation of Thrl4 and Tyrl5, by putative CAK- and Weel-related 
kinases, respectively, followed by the subsequent dephosphorylation of Thrl4 and 
Tyrl5 by a cdc25-related phosphatase. Alternatively, activation may involve only 
Serl59 phosphorylation. Functionally, both Cdkl-cyclin B and Cdk5-p35 appear to 
phosphorylate cytoskeletal proteins and may ultimately function to control cytoskeletal 
dynamics. Broken arrows indicate putative pathways. 
p35 has no significant homology to cyclins, with only eight out of a hundred identical 
residues in the central conserved cyclin box, and failing to match four out of five 
residues highly conserved among cyclins. Only the sequence of 17 residues (residues 
222 to 238) LQAVLLTCLYLSYSYSYMG shows any similarity to the equivalent 
region of the cyclin box consensus sequence, or to other distantly related cyclin-like 
proteins (113). There is evidence however of the existence of a cyclin fold in this 
neuronal Cdk5 activator (122). p35 is a highly specific regulatory partner for Cdk5 and 
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does not activate any other Cdk. It can directly activate bacterially expressed Cdk5 in 
the absence of phosphorylation by other protein kinases, despite the fact that the 
surrounding sequences of Ser-159 in Cdk5 (the Thrl 61 -equivalent residue) are similar 
to other Cdk-s. Moreover, no autophosphorylation of Cdk5 was observed under those 
conditions. This fact does not exclude the involvement of other proteins in the 
activation process in vivo (113,118,121,123). Recently a p35 isoform has been 
discovered which can also activate Cdk5. This protein which is called p39 is both 
necessary and sufficient for neurite outgrowth in hippocampal cells (124). p25, p35 
and p39 may represent a subfamily of protein kinase activator proteins distinct from 
cyclins, which are regulators for a subfamily of Cdk5-related Cdk-s (125-128). 
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Figure 5. Structural determinants of Cdk5 substrate peptide (127). 
Positive or negative determinants are the amino acid residues whose substitution for 
alanine results in an increase or a decrease in substrate activity of the peptide, 
respectively. Substitution of any of the boxed amino acid residues by alanine abolishes 
the substrate activity of the peptide. 
The Cdk5/p35 complex is phosphorylating histone HI (102,118,129), pRb (130) and 
p35 in vitro. The best in vitro substrate of the enzyme identified to date is histone HI. 
A peptide derived from the phosphorylation site sequence of histone HI is as good a 
substrate as histone HI itself (129) suggesting that the substrate activity determinants 
are restricted to the primary sequence around the phosphorylation sites. In comparison 
with a peptide called pro-Src, based on the phosphorylation site sequence of the proto-
oncogene c-Src (57,58,96) which was used to purify Cdk5 from bovine brain (109), 
the histone HI peptide is over 50 fold more efficient as a substrate for Cdk5/p35. 
Using a set of synthetic peptides systematically modified from the histone HI peptide, 
the substrate determinants of the peptide, both positive and negative, have been 
elucidated as schematically represented in figure 5 (126,127). 
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Activated Cdk5 kinase phosphorylates a number of cytoskeletal proteins including 
neurofilament protein NF-M, NF-H (106, 131-137), the neuron-specific microtubule 
associated protein tau (138-140) and the actin binding protein caldesmon in vitro 
(127). Phosphorylation of cytoskeletal proteins may play an important role in the 
polymerization and assembly of cytoskeletal elements which, in turn, may effect the 
growing neurites suggesting that Cdk5 is involved in the growth and maintenance of 
neurites. The phosphorylation status of tau and NF-H/NF-M on at least some of the 
putative Cdk5 phosphorylated residues is dynamic: Tau is more heavily 
phosphorylated during development than in the adult (141-144) and NF-H/NF-M side-
arms are largely nonphosphorylated in perikarya but are increasingly more heavily 
phosphorylated on serine and threonine residues in the carboxyl-terminal regions as 
NFs move down the axon (145-149). 
In addition, Cdk5 phosphorylates neurofilament proteins exclusively at sites 
phosphorylated in Lewy body pathologies (150,151), i.e. diffuse Lewy body disease 
(dementia), Parkinson's disease (152,153) and amyothrophic lateral sclerosis 
(154,155), whereas Cdk5 phosphorylates tau protein at sites phosphorylated in 
Alzheimer's disease (138-140, 156-158). Comparison of tau protein kinase (TPK) II 
and Cdk5/p35 showed that these two kinases are identical or highly homologous 
(113,118,158). Cdk5 kinase activity correlates with the extend of differentiation of 
neuronal cells (99,113,118,159-161) and colocalizes with neurofilament tracts in the 
axons of neuronal cells in culture. Cdk5/p35 has been demonstrated to play a key role 
in neurite outgrowth (162) and neuronal migration during neuronal differentiation 
(163). This makes Cdk5 a strong candidate for catalyzing neurofilament and tau 
phosphorylation in vivo (113,117,164). Whilst Cdk5 activity is important during 
differentiation, hyperphosphorylation of neurofilaments and tau because of 
uncontrolled Cdk5 activity may be the cause of several neurodegenerative diseases. 
It has been reported that cyclin D (35,165-167) and E (99) bind to Cdk5 but these 
complexes have never been shown to be enzymatically active. p67 (Munc-18), which 
is exclusively expressed in neurons and highly enriched in axons, binds to Cdk5 and 
has a positive effect on its kinase activity (87,161). Recently a novel role for Cdk5 has 
been demonstrated in regulating myogenesis in the early embryo (168,169). Unlike 
most other Cdk-cyclin complexes, Cdk5/p35 is not inhibited by the p21cnM/WAF1 (34) or 
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p27KIP1 (35) Cdk inhibitors. There is some evidence, however, that a population of 
Cdk5/p35 exists as an inactive form within a macromolecular structure, suggesting 
Cdk5/p35 may bind to inhibitors in the brain (125). Presence of Cdk5 in reproductive 
organs provide new insight into the possible function of this Cdk during both 
differentiation and apoptosis (170,171). Activation of Cdk5 by p35 can be blocked by 
coexpression of dominant-negative mutants of Cdk5. This technique has widely been 
used in lots of experiments demonstrating the possible roles of Cdk5 
(118,128,137,162,168,169,172). 
1.8.3 Neurofilaments 
Neurofilaments, the neuron-specific intermediate filaments represent the major 
cytoskeletal organelle in axons in terms of mass and volume (173-175). In mature 
mammalian brains, neurofilaments are composed of three subunits of different 
molecular weights which are referred to as low (68 kDa), medium (95 kDa) and high 
molecular weight (115 kDa) neurofilament proteins: NF-L, NF-M and NF-H 
respectively (176). Each of the subunits contains an alpha-helical rich conserved 
central core which is involved in the coiled-coil assembly of the filamentous structure 
(177). The amino terminal side of the core domain is a conserved globular domain 
which contains multiple second messenger regulated phosphorylation sites and is 
therefore suggested to play a role in regulating the filament assembly (178-185). The 
carboxyl terminal regions of the neurofilament subunits are the regions discriminating 
the three neurofilament subunits (149,175). NF-M and NF-H but not NF-L contain 
long carboxyl-terminal extensions which are rich in proline-directed serine/threonine 
residues (186-189). This is especially true for NF-H which has more than 50 such sites 
(189). These sites are heavily phosphorylated in neurons. Several studies have shown 
that NF-H and NF-M can be phosphorylated by Cdk5 or related kinases 
(100,114,175,190-192). Furthermore functional association of Cdk5 with 
neurofilaments has been shown (193). 
The proline-directed phosphorylation appears to play important roles in neuron-
skeleton structure and function. Dephosphorylated NF-H displays specific binding to 
microtubules in vitro whereas the phosphorylated form of the protein does not bind 
microtubules (136). The phosphorylation is under strict spatial and temporal control. 
The assembly of neurofilaments occurs in the cell body (194,195); once assembled, the 
filaments are transported along the axon. During the axonal transport, the subunits NF-
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M and NF-H become heavily phosphorylated on the proline-directed sites (196,197). It 
has been suggested that the phosphorylation depends on the presence of myelin sheath 
(197). A mouse strain with defective myelin, trembling mouse, has been found to have 
greatly reduced neurofilament phosphorylation. Abnormality in NF-H and NF-M 
phosphorylation has also been implicated in Lewy body pathologies (150,151,154). 
Hypo- or hyperphosphorylation of neurofilaments are important symptomes in 
neurodegenerative diseases. Malfunction of the Cdk5 kinase may be intrumental in 
this. 
1.8.4 Alzheimer's disease and tau protein 
The mechanisms that result in neuronal loss in Alzheimer's disease are not clearly 
understood. The discovery of several different mutations in the gene for the amyloid 
precursor protein in some pedigrees with familial Alzheimer's disease has given 
support to the "amyloid cascade" hypothesis, in which the extracellular deposition of 
(3-amyloid is an early pathogenic event. A consensus has not yet been reached, 
however, on how deposition of P-amyloid in the brain results in neurodegeneration, 
and hence dementia (198). On the other hand, neurons containing neurofibrillary 
tangles are almost certainly unable to function normally and many such neurons die, as 
is evident from the presence of "ghost" tangles, the residue of dead, tangle-bearing 
neurons, in the brains of patients with Alzheimer's disease. Neurofibrillary tangles are 
composed of paired helical filaments (PHFs) and, indeed, PHF pathology is 
widespread in Alzheimer's disease, giving rise also to neurophil threads and filling 
many dystrophic neurites that surround the P-amyloid cores of senile plaques. PHFs 
are composed of hyperphosphorylated tau (199-207), and appear to be the residue of a 
disintegrated neuronal cytoskeleton because microtubules and neurofilaments are 
absent from neuronal cytoplasm rich in PHFs (208-211). Most of the phosphorylated 
residues in PHF-tau are serine and threonine residues that are amino-terminal to a 
proline residue (200,212-216). In foetal brain, however, tau is also 
hyperphosphorylated, and the phosphorylation sites identified in foetal tau are also 
phosphorylated in PHF-tau. This suggests that PHF-tau may arise from a loss of 
regulatory control of tau phosphorylation in degenerating neurons that results in the 
reappearance of a foetal phosphorylation pattern (217,218). 
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Tau protein exists in adult neurons as a set of six isoforms derived from a single gene 
by alternative mRNA splicing (219,220). One property of tau is to stabilize assembled 
microtubules (221). This function is likely to be modulated by phosphorylation, as 
phosphorylated tau has a reduced ability to promote microtubule assembly in vitro. 
Indeed, PHF-tau does not bind to microtubules (222). Consequently, 
hyperphosphorylation of tau in Alzheimer's disease may lead to disruption of the 
neuronal cytoskeleton, and this could be a crucial event contributing to 
neurodegeneration. 
A number of kinases, including MAP kinase (223-226), glycogen synthase kinase 
(GSK)-3ct, GSK-3P (159,226-229) and Cdk5 (138-140,156-158), phosphorylate 
recombinant tau in vitro so that it resembles PHF-tau. A detailed study of tau protein 
phosphorylation in crude brain extracts has led to the suggestion that Cdk5 is the 
major kinase phosphorylating tau proteins in vivo (138,190). Recently is has been 
proposed that disregulation of various components of the cell cycle is a significant 
contributor to regionally specific neuronal death in Alzheimer's disease (230). 
1.9 Saccharomyces cerevisiae as a useful tool in cell cycle research 
The long association of yeast with human culture stems from the ability of certain 
yeast species to produce efficiently two important metabolites, ethanol for alcoholic 
beverages, and carbon dioxide for the leavening of bread, without simultaneously 
producing toxic by-products. Commercial exploitation of yeast has led to highly 
developed, technology-based industries involved in brewing, baking, wine making, 
distilling, industrial ethanol production and the manufacture of yeast-based foods. 
In industrial production it is desirable, and often necessary, to adapt the performance 
of the organism to manufacturing needs. In yeast these adaptations can be brought 
about either by physiological conditioning of cultures or through genetic changes, 
traditionally done by strain selection. Today, DNA manipulation itself presents a short 
cut to the desired aim. 
Recombinant DNA technology, i.e. the improvement of cellular activities by 
manipulation of enzymatic, transport, and regulatory functions of the cell, has offered 
the possibility of developing the capabilities of yeast and dramatically extending the 
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industrial potential of these organisms. Commercial yeast species can be specifically 
modified to enhance their suitability for existing processes and to generate strains for 
new manufacturing applications. Furthermore, predefined modifications of this type 
are not subject to the undesirable side effects frequently encountered in hybrids and 
mutagenised cells. 
Stable inheritance of introduced genes depends on their insertion into yeast 
chromosomes by recombination, or their linkage to a piece of DNA, a plasmid, which 
replicates autonomously and segregates to daughter cells. The pool of genetic material 
available for manipulation is almost unlimited since it is possible not only to remove, 
modify and reintroduce yeast genes but also to take genes from other organisms and 
make them function in yeast. 
Morphologically, yeasts are unicellular fungi that reproduce by budding or fission. 
Taxonomically, the budding yeast Saccharomyces cerevisiae, generally known as 
baker's yeast, belongs to the class Hemiascomycetes (ascomycotina that lack 
ascocarps and ascogenous hyphae), and the family of Saccharomycetaceae of the order 
Endomycetales. The biochemistry and molecular biology of baker's yeast have been 
studied in detail over the years, although many aspects of its metabolism and life cycle 
remain unclear. However, as baker's yeast has been characterized better than any other 
fungus, the techniques of genetic engineering are especially well suited for the 
manipulation of this yeast (231). 
1.9.1 The yeast-two-hybrid system 
The two-hybrid system uses the efficacy of yeast genetic assays to identify protein-
protein interactions. It permits the rapid cloning of genes encoding products that 
interact with a given protein of interest. While the current assay is carried out in yeast, 
genes from any organism may be used in the screen. 
The conceptual basis for the two-hybrid system, as reported by Fields and Song (232), 
was established by studies on the regulation of eukaryotic transcription. Certain 
transcription factors, such as the yeast GAL4 and GCN4 proteins, were shown to 
comprise two distinct and separable domains: a site-specific DNA-binding domain, 
and an acidic region that is required for transcriptional activation. Functionally 
competent chimeric proteins were generated that consist of the DNA-binding region of 
one factor and the activation domain of another. In addition, heterodimeric complexes, 
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consisting of an activation domain and a DNA-binding domain encoded by separate 
genes, could activate transcription. 
(a) ^ 
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Figure 6. The basic two-hybrid system using a dual selection/screen (234) 
(a) A protein (A) fused to the DNA-binding domain of LEXA is expressed in a yeast 
strain carrying two reporter genes, HIS3 and lacZ, under the control of the LEXA 
promoter. Since the hybrid protein lacks transcriptional activation potential, the 
reporter genes are not transcribed and the strain remains His" and does not hydrolyse 
the chromogenic indicator X-Gal. (b) A second plasmid that expresses a hybrid protein 
consisting of a protein (B) fused to the GAL4 transcriptional activation domain (GAD) 
is introduced into the strain. If protein B and protein A physically associate, the GAD 
will be localized to the promoters of the reporter genes, thereby activating their 
transcription and producing HIS3 and lacZ transcripts. 
In its current form, the yeast-based two-hybrid system utilizes hybrid genes to detect 
protein-protein interactions via the activation of reporter-gene expression. This gene 
expression occurs as a result of reconstitution of a functional transcription factor 
caused by the association of two hybrid proteins. Typically, a gene encoding a protein 
of interest is fused to the DNA-binding domain of a well-characterized transcription 
factor (e.g. GAL4, LEXA) while another gene is fused to a transcriptional activation 
domain (GAL4, VP16) (233). The activation-domain hybrid is introduced into a yeast 
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strain expressing the DNA-binding-domain hybrid and the resulting strain is assayed 
for association of the two proteins. A productive interaction between the proteins of 
interest localizes the activation domain to the DNA-binding domain. This results in 
transcription of an adjacent reporter gene, typically a nutritional marker, which 
provides a scorable phenotype or lacZ (Fig. 6). 
There are several advantages of dual screen/selection assays. First, the ability to select 
for nutritional prototrophy greatly increases the number of library transformants that 
can be screened for lacZ activity. This is particularly important when large, high-
quality libraries are available and low-abundance binding partners are sought. In 
addition, the requirement for expression of two reporter genes with different promoter 
contexts significantly reduces the number of false-positive signals since separate 
transciptional events must be maintained at distinct chromosomal loci (234). 
Searches have been carried out with a large number of proteins of disparate subcellular 
location and function. Cytoplasmic, nuclear and membrane-associated proteins from a 
variety of species have been used successfully. A few examples include interactions 
between yeast RAP1 and RIF1 (235),
 p21CIP1/WAFl with Cdk2 (33) and p i6""^ with 
Cdk4 (236). 
Library screens can select for proteins that are initially found to activate reporter-gene 
expression in the presence of a specific DNA-binding-domain hybrid protein, but that 
are later observed to promote transcription in concert with a number of different hybrid 
partners. While the biophysical basis of these 'false-positive' interactions is not clear, 
some proteins may contain regions with surfaces that have low affinities for many 
different proteins, for example, large hydrophobic surfaces. These proteins may form 
complexes with a number of other proteins that are stable enough to result in a 
recognizable phenotype. 
A rapid genetic assay has been designed to eliminate false positives isolated in the 
system (33). Briefly, a collection of false-positive detector strains that express different 
DNA-binding-domain hybrids are used in mating assays with strains expressing 
putative interactors. A nonspecific hybrid interactor will generally activate reporter-
gene expression in one or more of the false-positive detectors. This allows many 
activation-domain hybrids to be quickly screened for specific interaction with a given 
target protein (Fig. 7). 
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(a) Curing 
(b) 
Mating 
Figure 7. Curing and mating of the positives 
(a) The positive (strain L40, Mat a) is cured from the pLEXA plasmid by selecting for 
the pGAD plasmid only using the appropriate auxotrophic markers. The cured positive 
should not express the reporter genes (b) This cured positive is mated with strains of 
the opposing sex (strain AMR70, Mat a) containing the pLEXA plasmid expressing 
putative interactors. The resulting diploids are assayed for nonspecific hybrid 
interactions in order to eliminate false-positives. 
Another method to generate supporting evidence that a given interaction is real 
involves testing the ability of hybrid proteins to associate when the target protein is 
switched to the activation domain and the library-derived protein is fused to the DNA-
binding domain. Observed interaction between reciprocal hybrids is a strong indication 
of true physical association. However, failure to detect association in this assay may 
not reflect a false-positive result since different fusion proteins probably have different 
properties (i.e. conformation and stability) that might prevent productive association. 
Importantly, the reciprocal transfer of sequences between the DNA-binding domain 
and the activation domain might not be experimentally trivial (234). 
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1.10 Outline of the thesis 
In order to understand the different roles the cyclin dependent kinases could have in 
either proliferating or differentiating human cells we investigated the roles of both 
Cdk4 and Cdk5. The Cdk4 kinase phosphorylates the Rb protein and therefore plays a 
very important role in the G,/S transition of the cell cycle. Whether a proliferating cell 
would undergo differentiation or not could thus be dependent on Cdk4 activity. Cdk5 
activity on the other hand has been shown only in differentiating cells although Cdk5 
is present in proliferating cells as well. With different activators Cdk5 could play 
different roles in cycling cells. Although D (35,165-167) and E (99) type cyclins are 
able to bind to Cdk5 no activity of the complex has been shown to date. It would be 
interesting to speculate on the requirement of Cdk4 for the onset of proliferation and 
on Cdk5 for the onset of differentiation. If this would be true the question arises why 
Cdk4 is expressed in differentiating cells and Cdk5 in proliferating cells (237). There 
is definitely much more to the fate of a cell than what is known till date. 
Aberrant activity of both cyclin dependent kinases due to overexpression of the 
catalytic subunit or its activating partner and misfunction of specific Cdk inhibitors 
may lead to hyperplasia in the case of Cdk4 and apoptosis in the case of Cdk5 linking 
malignant function of both kinases to cancer and neurodegenerative diseases 
respectively. 
Since pl6INK4A is missing or mutated in a lot of tumours and the Cdk4/cyclin D 
complex upregulated (70), molecules mimicing pl6INK4A or other molecules 
specifically inhibiting Cdk4 activity could be potential antineoplastic drugs. If these 
compounds specifically inhibit Cdk4 activity, the malignant cells could be stopped at 
the G,/S checkpoint without interfering with other processes in the cell cycle. The 
arrested cells may be killed off or forced to undergo apoptosis by chemotherapeutic 
agents or irradiation enhancing the therapeutic effects of the currently used anti-
tumour agents (1,5). In this context, the Cdk inhibitor flavopiridol is entering phase 3 
studies as an anti-tumour agent. However flavopiridol is not a Cdk4 specific antagonist 
(Table 2). Other compounds are still under investigation. 
Chapter 2 of this thesis shows a method developed in yeast to screen possible 
antineoplastic agents. Cdk4 is expressed in the yeast S. cerevisiae under the control of 
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the GAL1-GAL10 promoter and inhibits cell growth when the yeast is grown on 
galactose. Known Cdk4 inhibitors like pie""*4* and flavopiridol restore cell growth. 
Cdk5 is present in both cycling and non-cycling cells and has been found in many 
tissues (102). The highest concentration however is found in neuronal cells. p35 which 
is expressed solely in the brain can activate Cdk5. Cdk5 is a likely candidate to 
catalyze the in vivo phosphorylation of the neurofilament proteins and tau. Cdk5 
phosphorylates neurofilament proteins exclusively at sites phosphorylated in Lewy 
body pathologies. In nerve cells of patients suffering from Alzheimer's disease tau 
protein is hyperphosphorylated at the Cdk5 phosphorylation sites (106,127). Cdk5 
activity is suggested to be involved in terminal neuron and muscle differentiation. 
In order to investigate about this interesting protein a search for new protein 
interactions in proliferating cells using the yeast-two-hybrid system was performed. A 
HeLa cervical carcinoma cDNA library was screened and DNA binding protein dbpA 
and 60S ribosomal protein L34 were found to interact with Cdk5. DbpA and L34 are 
not only binding to Cdk5 but also to Cdk4 and not to Cdk2 or Cdkl. Kinase assays 
show that both proteins inhibit the kinase activities of both Cdk5/p35 and Cdk4/cyclin 
Dl kinases and not that of Cdk2/cyclin A. These results are depicted in chapters 3 and 
4. 
In chapter 5 an endogenously present kinase-defective Cdk5 isoform is presented. This 
protein lacks subdomain VI, a domain highly conserved amongst the serine/threonine 
protein kinases. The isoform has lost its ability of autophosphorylation and is very 
weakly active. Furthermore it can compete with wildtype Cdk5 for binding to p35. 
In this thesis a screen is presented to search for Cdk4 antagonists. Furthermore the 
Cdk5 interacting proteins presented and the Cdk5 isoform could be tested for their 
ability to regulate the Cdk5 kinase in vivo. 
30 
References 
1. Hartwell, L.H. and Kastan M.B. (1994) Cell Cycle Control and Cancer. Science 
266,1821-1828. 
2. Murray, A. and Hunt, T. (1993) The Cell Cycle, Oxford University Press, 
Oxford, U.K. 
3. Hartwell, L. and Weinert, T. (1989) Checkpoints: controls that ensure the order 
of cell cycle events. Science 246,629-634. 
4. Elledge, SJ. and Harper J.W. (1994) Cdk inhibitors: on the threshold of 
checkpoints and development. Curr. Opin. CellBiol.6, 847-852. 
5. Meijer, L., Borgne, A., Mulner, O., Chong, J.P.J., Blow, J.J., Inagaki, N., 
Inagaki, M., Delcros, J.-G. and Moulinoux, J.-P. (1997) Biochemical and cellular 
effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent 
kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 243, 527-536. 
6. Morgan, D.O. (1995) Principles of CDK regulation. Nature 374,131-134. 
7. Pines, J. (1994) Arresting developments in cell-cycle control. TIBS 19,143-145. 
8. Weinberg, R.A. (1995) The Retinoblastoma Protein and Cell Cycle Control. Cell 
81, 323-330. 
9. Ross, M.E. and Risken, M. (1994) MN20, a D2 Cyclin Found in Brain, Is 
Implicated in Neural Differentiation. J. Neurosci. 14, 6384-6391. 
10. Heichman, K.A. and Roberts, J.M. (1994) Rules to replicate by. Cell 79, 557-
562. 
11. Ohtsubo, M. and Roberts, J.M. (1993) Cyclin-dependent regulation of Gl in 
mammalian fibroblasts. Science 259,1908-1912. 
12. Sherr, C.J. (1993) Mammalian Gl cyclins. Cell 73,1059-1065. 
13. Sherr, CJ. (1994) Gl phase progression: cycling on cue. Cell 79, 551-555. 
14. King, R.W., Jackson, P.K. and Kirschner, M.W. (1994) Mitosis in transition. 
Cell 79, 563-571 
15. Solomon, M. Lee, T. and Kirschner, M.W. (1992) The role of phosphorylation in 
p34CDC2 activation: identification of an activating kinase. Mol. Biol. Cell 3, 13-
27. 
16. Fesquet, D., Labbe, J.C., Derancourt, J., Capony, J.P., Galas, S., Girard, F., 
Lorca, T., Shuttleworth, J., Doree, M. and Cavadore, J.C. (1993) The M015 
31 
gene encodes the catalytic subunit of a protein kinase that activates cdc2 and 
other cyclin-dependent kinases (cdks) through phosphorylation ofThr 161 and 
its homologues. EMBOJ. 12,3111-3121. 
17. Poon, R.Y.C., Yamashita, K., Adamczewski, J.P., Hunt, T. and Shuttleworth, 
J. (1993) The cdc2-related protein p40MO15 is the catalytic subunit of a protein 
kinase that can activate p33c,lk2 and p34cdc2. EMBOJ. 12, 3123-3132. 
18. Fischer, R.P. and Morgan D.O. (1994) A novel cyclin associates with 
M015/CDK7 to form the CDK-activating kinase. Cell 78, 713-724. 
19. Poon, R.Y.C. and Hunter, T. (1995) Cell regulation. Innocent bystanders or 
chosen collaborators? Curr. Biol. 5, 1243-1247. 
20. Devault, A., Martinez, A.-M., Fesquet, D., Labbe, J.-C, Morin, N., Tassan, J.P., 
Nigg, E.A., Cavadore, J.-C. and Doree, M. (1995) MAT1 ('menage a trois') a 
new RING finger protein subunit stabilizing cyclin H-cdk7 complexes in starfish 
and Xenopus CAK. EMBOJ. 14, 5027-5036. 
21. Poon, R.Y.C. and Hunter, T. (1995) Dephosphorylation of Cdk2 Thrl60 by the 
cyclin-dependent kinase-interacting phosphatase KAP in the absence of cyclin. 
Science 270, 90-93. 
22. Parker, L.L. and Piwnica-Worms, H. (1992) Inactivation of the p34CDC2 cyclin B 
complex by the human Weel tyrosine kinase. Science 257,1955-1957. 
23. Watanabe, N., Broome, M. and Hunter, T. (1995) Regulation of the human 
WeelHuCDK tyrosine 15-kinase during the cell cycle. EMBO J. 14, 1878-1891. 
24. Meuller, P.R., Coleman, T.R., Kumagai, A. and Dunphy, W.G. (1995) Mytl: a 
membrane-associated inhibitory kinase that phosphorylates cdc2 on both 
threonine-14 and tyrosine-15. Science 270, 86-90. 
25. Dunphy, W.G. and Kumagai, A. (1991) The cdc25 protein contains an intrinsic 
phosphatase activity. Cell 167,189-196. 
26. Gautier, J., Solomon, M.J., Booher, R.N., Bazan, J.F. and Kirschner, M.W. 
(1991) Cdc25 is a specific tyrosine phosphatase that directly activates p34cdc2. 
Cell 67, 197-212. 
27. Strausfeld, U., Labbe, J.C:, Fesquet, D., Cavadore, J.C., Picard, A., Sadhu, K., 
Russel, P. and Doree, M. (1991) Dephosphorylation and activation of a 
p34cdc2/cyclin B complex in vitro by human CDC25 protein. Nature 351, 242-
244. 
32 
28. Sebastian, B., Kakizuka, A. and Hunter, T. (1993) Cdc25M2 activation of 
cyclin-dependent kinase by dephosphorylation of threonine-14 and tyrosine-15. 
Proc. Natl. Acad. Sci. U.S.A. 90, 3521-3524. 
29. Peter, M. and Herskowitz, I. (1994) Joining the Complex: Cyclin-Dependent 
Kinase Inhibitory Proteins and the Cell Cycle. Cell 79,181-184. 
30. Lee, E.Y.-H.P., Hu, N., Yuan, S.-S.F., Cox, L.A., Bradley, A., Lee, W.-H. and 
Herrup, K. (1994) Dual roles of the retinoblastoma protein in cell cycle 
regulation and neuron differentiation. Genes & Dev. 8,2008-2021. 
31. Moreno, S. and Nurse, P. (1994) Regulation of progression through the Gl phase 
of the cell cycle by the rum+ gene. Nature 367,236-242. 
32. Moreno, S., Labib, K., Correa, J. and Nurse, P. (1994)) Regulation of the cell 
cycle timing of Start in fission yeast by the rum+ gene. J.Cell Sci. (Suppl.) 18, 
63-68. 
33. Harper, J.W., Adami, G.R., Wei, N., Keyomarsi, K. and Elledge, S.J. (1993) The 
p21 Cdk-Interacting Protein Cipl Is a Potent Inhibitor of Gl Cyclin-Dependent 
Kinases. Cell 75, 805-816. 
34. Harper, J.W., Elledge, S.J., Keyomarsi, K., Dynlacht, B., Tsai, L.H., Zhang, P., 
Dobrowolski, S., Bai, C, Connel-Crowley, L. and Swindell, E. (1995) Inhibition 
of cyclin-dependent kinases by p21. Mol. Biol. Cell 6, 387-400. 
35. Lee, M.H., Nikolic, M., Baptista, C.A., Lai, E., Tsai, L.H. and Masague, J. 
(1996) The brain-specific activator p35 allows Cdk5 to escape inhibition by 
p27KIP1 in neurons. Proc. Natl. Acad. Sci. U.S.A. 93, 3259-3263. 
36. Toyoshima, H. and Hunter, T. (1994) p27, a Novel Inhibitor of Gl Cyclin-Cdk 
Protein Kinase Activity, Is Related to p21. Cell 78, 67-74. 
37. Polyak, K., Lee, M.-H., Erdjument-Bromage, H., Koff, A., Roberts, J.M., 
Tempst, P. and Massague, J. (1994) Cloning of p27Kipl, a cyclin-dependent 
kinase inhibitor and a potential mediator of extracellular antimitogenic signal. 
Cell 78, 59-66. 
38. Xiong, Y., Hannon, G.J., Zhang, H., Casso, D., Kobayashi, R. and Beach, D. 
(1993) p21 is a universal inhibitor of cyclin kinases. Nature 366, 701-704. 
39. Guan, K.-L., Jenkins, C.W., Li, Y., Nichols, M.A., Wu, X., O'Keefe, C.L., 
Matera, A.G. and Xiong, Y. (1994) Growth suppression by pl8, a pl6mK4MTSJ-
and pl4WK<B/Mm-related CDK6 inhibitor, correlates with wild-type pRb function. 
Genes & Dev.8, 2939-2952. 
33 
40. Hirai, H., Roussel, M.F., Kato, J.Y., Ashmun, R.A. and Sherr, CJ. (1995) Novel 
INK4 Proteins, pl9 and pl8, Are Specific Inhibitors of the Cyclin D-Dependent 
Kinases CDK4 and CDK6. Mol. Cell. Biol. 15,2672-2681. 
41. Lees, E. (1995) Cyclin dependent kinase regulation. Curr. Opin. Cell Biol. 7, 
773-780. 
42. Sherr, C.J. and Roberts, J.M. (1995) Inhibitors of mammalian Gl cyclin-
dependent kinases. Genes & Dev. 9, 1149-1163. 
43. Pines, J. (1995) Cyclins and cyclin-dependent kinases: a biochemical view. 
Biochem. J. 308, 697-711. 
44. Ewen, M.E., Oliver, C.J., Sluss, H.K., Miller, S.J. and Peeper, D.S. (1995) p53-
Dependent repression of CDK4 translation in TGF-(3-induced G, cell-cycle 
arrest. Genes & Dev. 9, 402-217. 
45. Ewen, M.E. (1996) p53-dependent repression of cdk4 synthesis in transforming 
growth factor-beta-induced Gl cell cycle arrest. J. Lab. Clin. Med. 128, 355-360. 
46. Ewen, M.E. and Miller, S.J. (1996) p53 and translational control. Biochim. 
Biophys. Acta 1242, 181-184. 
47. Polyak, K., Kato, J.-Y., Solomon, M.J., Sherr, C.J., Massague, J., Roberts, J.M. 
and Koff, A. (1994) p27K,pl, a cyclin-cdk inhibitor, links transforming growth 
factor-p and contact inhibition to cell cycle arrest. Genes & Dev. 8, 9-22. 
48. Rudolph, B., Saffrich, R., Zwicker, J., Henglein, B., Miiller, R., Ansorge, W. and 
Eilers, M. (1996) Activation of cyclin-dependent kinases by Myc mediates 
induction of cyclin A, but not apoptosis. EMBOJ. 15, 3065-3076. 
49. Hannon, G.J. and Beach, D. (1994) plS™"8 is a potential effector of TGF-P-
induced cell cycle arrest. Nature 371, 257-261. 
50. Serrano, M., Gomez-Lahoz, E., DePinho, R.A., Beach, D. and Bar-Sagi, D. 
(1995) Inhibition of Ras-Induced Proliferation and Cellular Transformation by 
pie"*4. Science 267, 249-252. 
51. Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C, Beach, D. and DePinho, 
R.A. (1996) Role of the INK4a Locus in Tumor Suppression and Cell Mortality. 
Cell 85, 27-37. 
52. Hanks, S.K. and Hunter, T. (1995) The eukaryotic protein kinase superfamily: 
kinase (catalytic) domain structure and classification. FASEB J. 9, 576-596. 
34 
53. De Bondt, H.L., Rosenblatt, J., Jancarik, J., Jones, H.D., Morgan, D.O. and Kim, 
S.-H. (1993) Crystal structure of cyclin-dependent kinase 2. Nature 363, 595-
602. 
54. Brown, N.R., Noble, M., Endicott, J.A., Garman, E.F., Wakatsuki, S., Mitchell, 
E., Rasmussen, B., Hunt, T. and Johnson, L.N. (1995) The crystal structure of 
cyclin A. Structure 3, 1235-1247. 
55. Jeffrey, P.D., Russo, A.A., Polyak, K., Gibbs, E., Hurwitz, J., Massague, J. and 
Pavletich, N.P. (1995) Mechanism of CDK activation revealed by the structure 
of a cyclinA-CDK2 complex. Nature 376, 313-320. 
56. Russo, A.A., Jeffrey, P.D. and Pavletich, N.P. (1996) Structural basis of cyclin-
dependent kinase activation by phosphorylation. Nat. Struct. Biol. 3, 696-700. 
57. Tang, D., Lee, K.-Y., Qi, Z., Matsuura, I. and Wang, J.H. (1996) Neuronal Cdc2-
like kinase: from cell cycle to neuronal function. Biochem. Cell Biol. 74, 419-
429. 
58. Shenoy, S., Choi, J.-K., Bagrodia, S., Copeland, T.D., Mailer, J.L. and 
Shalloway, D. (1989) Purified maturation promoting factor phosphorylates 
pp60c-src at the sites phosphorylated during fibroblast mitosis. Cell, 57, 763-
744. 
59. Ewen, M.E. (1994) The cell cycle and the retinoblastoma protein family. Cancer 
Metastasis Rev. 13, 45-66. 
60. Dowdy, S.F., Hinds, P.W., Louie, K., Reed, S.I., Arnold, A. and Weinberg, R.A. 
(1993) Physical interaction of the retinoblastoma protein with human D cyclins. 
Cell 73, 499-511. 
61. Ewen, M.E., Sluss, H.K., Sherr, C.J., Matsushime, H., Kato, J.-Y. and 
Livingston D.M. (1993) Functional interactions of the retinoblastoma protein 
with mammalian D-type cyclins. Cell 73, 487-497. 
62. Hinds, P.W., Mittnacht, S., Dulic, V., Arnold, A., Reed, S.I. and Weinberg, R.A. 
(1992) Regulation of retinoblastoma protein functions by ectopic expression of 
human cyclins. Cell 70, 993-1006. 
63. Kato, J.-Y., Matsushime, H., Hiebert, S.W., Ewen, M.E. and Sherr, C.J. (1993) 
Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb 
phosphorylation by the cyclin D-dependent kinase cdk4. Genes & Dev. 7, 331-
342. 
35 
64. Kim, T.A., Lim, J. Ota, S., Raja, S., Rogers, R., Rivnay, B., Avraham, H. and 
Avraham, S. (1998) NRP/B, a Novel Nuclear Matrix Protein, Associates With 
pllO"8 and Is Involved in Neuronal Differentiation. J. Cell Biology 141, 553-
566. 
65. Helin, K., Wu, C.L., Fattaey, A.R., Lees, J.A., Dynlacht, B.D., Ngwu, C. and 
Harlow, E. (1993) Heterodimerization of the transcription factors E2F-1 and DP-
1 leads to cooperative trans-activation. Genes & Dev. 7, 1850-1861. 
66. Lees, J.A., Saito, M., Vidal, M., Valentine, M., Look, T., Harlow, E., Dyson, N. 
and Helin K. (1993) The retinoblastoma protein binds to a family of E2F 
transcription factors. Mol. Cell. Biol. 13, 7813-7825. 
67. Ivey-Hoyle, M., Conroy, R., Huber, H.E., Goodhart, P.J., Oliff, A. and 
Heimbrook, D.C. (1993) Cloning and characterization of E2F-2, a novel protein 
with the biochemical properties of transcription factor E2F. Mol. Cell. Biol. 13, 
7802-7812. 
68. Zhu, L., van den Heuvel, S., Helin, K., Fattaey, A., Ewen, M. Livingston, D., 
Dyson, N. and Harlow, E. (1993) Inhibition of cell proliferation by pi07, a 
relative of the retinoblastoma protein. Genes & Dev. 7, 1111-1125. 
69. Sellers, W.R., Novitch, B.G., Miyake, S., Heith, A., Otterson, G.A., Kaye, F.J., 
Lassar, A.B. and Kaelin, W.G.Jr. (1998) Stable binding to E2F is not required 
for the retinoblastoma protein to activate transcription, promote differentiation, 
and suppress tumor cell growth. Genes & Dev. 12, 95-106. 
70. Kamb, A. (1995) Cell-cycle regulators and cancer. TIG 11,136-140. 
71. Hartwell, L. (1992) Defects in cell cycle checkpoint may be responsible for the 
genomic instability of cancer cells. Cell 71, 543-546. 
72. Hinds, P.W., Dowdy, S.F., Eaton, E.N., Arnold, A. and Weinberg, R.A. (1994) 
Function of a human cyclin gene as an oncogene. Proc. Natl. Acad. Sci. U.S.A. 
91,709-713. 
73. Leach, F.S., Elledge, S.J., Sherr, C.J., Willson, J.K.V., Markowitz, S., Kinzler, 
K.W. and Vogelstein, B. (1993) Amplification of cyclin genes in colorectal 
carcinomas. Cancer Res. 53, 1986-1989. 
74. Motokura, T. and Arnold, A. (1993) Cyclin D and oncogenesis. Curr. Opin. 
Genet. Dev. 3, 5-10. 
36 
75. Khatib, Z.A., Matsushime, H., Valentine, M., Shapiro, D.N., Sherr, C.J. and 
Look, A.T. (1993) Coamplification of the CDK4 gene with MDM2 and GLI in 
human sarcomas. Cancer Res. 53, 5535-5541. 
76. Reifenberger, G., Reifenberger, J., Ichimura, K., Meltzer, P.S. and Collins V.P. 
(1994) Amplification of multiple genes from chromosomal region 12ql3-14 in 
human malignant gliomas: Preliminary mapping of the amplicons shows 
preferential involvement of CDK4, SAS, and MDM2. Cancer Res. 54, 4299-
4303. 
77. Keyomarsi, K. and Pardee, A.B. (1993) Redundant cyclin overexpression and 
gene amplification in breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 90, l i m -
i n e . 
78. Eliyahu, D., Michalovitz, D. and Oren, M. (1985) Overproduction of p53 antigen 
makes established cells highly tumorigenetic. Nature 316,158-160. 
79. Gerwin, B.I., Spillare, E., Forrester, K., Lehman, T.A., Kispert, J., Welsh, J.A., 
Pfeifer, A.M.A., Lechner, J.F., Baker, S.J., Vogelstein, B. and Harris, C.C. 
(1992) Mutant p53 can induce tumorigenic conversion of human bronchial 
epithelial cells and reduce their responsiveness to a negative growth factor, 
transforming growth factor p,. Proc. Natl. Acad. Sci. U.S.A. 89, 2759-2763. 
80. Kern, S.E., Pietenpol, J.A., Thiagaligam, S., Seymour, A., Kinzler, K.W. and 
Vogelstein, B. (1992) Oncogenic forms of p53 inhibit p53 regulated gene 
expression. Science 256, 827-830. 
81. Momand, J., Zambetti, G.P., Olson, D.C., George, D. and Levine, A.J. (1992)) 
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits 
p53 mediated transactivation. Cell 69,1237-1245. 
82. Wu, X., Bayle, J.H., Olson, D. and Levine, A.J. (1993) The p53-mdm-2 
autoregulatory feedback loop. Genes & Dev. 7,1126-1132. 
83. Yang, Z.-Y., Perkins, N.D., Ohno, T., Nabel, E.G. and Nabel, G.J. (1995) The 
p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nature 
Med. 1, 1052-1056. 
84. Nishio, K., Ishida, T., Arioka, H., Kurokawa, H., Fukuoka, K., Nomoto, T., 
Fukumoto, H., Yokote, H. and Saijo, N. (1996) Antitumor effects of 
butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell 
lines. Anticancer Res. 16, 3387-3395. 
37 
85. Schulze-Gahmen, U., Brandsen, J., Jones, H.D., Morgan, D.O., Meijer, L., 
Veseley, J. and Kim, S.H. (1995) Multiple modes of ligand recognition: crystal 
structures of cyclin-dependent protein kinase 2 in complex with ATP and two 
inhibitors, olomoucine and isopentenyladenine. Proteins 22, 378-391. 
86. Vesely, J., Havlicek, L. Stmad, M., Blow, J.J., Donella-Deana, A., Pinna, L., 
Letham, D.S., Kato, J.-Y., Detivaud, L., Leclerc, S. and Meijer, L. (1994) 
Inhibition of cyclin-dependent kinases by purine analogues. Eur. J. Biochem. 
224,771-786. 
87. Veeranna, Shetty, K.T., Amin, N., Grant, P., Albers, R.W. and Pant, H.C. (1996) 
Inhibition of Neuronal Cyclin-Dependent Kinase-5 by Staurosporine and Purine 
Analogs Is Independent of Activation by Munc-18. Neurochem. Res. 21, 629-
636. 
88. Orr, M.S., Reinhold, W., Yu, L, Schreiber-Agus, N. and O'Connor, P.M. (1998) 
An Important Role for the Retinoblastoma Protein in Staurosporine-induced G, 
Arrest in Murine Embryonic Fibroblasts. J. Biol. Chem. 273, 3803-3807. 
89. De Azevedo, W. F., Leclerc, S., Meijer, L, Havlicek, L., Strnad, M. and Kim, S.-
H. (1997) Inhibition of cyclin-dependent kinases by purine analogues Crystal 
structure of human cdk2 complexed with roscovitine. Eur. J. Biochem. 243, 518-
526. 
90. Meijer, L. (1996) Chemical inhibitors of cyclin-dependent kinases. Trends in 
Cell Biol. 6,393-397. 
91. Tassan, J.P., Jaquenoud, M., Fry, A.M., Frutiger, S., Hughes, G.J. and Nigg, 
E.A. (1995) In vitro assembly of a functional human CDK7-cyclin H complex 
requires MAT1, a novel 36 kDa RING finger protein. EMBO J. 14, 5608-5617. 
92. Tassan, J.P., Jaquenoud, M., Leopold, P., Schultz, S.J. and Nigg, E.A. (1995) 
Identification of human cyclin-dependent kinase 8, a putative protein kinase 
partner for cyclin C. Proc. Natl. Acad. Sci. U.S.A. 92, 8871-8875. 
93. Zindy, F., Soares, H., Herzog, K.H., Morgan, J., Sherr, C.J. and Roussel, M.F. 
(1997) Expression of INK4 inhibitors of cyclin D-dependent kinases during 
mouse brain development. Cell Growth Differ. 8,1139-1150. 
94. Okano, H.J., Pfaff, D.W. and Gibbs, R.B. (1993) RB and Cdc2 expression in 
brain: correlations with 3H-thymidine incorporation and neurogenesis. J. 
Neurosci. 13, 2930-2938. 
38 
95. Helin, K., Lees, J.A., Vidal, M., Dyson, N., Harlow, E. and Fattaey, A. (1992) A 
cDNA encoding a pRB-binding protein with properties of the transcription factor 
E2F. Cell 70, 337-350. 
96. Martinez, R., Mathey-Prevot, B., Bernards, A. and Baltimore, D. (1987) 
Neuronal pp60csrc contains a six-amino acid insertion relative to its non-neuronal 
counterpart. Science, 237, 411-415. 
97. Tamaru, T., Okada, M. and Nakagawa, H. (1994) Differential expression of D 
type cyclins during neuronal maturation. Neurosci. Lett. 168, 229-232. 
98. Tamaru, T., Trigun, S.K., Okada, M. and Nakagawa, H. (1993) Identification of 
cells expressing a D type Gl cyclin in matured brain: implication for its role in 
neuronal function. Neurosci. Lett. 153,169-172. 
99. Miyajima, M., Nornes, H.O. and Neuman, T. (1995) Cyclin E is expressed in 
neurons and forms complexes with Cdk5. NeuroReport 6, 1130-1132. 
100. Hellmich, M.R., Pant, H.P., Wada, E. and Battey, J.F. (1992) Neuronal cdc2-like 
kinase: a cdc2-related protein kinase with predominantly neuronal expression. 
Proc. Natl. Acad. Sci. U.S.A. 89, 10867-10871. 
101. Ino, H., Ishizuka, T., Chiba. T. and Tatibana, M. (1994) Expression of CDK5 
(PSSALRE kinase), a neuronal cdc2-related protein kinase, in the mature and 
developing mouse central and peripheral nervous systems. Brain Res. 661, 196-
206. 
102. Tsai, L.-H., Takahashi, T., Caviness, V.S.Jr. and Harlow, E. (1993) Activity and 
expression pattern of cyclin-dependent kinase 5 in the embryonic mouse nervous 
system. Development 119, 1029-1040. 
103. Hayes, T.E., Valtz, N.L. and McKay, R.D. (1991) Downregulation of CDC2 
upon terminal differentiation of neurons. New Biol. 3,259-269. 
104. Hopkins, S.J. and Rothwell, N.J. (1995) Cytokines and the nervous system I: 
expression and recognition. TINS 18, 83-88. 
105. Meyerson, M., Enders, G.H., Wu, C.-L., Su, L.-K., Gorka, C, Nelson, C, 
Harlow, E and Tsai, L.-H. (1992) A family of human cdc2-related protein 
kinases. EMBOJ. 11, 2909-2917. 
106. Lew, J. and Wang, J.H. (1995) Neuronal cdc-2-like kinase. TIBS 20, 33-37. 
107. Demetrick, D.J., Zhang, H. and Beach, D.H. (1994) Chromosomal mapping of 
human CDK2, CDK4, and CDK5 cell cycle genes. Cytogenet. Cell. Genet. 66, 
72-74. 
39 
108. Ohshima, T., Nagle, J.W., Pant, H.C., Joshi, J.B., Kozak, C.A., Brady, R.O. and 
Kulkarni, A.B. (1995) Molecular cloning and chromosomal mapping of the 
mouse cyclin-dependent kinase 5 gene. Genomics 28, 585-588. 
109. Lew, J., Beaudette, K., Litwin, CM. and Wang, J.H. (1992) Purification and 
characterization of a novel proline-directed protein kinase from bovine brain. J. 
Biol. Chem. 267, 13383-13390. 
110. Azzi, L., Meijer, L., Ostvold, A.-C, Lew, J. and Wang, J.H. (1994) Purification 
of a 15-kDa cdk4- and cdk5-binding protein. J. Biol. Chem. 269,13279-12288. 
111. Ino, H. and Chiba, T. (1996) Intracellular localization of cyclin-dependent kinase 
5 (CDK5) in mouse neuron: CDK5 is located in both nucleus and cytoplasm. 
Brain Res. 732, 179-185. 
112. Lew, J., Winkfein, R.J., Paudel, H.K. and Wang, J.H. (1992) Brain proline-
directed protein kinase is a neurofilament kinase which displays high sequence 
homology to p34cdc2. J. Biol. Chem. 267, 25922-25926. 
113. Lew, J., Huang, Q.-Q., Qi, Z., Winkfein, R.J., Aebersold, R., Hunt, T., Wang, 
J.H. (1994) ) A brain-specific activator of cyclin-dependent kinase 5. Nature 
371, 423-426. 
114. Shetty, K.T., Link, W.T. and Pant, H.C. (1993) Cdc2-like kinase from rat spinal 
cord specifically phosphorylates KSPXK motifs in Neurofilament proteins: 
Isolation and characterization. Proc. Natl. Acad. Sci. U.S.A. 90, 6844-6848. 
115. Matsushita, M., Matsui, H., Itano, T., Tomizawa, K., Tokuda, M., Suwaki, H., 
Wang, J.H. and Hatase O. (1995) Developmental changes of cyclin dependent 
kinase 5 subcellular localization in the rat cerebellum. Neuroreport 6, 1267-
1270. 
116. Dellale, I, Bhide, P.G., Caviness, V.S.Jr. and Tsai, L.H. (1997) Temporal and 
spatial patterns of expression of p35, a regolatory subunit of cyclin-dependent 
kinase 5, in the nervous system of the mouse. J. Neurocytol. 26, 283-296. 
117. Tomizawa, K., Matsui, H., Matsushita, M. Lew, J., Tokuda, M., Itano, T., 
Konishi, R., Wang, J.H. and Hatase, O. (1996) Localization and developmental 
changes in the neuron-specific cyclin-dependent kinase 5 activator (p35nck5a) in 
the rat brain. Neuroscience 74, 519-529. 
118. Tsai, L.-H., Delalle, I., Caviness, V.S.Jr., Chae, T. and Harlow, E. (1994)) p35 
is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature 371, 
419-423. 
40 
119. Ishiguro, K., Kobayashi, S., Omori, A., Takamatsu, M., Yonekura, S., Anzai, K., 
Imahori, K. and Uchida, T. (1994) Identification of the 23 kDa subunit of tau 
protein kinase II as a putative activator of cdk5 in bovine brain. FEBS Lett. 342, 
203.208. 
120. Uchida, T., Ishiguro, K., Ohnuma, J., Takamatsu, M., Yonekura, S. and Imahori, 
K. (1994) Precursor of cdk5 activator, the 23 kDa subunit of tau protein kinase 
II: its sequence and developmental change in brain. FEBS Lett. 355, 35-40. 
121. Qi, Z., Huang, Q.-Q, Lee, K.-Y., Lew, J. and Wang, J.H. (1995) Reconstitution 
of neuronal cdc2-like kinase from bacteria-expressed Cdk5 and active fragment 
of the brain-specific activator. J. Biol. Chem. 270,10847-10854. 
122. Tang, D., Chun, A.C.S., Zhang, M. and Wang, J.H. (1997) Cyclin-dependent 
kinase 5 (Cdk5) activation domain of neuronal Cdk5 activator. Evidence of the 
existence of cyclin fold in neuronal Cdk5a activator. J. Biol. Chem. 272, 12318-
12327. 
123. Poon, R.Y.C., Lew, J. and Hunter, T. (1997) Identification of functional domains 
in the neuronal Cdk5 activator protein. J. Biol. Chem. 272, 5703-5708. 
124. Tang, D., Yeung, J. Lee, K.-Y, Matsushita, M. Masui, H. Tomizawa, K., Hatase, 
O. and Wang, J.H. (1995) An isoform of the neuronal cyclin-dependent kinase 5 
(cdk5) activator. J. Biol. Chem. 270, 26897-26903. 
125. Lee, K.-Y., Rosales, J.L., Tang, D. and Wang, J.H. (1996) Interaction of cyclin-
dependent kinase 5 (Cdk5) and neuronal Cdk5 activator in bovine brain. J. Biol. 
Chem. 271,1538-1542. 
126. Lew, J., Qi, Z., Huang, Q.-Q., Paudel, H., Matsuura, I., Matsushita, M., Zhu, X. 
and Wang, J.H. (1995) Structure, function, and regulation of neuronal Cdc2-like 
protien kinase. Neurobiol. Aging 16, 263-278; discussion 268-270. 
127. Tang, D. and Wang, J.H. (1996) Structure, function, and regulation of neuronal 
Cdc2-like protien kinase. Prog. Cell Cycle Res. 2,205-216. 
128. Xiong, W., Pestell, R. and Rosner, M.R. (1997) Role of cyclins in neuronal 
differentiation of immortalized hippocampal cells. Mol. Cell. Biol. 17, 6585-
6597. 
129. Beaudette, K.N., Lew, J. and Wang, J.H. (1993) Substrate specificity 
characterization of a cdc2-like protein kinase purified from bovine brain. J. Biol. 
Chem. 268, 20825-20830. 
41 
130. Lee, K.-Y., Helbing, C.C., Choi, K.-S., Johnston, R.N. and Wang, J.H. (1997) 
Neuronal Cdc2-like Kinase (Nclk) Binds and Phosphorylates the Retinoblastoma 
Protein. J. Biol. Chem. Ill, 5622-5626. 
131. Bajaj, N.P.S. and Miller, C.CJ. (1997) Phosphorylation of neurofilament heavy-
chain side-arm fragments by cyclin-dependent kinase-5 and glycogen synthase 
kinase-3a in transfected cells. J. Neurochem. 69, 737-743. 
132. Guidato, S., Bajaj, N.P.S. and Miller, C.C.J. (1996) Cellular phosphorylation of 
neurofilament heavy-chain by cyclin-dependent kinase-5 masks the epitope for 
monoclonal antibody N52. Neurosci. Lett. 217, 1-4. 
133. Guidato, S., Tsai, L.-H., Woodgett, J. and Miller, C.C.J. (1996) Differential 
cellular phosphorylation of neurofilament heavy side-arms by glycogen synthase 
kinase-3 and cyclin-dependent kinase-5. J. Neurochem. 66, 1698-1706. 
134. Hisanaga, S., Ishiguro, K., Uchida, T., Okumura, E., Okano, T. and Kishimoto, 
T. (1993) Tau protein kinase II has a similar characteristic to cdc2 kinase for 
phosphorylating neurofilament proteins. J. Biol. Chem. 268, 15056-15060. 
135. Hisanaga, S., Uchiyama, M., Hosoi, T., Yamada, K., Honma, N., Ishiguro, K., 
Uchida, T., Dahl, D., Ohsumi, K. and Kishimoto, T. (1995) Porcine brain 
neurofilament-H tail domain kinase: its identification as cdk5/p26 complex and 
comparison with cdc2/cyclin B kinase. CellMotil. Cytoskel. 31, 283-297. 
136. Miyasaka, H., Okabe, S., Ishiguro, K., Uchida, T. and Hirokawa, N. (1993) 
Interaction of the tail domain of high molecular weight subunits of 
neurofilaments with the COOH-terminal region of tubulin and its regulation by x 
protein kinase II. J. Biol. Chem. 268, 22695-22702. 
137. Sun, D., Leung, C.L. and Liem, R.K.H. (1996) Phosphorylation of the high 
molecular weight neurofilament protein (NF-H) by Cdk5 and p35. J. Biol. Chem. 
271, 14245-14251. 
138. Baumann, K., Mandelkow, E.M., Biernat, J., Piwnica-Worms, H, and 
Mandelkow, E. (1993) Abnormal Alzheimer-like phosphorylation of tau-protein 
by cyclin-dependent kinases cdk2 and cdk5. FEBSLett. 336, 417-424. 
139. Paudel, H.K., Lew, J,Ali, Z. and Wang, J.H. (1993) Brain proline-directed 
protein kinase phosphorylates tau on sites that are abnormally phosphorylated in 
tau associated with Alzheimer's paired helical filaments. J. Biol. Chem. 268, 
23512-23518. 
42 
140. Sengupta, A., Wu, Q„ Grandke-Iqbal, I, Iqbal, K. and Singh, T.J. (1997) 
Potention of GSK-3-catalyzed Alzheimer-like phosphorylation of human tau by 
cdk5. Mol. Cell. Biochem. 167, 99-105. 
141. Bramblett, G.T., Goedert, M., Jakes, R., Merrick, S.E., Trojanowski, J.Q. and 
Lee, V.M.-Y. (1993) Abnormal tau phosphorylation at ser396 in Alzheimer's 
disease recapitulates development and contributes to reduced microtubule 
binding. Neuron 10,1089-1099. 
142. Brion J.-P., Smith, C, Couck, A.-M, Gallo, J.-M. and Anderton, B.H. (1993) 
Developmental changes in x phosphorylation: fetal x is transiently 
phosphorylated in a manner similar to paired helical filament-T characteristic of 
Alzheimer's disease. J. Neurochem. 61, 2071-2080. 
143. Goedert, M., Jakes, R., Crowther, R.A., Six, J., Lilbke, U., Vandermeeren, M., 
Cras, P., Trojanowski, J.Q. and Lee V.M.-Y. (1993) The abnormal 
phosphorylation of tau protein at Ser-202 in Alzheimer disease recapitulates 
phosphorylation during development. Proc. Natl. Acad. Sci. U.S.A. 90, 5066-
5070. 
144. Mawal-Dewan, M., Henley, J., Van de Voorde, A., Trojanowski, J.Q. and Lee, 
V.M.-Y. (1994) The phosphorylation state of tau in the developing rat brain is 
regulated by phosphoprotein phosphatases. J. Biol. Chem. 269, 30981-30987. 
145. Carden, M.J., Trojanowski, J.Q., Schlaepfer, W.W. and Lee V.M.-Y. (1987) 
Two-stage expression of neurofilament polypeptides during rat neurogenesis 
with early establishment of adult phosphorylation patterns. J. Neurosci. 7, 3489-
3504. 
146. Jones, S., and Williams, R. (1982) Phosphate content of mammalian 
neurofilaments. J. Biol. Chem. 257, 9902-9905. 
147. Julien, J.P. and Mushinski, W.E. (1983) The distribution of phosphorylation 
sites among identified proteolytic fragments of mammalian neurofilaments. J. 
Biol. Chem. 258, 4019-4025. 
148. Nixon, R.A., Paskevich P.A., Sihag, R.K. and Thayer C. (1994) Phosphorylation 
on carboxy terminus domains of neurofilament proteins in retinal ganglion cell 
neurons in vivo: influences on regional neurofilament spacing, and axon caliber. 
J. Cell Biol. 126, 1031-1046. 
43 
149. Nixon, R.A. and Sihag, R.K. (1991) Neurofilament phosphorylation: a new look 
at regulation and function. Trends Neurosci. 14, 501-506. 
150. Pollanen, M.S., Dickson, D.W. and Bergeron, C. (1993) Pathology and biology 
of the Lewy body. Neuropathol. Exp. Neurol. 52,183-191. 
151. Xu, Z.S., Cork, L.C., Griffin, J.W. and Cleveland D.W. (1993) Involvement of 
neurofilaments in motor neuron disease. J. Cell Sci. 106(Suppl. 17), 101-108. 
152. Henchcliffe, C. and Burke R.E. (1997) Increased expression of cyclin-dependent 
kinase 5 in induced apoptotic neuron death in rat substantia nigra. Neurosci. Lett. 
230,41-44. 
153. Brion, J.-P. and Couck, A.-M. (1995) Cortical and Brainstem-Type Lewy Bodies 
Are Immunoreactive for the Cyclin-Dependent Kinase 5. Am. J. Pathol. 147, 
1465-1476. 
154. Hirano, A. (1991) Cytopathology of amyotrophic lateral sclerosis. Adv. Neurol. 
56, 91-102. 
155. Nakamura, S., Kawamoto, Y., Nakano, S., Ikemoto, A., Akiguchi, I. and 
Kimura, J. (1997) Cyclin-dependent kinase 5 in Lewy body-like inclusions in 
anterior horn cells of a patient with sporadic amyotrophic lateral sclerosis. 
Neurology 48, 267-270. 
156. Imahori, K. and Uchida, T. (1997) Physiology and pathology of tau kinases in 
relation to Alzheimer's disease. J. Biochem.-Tokyo 121, 179-188. 
157. Ishiguro, K., Omori, A., Sato, K., Tomizawa, K., Imahori, K. and Uchida, T. 
(1991) A serine/threonine proline kinase activity is included in the tau protein 
kinase fraction forming a paired helical filament epitope. Neurosci. Lett. 128, 
195-198. 
158. Kobayashi, S., Ishiguro, K., Omori, A., Takamatsu, M., Arioka, M., Imahori, K. 
and Uchida, T. (1993) A cdc2-related kinase PSSALRE/cdk5 is homologous 
with the 30 kDA subunit of tau protein kinase II, a proline-directed protein 
kinase associated with microtubule. FEES Lett. 335,171-175. 
159. Lovestone, S., Reynolds, C.H., Latimer, D., Davis, D.R., Anderton, B.H., Gallo, 
J.-M., Hanger, D., Mulot, S., Marquardt, B., Stabel, S., Woodgett, J.R. and 
Miller, C.C.J. (1994) Alzheimer's disease-like phosphorylation of the 
microtubule-associated protein tau by glycogen synthase kinase-3 in transfected 
mammalian cells. Curr. Biol. 4, 1077-1086. 
44 
160. Ohshima, T., Ward, J.M., Huh, C.-G., Longenecker, G., Veeranna, Pant, H.C., 
Brady, R.O., Martin, L.J. and Kulkarni, A.B. (1996) Targeted disruption of the 
cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal 
pathology and perinatal death. Proc. Natl. Acad. Sci. U.S.A. 93,11173-11178. 
161. Shetty, K.T., Kaech, S., Link, W.T., Jaffe, H., Flores, CM., Wray, S., Pant, H.C. 
and Beushausen, S. (1995) Molecular Characterization of a Neuronal-Specific 
Protein that Stimulates the Activity of Cdk5. J. Neurochem. 64,1988-1995. 
162. Nikolic, M., Dudek, H., Kwon, Y.T., Ramos, Y.F. and Tsai, L.H. (1996) The 
cdk5/p35 kinase is essential for neurite outgrowth during neuronal 
differentiation. Genes & Dev. 10, 816-825. 
163. Chae, T., Kwon, Y.T. Branson, R., Dikkes, P., Li, E. and Tsai, L.H. (1997) Mice 
lacking p35, a neuronal specific activator of Cdk5, display cortical lamination 
defects, seizures, and adult lethality. Neuron 18,29-42. 
164. Matsushita, M., Tomizawa, K., Lu, Y.F., Moriwaki, A., Tokuda, M., Itano, T., 
Wang, J.H., Hatase, O. and Matsui, H. (1996) Distinct cellular compartment of 
cyclin-dependent kinase 5 (Cdk5) and neuron-specific Cdk5 activator protein 
(p35nck5a) in the developing rat cerebellum. Brain Res. 734, 319-322. 
165. Xiong, Y., Zhang, H. and Beach, D. (1992) D type cyclins associate with 
multiple protein kinases and the DNA replication and repair factor PCNA. Cell 
71,505-514. 
166. Bates, S., Bonetta, L., MacAllan, D., Parry, D., Holder, A., Dickson, C. and 
Peters, G. (1994) CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of 
the cyclin-dependent kinases that associate with cyclin Dl. Oncogene 9, 71-79. 
167. Guidato, S., McLoughlin, D.M., Grierson, A.J. and Miller, C.C.J. (1998) Cyclin 
D2 interacts with cdk-5 and modulates cellular cdk-5/p35 activity. J. 
Neurochem. 70, 335-340. 
168. Lazaro, J.B., Kitzmann, M. Poul, M.A., Vandromme, M., Lamb, N.J. and 
Fernandez, A. (1997) Cyclin dependent kinase 5, cdk5, is a positive regulator of 
myogenesis in mouse C2 cells. J. Cell Sci. 110, 1251-1260. 
169. Philpott, A., Porro, E.B., Kirschner, M.W. and Tsai, L.H. (1997) The role of 
cyclin-dependent kinase 5 and a novel regulatory subunit in regulating muscle 
differentiation and patterning. Genes & Dev. 11, 1409-1421. 
170. Ahuja, H.S., Zhu, Y. and Zakeri, Z. (1997) Association of cyclin-dependent 
kinase 5 and its activator p35 with apoptotic cell death. Dev.-Genet. 21,258-267. 
45 
171. Zhang, Q., Ahuja, H.S., Zakeri, Z.F. and Wolgemuth, D.J. (1997) Cyclin-
dependent kinase 5 is associated with apoptotic cell death during development 
and tissue remodeling. Dev. Biol. 183, 222-233. 
172. Van den Heuvel, S. and Harlow, E. (1993) Distinct roles for cyclin-dependent 
kinases in cell cycle control. Science 262,2050-2054. 
173. Liem, R.K. (1993) Molecular biology of neuronal intermediate filaments. Curr. 
Opin. Cell Biol. 5,12-16. 
174. Steinert, P.M. and Roop, D.R. (1988) Molecular and cellular biology of 
intermediate filaments. Annu. Rev. Biochem. 57, 593-625. 
175. Pant, H.C. and Veeranna (1995) Neurofilament phosphorylation. Biochem. Cell 
Biol. 73, 575-592. 
176. Fliegner, K.H. and Liem, R.K. (1991) Cellular and molecular biology of 
neuronal intermediate filaments. Int. Rev. Cytol. 131,109-167. 
177. Parry, D.A. and Steinert, P.M. (1992) Intermediate filament structure. Curr. 
Opin. Cell Biol. 4,94-98. 
178. Gill, S.R., Wong, P.C., Monteiro, M.J. and Cleveland, D.W. (1990) Assembly 
properties of dominant and recessive mutations in the small mouse 
neurofilament (NF-L) subunit. J. Cell Biol. I l l , 2005-2019. 
179. Sihag, R.K. and Nixon, R.A. (1989) In vivo phosphorylation of distinct domains 
of the 70-kilodalton neurofilament subunit involves different protein kinases. J. 
Biol. Chem. 264,457-464. 
180. Sihag, R.K. and Nixon, R.A. (1990) Phosphorylation of the amino-terminal head 
domain of the middle molecular mass 145-kDa subunit of neurofilaments. 
Evidence for regulation by second messenger-dependent protein kinases. J. Biol. 
Chem. 265,4166-4171. 
181. Sihag, R.K. and Nixon, R.A. (1991) Identification of Ser-55 as a major protein 
kinase A phosphorylation site on the 70-kDa subunit of neurofilaments. Early 
turnover during axonal transport. J. Biol. Chem. 266, 18861-18867. 
182. Hisanaga, S., Gonda, Y., Inagaki, M., Ikai, A. and Hirokawa, N. (1990) Effects 
of phosphorylation of the neurofilament L protein on filamentous structures. Cell 
Regul. 1, 237-248. 
183. Nakamura, Y., Takeda, M. Angelides, K.J., Tanaka, T., Tada, K. and Nishimura, 
T. (1990) Effect of phosphorylation on 68 kDa neurofilament subunit protein 
46 
assembly by the cyclic AMP dependent protein kinase in vitro. Biochem. 
Biophys. Res. Commun. 169, 744-750. 
184. Dosemeci, A., Floyd, C.C. and Pant, H.C. (1990) Characterization of 
neurofilament-associated protein kinase activities from bovine spinal cord. Cell. 
Mol. Neurobiol. 10, 369-382. 
185. Dosemeci, A. and Pant, H.C. (1992) Association of cyclic-AMP-dependent 
protein kinase with neurofilaments. Biochem. J. 282,477-481. 
186. Lee, V.M.-Y., Carden, M.J., Schlaepfer, W.W. and Trojanowski, J.Q. (1987) 
Monoclonal antibodies distinguish several differentially phosphorylated states of 
the two largest rat neurofilament subunits (NF-H and NF-M) and demonstrate 
their existence in the normal nervous system of adult rats. J. Neurosci. 7, 3474-
3488. 
187. Lee, V.M.-Y., Otvos, L.Jr., Carden, M.J., Hollosi, M., Dietzschold, B. and 
Lazzarini, R.A. (1988) Identification of the major multiphosphorylation site in 
mammalian neurofilaments. Proc. Natl. Acad. Sci. U.S.A. 85, 1998-2002. 
188. Xu, Z.S., Liu, W.S. and Willard, M.B. (1992) Identification of six 
phosphorylation sites in the COOH-terminal tail region of the rat neurofilament 
protein M. J. Biol. Chem. 267, 4467-4471. 
189. Elhanany, E., Jaffe, H., Link, W.T., Sheeley, D.M., Gainer, H. and Pant, H.C. 
(1994) Identification of endogenously phosphorylated KSP sites in the high-
molecular-weight rat neurofilament protein. J. Neurochem. 63, 2324-2335. 
190. Hosoi, T., Uchiyama, M., Okumura, E., Saito, T., Ishiguro, K., Uchida, T., 
Okuyama, A., Kishimoto, T. and Hisanaga, S.-I. (1995) Evidence for cdk5 as a 
major activity phosphorylating tau protein in porcine brain extract. J. Biochem. 
117,741-749. 
191. Pant, A.C., Veeranna, Pant, H.C. and Amin, N. (1997) Phosphorylation of 
human high molecular weight neurofilament protein (hNF-H) by neuronal 
cyclin-dependent kinase 5 (cdk5). Brain Research 765, 259-266. 
192. Qi, Z., Tang, D., Matsuura, I., Lee, K.Y., Zhu, X., Huang, Q.Q. and Wang J.H. 
(1995) Regulatory properties of neuronal cdc2-like kinase. Mol. Cell. Biochem. 
149-150, 35-39. 
193. Lee, K.-Y. and Johnston, R.N. (1997) Neurofilaments are part of the high 
molecular weight complex containing neuronal cdc2-like kinase (nclk). Brain 
Research 773,197-202. 
47 
194. Lasek, R.J., Garner, J.A. and Brady, S.T. (1984) Axonal transport of the 
cytoplasmic matrix. J. Cell Biol. 99,212-221. 
195. Hollenbeck, P.J. (1989) The transport and assembly of the axonal cytoskeleton. 
J. Cell Biol. 108,223-227. 
196. Ksiezak-Reding, H. and Yen, S.H. (1987) Phosphatase and carbocyanine dye 
binding define different types of phosphate groups in mammalian 
neurofilaments. J. Neurosci. 7, 3554-3560. 
197. De Waegh, S.M., Lee, V.M. and Brady, S.T. (1992) Local modulation of 
neurofilament phosphorylation, axonal caliber, and slow axonal transport by 
myelinating Schwann cells. Cell, 68,451-463. 
198. Kosik, K.S. (1992) Alzheimer's disease: a cell biological perspective. Science 
256, 780-783. 
199. Anderton, B.H. (1993) Expression and processing of pathologic proteins in 
Alzheimer's disease. Hippocampus 3, 227-237. 
200. Lee, V.M.-Y., Balin, B.J., Otvos, L.Jr. and Trojanowski, J.Q. (1991) A68-a 
major subunit of paired helical filaments and derivatized forms of normal tau. 
Science 251,675-678. 
201. Grenberg, S.G. and Davies, P. (1990) A preparation of Alzheimer paired helical 
filaments that displays distinct T proteins by polyacrylamide gel electrophoresis. 
Proc. Natl. Acad. Sci. U.S.A. 87, 5827-5831. 
202. Wischik, CM., Novak, M., Thogersen, H.C., Edwards, P.C., Runswick, M.J., 
Jakes, R., Walker, J.E., Milstein, C, Roth, M. and Klug, A. (1988) Isolation of a 
fragment of tau derived from the core of the paired helical filament of Alzheimer 
disease. Proc. Natl. Acad. Sci. U.S.A. 85,4506-4510. 
203. Kosik, K.S. and Greenberg, S.M. (1992) Tau protein and Alzheimer disease. In 
Alzheimer Disease (Terry, R.D., Katzmann, R. and Bick, K.L., Eds.) Raven 
Press, New York, U.S.A., pp. 335-344. 
204. Grundke-Iqbal, I., Iqbal, K., Tung, Y., Quinlan, M., Wisniewski, H. and Binder, 
L. (1986) Abnormal phosphorylation of the microtubule-associated tau in 
Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. U.S.A. 83,4913-4917. 
205. Ksiezak-Reding, H., Liu, W.K. and Yen, S.H. (1992) Phosphate analysis and 
dephosphorylation of modified tau associated with paired helical filaments. 
Brain. Res. 597, 209-219. 
48 
206. Kondo, J. Honda, T., Mori, H., Hamada, Y., Miura, R., Ogawara, M. and Ihara, 
Y. (1988) The carboxyl third of tau is tightly bound to paired helical filaments. 
Neuron 1, 827-834. 
207. Mandelkow, E.M. and Mandelkow, E. (1993) Tau as a marker for Alzheimer's 
disease. Trends Biochem. Sci. 18, 480-483. 
208. Goedert, M. (1993) Tau protein and the neurofibrillary pathology of Alzheimer's 
disease. Trends Neurosci. 16,460-465. 
209. Lee, V.M.-Y (1995) Disruption of the cytoskeleton in Alzheimer's disease. Curr. 
Opin. Neurobiol. 5, 663-668. 
210. Lee, V.M.-Y. and Trojanowski, J.Q. (1992) The disordered neuronal 
cytoskeleton in Alzheimer's disease. Curr. Opin. Neurobiol. 2, 653-656. 
211. Trojanowski, J.Q., Schmidt, M.L., Shin, R.-W., Bramblett, G.T., Rao, D. and 
Lee V.M.-Y. (1993) Altered tau and neurofilament proteins in neurodegenerative 
diseases: diagnostic implications for Alzheimer's and Lewy body dementias. 
Brain Pathol. 3, 45-54. 
212. Hasegawa, M., Morishima-Kawashima, M., Takio, K., Suzuki, M., Titani, K. 
and Ihara, Y. (1992)) Protein sequence and mass spectrometric analyses of tau 
in the Alzheimer's disease brain. J. Biol. Chem. 267,17047-17054. 
213. Biernat, J., Mandelkow, E.M., Schroter, C, Lichtenberg-Kraag, B., Steiner, B., 
Berling, B., Meyer, H., Merken, M., Vandermeeren, A., Goedert, M. and 
Mandelkow, E. (1992) The switch of tau protein to an Alzheimer-like state 
includes the phosphorylation of two serine-proline motifs upstream of the 
microtubule binding region. EMBOJ. 11,1593-1598. 
214. Kosik, K.S., Orecchio, L.D., Binder, L., Trojanowski, J.Q., Lee, V.M.-Y. and 
Lee, G. (1988) The carboxyl third of tau is tightly bound to paired helical 
filaments. Neuron 1, 817-825. 
215. Lichtenberg-Kraag, B., Mandelkow, E.-M., Biernat, J., Steiner, B., Schroter, C, 
Gustke, N., Meyer, H.E. and Mandelkow, E. (1992) Phosphorylation dependent 
interaction of neurofilament antibodies with tau protein: epitopes, 
phosphorylation sites, and relationship with Alzheimer tau. Proc. Natl. Acad. 
Sci. U.S.A. 89, 5384-5388. 
216. Vulliet, R., Halloran, S.M., Braun, R.K., Smith, A.J. and Lee, G. (1992) Proline-
directed phosphorylation of human Tau protein. J. Biol. Chem. 267, 22570-
22574. 
49 
217. Kanamaru, K., Takio, K., Miura, R., Titani, K. and Diara, Y. (1992) Fetal-type 
phosphorylation of tau in paired helical filaments. Neurochemistry 58, 1667-
1675. 
218. Morishima-Kawashima, M., Hasegawa, M., Takio, K., Suzuki, M., Yoshida, H., 
Titani, K. and Diara, Y. (1995) Proline-directed and Non-proline-directed 
Phosphorylation of PHF-tau. J. Biol. Chem. 270, 823-829. 
219. Goedert, M., Spillantini, M.G., Jakes, R., Rutherford, D. and Crowther, R.A. 
(1989) Multiple isoforms of human microtubule-associated protein tau: 
sequences and localization in neurofibrillary tangles of Alzheimer's disease. 
Neuron 3, 519-526. 
220. Himmler, A., Drechsel, D., Kirschner, M.W. and Martin, D.W.Jr. (1989) Tau 
consists of a set of proteins with repeated C-terminal microtubule-binding 
domains and variable N-terminal domains. Mol. Cell. Biol. 9, 1381-1388. 
221. Mandelkow, E.M., Biernat, J., Drewes, G., Gustke, N., Trinczek, B. and 
Mandelkow, E. (1995) Tau domains, phosphorylation, and interactions with 
microtubules. Neurobiol. Aging 16, 355-363. 
222. Biernat, J., Gustke, N., Drewes, G., Mandelkow, E.M. and Mandelkow, E. 
(1993) Phosphorylation of Ser262 strongly reduces binding of tau to 
microtubules: distinction between PHF-like immunoreactivity and microtubule 
binding. Neuron 11,153-163. 
223. Drewes, G., Lichtenberg-Kraag, B., Doring, F., Mandelkow, E.-M., Biernat, J., 
Goris, J., Doree M. and Mandelkow E. (1992) Mitogen activated protein (MAP) 
kinase transforms tau protein into an Alzheimer-like state. EMBO J. 11, 2131-
2138. 
224. Goedert, M., Cohen, E.S., Jakes, R. and Cohen, P (1992) p42 MAP kinase 
phosphorylation sites in microtubule-associated protein tau are dephosphorylated 
by protein phosphatase 2A1: implications for Alzheimer's disease. FEBS Lett. 
312,95-99. 
225. Ledesma, M.D., Correas, I., Avilla, J. and Diaz-Nido, J. (1992) Implication of 
brain cdc2 and MAP2 kinases in the phosphorylation of tau protein in 
Alzheimer's disease. FEBS Lett. 303, 218-224. 
226. Mandelkow, E.M., Biernat, J., Drewes, G., Steiner, B., Lichtenberg-Kraag, B., 
Wille, H., Gustke, N. and Mandelkow, E. (1993) Microtubule-associated protein 
50 
tau, paired helical filaments, and phosphorylation. Ann. N. Y. Acad. Sci. 695, 209-
216. 
227. Hanger, D.P., Hughes, K. Woodgett, J.R., Brion, J.P. and Anderton, B.H. (1992) 
Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of 
tau: generation of paired helical filaments epitopes and neuronal localization of 
the kinase. Neurosci. Lett. 147, 58-62 
228. Ishiguro, K., Shiratsuchi, A., Sato, S., Omori, A., Arioka, M., Kobayashi, S., 
Uchida, T. and Imahori, K. (1993) Glycogen synthase kinase 3 beta is identical 
to tau protein kinase I generating several epitopes of paired helical filaments. 
FEBSLett. 325, 167-172. 
229. Mandelkow, E.M., Drewes, G., Biernat, J., Gustke, N., Van Lint, J., 
Vandenheede, J.R. and Mandelkow, E. (1992) Glycogen synthase kinase-3 and 
the Alzheimer-like state of microtubule-associated protein tau. FEBS Lett. 314, 
315-321. 
230. Busser, J., Geldmacher, D.S. and Herrup, K. (1998) Ectopic cell cycle proteins 
predict the sites of neuronal cell death in Alzheimer's disease brain. J. Neurosci. 
18, 2801-2807. 
231. Tunnela, O. (1994) Trehalose synthesis in Baker's yeast. Academic dissertation, 
Research laboratories of ALKO Ltd, Helsinki and Department of Biochemistry, 
University of Helsinki, pp. 1-23. 
232. Fields, S. and Song, O. (1989) A novel genetic system to detect protein-protein 
interactions. Nature 340, 245-246. 
233. Sadowski, I., Bell, B., Broad, P. and Hollis, M. (1992) GAL4 fusion vectors for 
expression in yeast or mammalian cells. Gene 118, 137-141. 
234. Allen, J.B., Walberg, M.W., Edwards, M.C. and Elledge, SJ. (1995) Finding 
prospective partners in the library: the two-hybrid system and phage display find 
a match. 7mS 20, 511-516. 
235. Hardy, C.F., Sussel, L. and Shore, D. (1992) A RAP 1-interacting protein 
involved in transcriptional silencing and telomere length regulation. Genes & 
Dev. 6, 801-814. 
236. Serrano, M. Hannon G.J. and Beach, D. (1993) A new regulatory motif in cell-
cycle control causing specific inhibition of cyclin D/Cdk4. Nature 366, 704-707. 
51 
237. Li, Z.-R., Hromchak, L.Z. and Bloch, A. (1997) Differential expression of 
proteins regulating cell cycle progression in growth vs. differentiation. Biochim. 
Biophys. Acta 1356, 149-159. 
52 
2. The pl6INK4A protein and flavopiridol restore 
yeast cell growth inhibited by Cdk4 
Mark Moorthamer, Mayur Panchal, William Greenhalf and Bhabatosh Chaudhuri 
(1998) Biochem. Biophys. Res. Commun. 250, 791-797 
53 
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 250, 791-797 (1998) 
ARTICLE NO. RC989348 
The p16INK4A Protein and Flavopiridol Restore Yeast 
Cell Growth Inhibited by Cdk4 
Mark Moorthamer, Mayur Panchal, William Greenhalf, and Bhabatosh Chaudhuri 1 
Oncology Research, Novartis Pharma AG, Basel, Switzerland 
Received August 7, 1998 
Cyclin-dependent kinase 4 (Cdk4) activity is mis-
regulated in most cancers. Loss of Cdk4 regulation can 
occur through overexpression of Cdk4 catalytic sub-
unit or its regulatory partner cyclin Dl , or if the Cdk4-
specific inhibitory protein pl6 I N K 4 A is inactive. We 
have attempted to express the two human subunits, 
Cdk4 and cyclin Dl , in the yeast Saccharomyces cer-
evisiae. Surprisingly, expression of Cdk4 alone, under 
control of the strong GAL promoter, inhibits cell 
growth. Coexpression of both subunits allows forma-
tion of an active Cdk4-cyclin Dl complex which accen-
tuates growth arrest. In cells expressing Cdk4 only, 
growth is restored by overexpressing human Cdc37, a 
Cdk4-binding molecular chaperone. Interestingly, the 
effect of Cdk4 on yeast is also overcome by both pl6-
and p21-families of Cdk-inhibitory proteins. Moreover, 
flavopiridol, a compound which inhibits Cdk4 enzyme 
activity, restores cell division. The fact that pie11""* 
and flavopiridol negate Cdk4-mediated suppression of 
yeast cell growth implies that this simple system can 
be used as a screen for identifying Cdk4-specific an-
tagonists which may mimic pl6 I N K 4 A in the cancer cell 
c y c l e . © 1998 Academic Press 
Key Words: Cdc37; Cdk4; Cdk4 Inhibitor; Flavopiri-
dol; pl6 I N K 4 A; Saccharomyces cerevisiae. 
Quiescent cells at GO enter the Gl phase of the cell 
cycle when stimulated by mitogens. The progress of the 
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Abbreviations: Cdk4, human cyclin dependent kinase; CEN, yeast 
centromere; CYClt, transcription terminator from the yeast CYC1 
gene; EGY48_CDK4, yeast strain EGY48 transformed with CEN-
URA3 plasmid encoding GALlp-cdk4-CYClt expression cassette; 
EGY48_CDK4_GSTD1, yeast strain EGY48_CDK4 transformed 
with CEN-LEU2 plasmid encoding GALlp-GST-cyclinJ)l-CYClt 
expression cassette; Gal, galactose; GALlp, promoter from the 
GAL1-GAL10 gene; Glu, glucose; GST, glutathione-S-transferase; 
HT444_CDK4, yeast strain HT444 transformed with CEN-URA3 
plasmid encoding GALlp-cdk4-CYCH expression cassette; PCR, 
polymerase chain reaction; pRb, human retinoblastoma protein. 
cell cycle is governed by the sequential activation-
inactivation of different cyclin-dependent kinases 
(Cdk-s). Cdk4 is the first Cdk that is activated in Gl 
(1). Activation of Cdk4 is followed by induction of Cdk2 
activity which permits entry into the DNA synthesis 
(S) phase of the cell cycle. 
Cdk4 is activated by binding to one of three D type 
cyclins and its activity is specifically inhibited by the 
pl6-family of proteins (1). The tumor suppressor reti-
noblastoma protein pRb is a natural substrate of Cdk4 
(1-4). Underphosphorylated pRb represses the activity 
of different transcription factors, for example, the func-
tion of the E2F family of proteins. When Cdk4 phos-
phorylates pRb, hyperphosphorylated pRb dissociates 
from E2F. Free E2F can then transcribe a set of genes 
that allow entry of the cell from Gl to S phase of the 
cell cycle. Cyclins E and A, two of the genes induced by 
E2F, activate Cdk2 which can also phosphorylate pRb 
(1). The activity of Cdk2 is regulated by the p21-family 
of inhibitory proteins that can inhibit Cdk4 too. Thus, 
active Cdk4 initiates a complex cascade of events that 
culminates in cell proliferation through the initial 
phosphorylation of pRb. 
Cdk4 activity is misregulated in most malignant 
cells (1). Besides Cdk4 and cyclin D l overexpression in 
different tumors, it is estimated that the Cdk4-specific 
inhibitory activity of p l6 I N K 4 A (one of four proteins of 
the pl6-family that do not inhibit Cdk2) is absent in 
the majority of cancers (5). Mice lacking a functional 
copy of the p l6 I N K 4 A protein are extremely susceptible 
to tumor formation confirming that pl6 l r is a tu-
mor suppressor (6). Expression of p l6 I N K 4 A has been 
shown to selectively block the growth of pl6 I N K 4 A-
deficient tumor cells (7) and it is suspected that this 
may lead to senescence (8-10). Oncogenic Ras-
mediated cell proliferation, as observed in different 
tumors, can also be blocked by the Cdk4 inhibitor 
pl6iNK4A ( 1 1 ) Therefore, it is of great interest to iden-
tify a small molecular weight compound that may 
mimic p l6 I N K 4 A and selectively inhibit Cdk4 in a can-
cer cell. 
We set out to investigate if coexpression of human 
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Cdk4 (12) and cyclin Dl (13) in the yeast Saccharomy-
ces cerevisiae would yield an active enzyme and if this 
would help in identifying unique Cdk4 antagonists. In 
order to obtain activity, it is essential that the catalytic 
subunit be phosphorylated on a conserved Thr-residue 
(viz. Thrl61 of Cdkl) (14-15). Phosphorylation is me-
diated by the Cdk-activating kinase (CAK) (15). There 
exists a CAK-like enzyme in yeast (CAK/Civl) (15) 
which could permit phosphorylation of the catalytic 
subunit of Cdk4 and thus provide activity to Cdk4 
bound to cyclin Dl. Therefore, it is possible that yeast 
would produce an active kinase by coexpression of 
Cdk4 and cyclin Dl. We thought it would be interesting 
to know the effects of this activity and to find if this 
would be inhibited in the same way as in mammalian 
cells by known Cdk inhibitors. 
MATERIALS AND METHODS 
Plasmid constructs. An EcoRI-Sall PCR fragment of human 
CDK4 (12) was first subcloned in pBluescriptKS( +) (Stratagene). A 
BamHI-Sall fragment of CDK4 from the resultant plasmid was then 
cloned in pRS416Gal (ATCC), a pCEN-URA3 plasmid containing the 
GAL1 promoter and the CYC1 terminator, for expression in yeast. 
The CDK4 gene lies directly downstream of the GAL1 promoter. 
An EcoRI-Sall PCR amplified fragment of the human cyclin Dl 
gene (13) was first subcloned in pBluescriptKS( +). For expression of 
cyclin Dl in yeast, a BamHI-Sall fragment from the pBlue-
scriptKS(+) derived plasmid was cloned in pRS415Gal (a pCEN-
LEU2 plasmid from ATCC). Furthermore, a Bglll-EcoRI PCR frag-
ment of GST (glutathione S-transferase fragment from pGEX4T-l, 
Pharmacia) and the EcoRI-Sall fragment of cyclin Dl was subcloned 
in pBluescriptKS(+). The Bglll-Sall fragment, which contains the 
fusion gene GST-cyclin_Dl, was then cloned in pRS415Gal (pCEN-
LEU2) for further expression in yeast. 
A BamHI-Nsil PCR fragment of human CDC37 (h_CDC37) (16) 
was first subcloned in pGEMllz(+) (Promega). Linkers which en-
code EQKLISEEDLING (the c-myc epitope) were tagged to the 5'-
end of the gene. This created a BamHI site at the 5'-end of the c-myc 
tag. A BamHI-Hindlll fragment of c-myc-h_CDC37 was cloned in 
both pRS415Gal (pCEN-LEU2) and pRS414Gal (a pCEN-TRPl plas-
mid; ATCC). 
The Cdk inhibitors were cloned in the following manner for further 
expression in yeast. An EcoRI-XhoI PCR fragment of p21CIF1 (17) 
which contains a 3'-end Sall-Xhol fragment encoding YPYDVPDYA 
(the HA-epitope tag), was subcloned in pBluescriptKS(+) to yield the 
plasmid BluKSp/p21-flu. EcoRI-Sall PCR fragments of pl6INK4A 
(18),pl8*NK4C (19),pltf"*40 (20), andp27iapi (21) were subcloned in 
the vector BluKSp/p21-flu, digested with EcoRI-Sall to yield the 
plasmids BluKSp/pl6-flu, BluKSp/pl8-flu, BluKSp/pl9-flu and 
BluKSp/p27-flu, respectively. BamHl-XhoI fragments containing the 
genes for the inhibitors were then cloned either in pRS415Gal 
(pCEN-LEU2) or pRS414Gal (pCEN-TRPl). 
Sequences of all PCR fragments were confirmed by automated 
DNA sequencing (LiCor). 
Yeast strains and media. The S. cerevisiae strains HT444 (MATa 
leu2-3 Ieu2-U2 his4-519 ura3 lys2 Gal¥) (22) and EGY48 (Mata 
ura3, trpl, his3, leu2 Gal+) (23) were used for yeast transformation. 
HT444 was used for stepwise transformation of pCEN-URA3 and 
pCEN-LEU2 plasmids whereas EGY48 was similarly used for trans-
formation of pCEN-URA3, pCEN-LEU2 and pCEN-TRPl plasmids. 
Plasmids were introduced into HT444 by electroporation while the 
lithium acetate protocol (23) allowed transformation of EGY48. The 
strain resulting from transformation of HT444 with pCEN-URA3/ 
CDK4 is referred to as HT444_CDK4 whereas the one obtained from 
transformation of EGY48 has been named EGY48_CDK4. 
HT444_CDK4 has been transformed with pCEN-LEU2 plasmids 
encoding either (a) h_CDC37 or (b) the Cdk inhibitors ipl6INK4A, 
pl8*NK4C, pl9*NK4D,
 P21CIP1, p27iapi). On the other hand, 
EGY48_CDK4 was first transformed with pCEN-LEU2 plasmids 
encoding (a) h_CDC37 or (b) the Cdk inhibitor pl6INK4A or (c) cyclin 
Dl, or GST-cyclin Dl. The EGY48 derivative which contains both 
CDK4 and GST-cyclin Dl was named EGY48_CDK4_GSTD1. pCEN-
TRPl plasmids which carry (a) the Cdk inhibitors ipl6INK4A, 
pl8iNK4Cr pl9iNK4Df p2lCIP1, P27KJP1) or (b) h_CDC37 were then 
transformed in EGY48_CDK4_GSTD1. 
The growth media used were mainly as described earlier (22). YEP 
being a rich medium and SD a defined minimal medium. For sim-
plicity, all defined media have been described simply as SD and the 
added supplements have not been specified (supplements being all 
those required for growth of the specific strain). The carbon sources 
were 2% (w/v) glucose or galactose. 
Spot tests. ~105 cells were suspended in 100 /xl of water and 5-/xl 
aliquots were spotted on appropriate minimal SD medium contain-
ing appropriate carbon sources. 
Affinity purification of Cdk4IGST-cyclin Dl, Cdk4, and kinase 
assay. The Cdk4/GST-cyclin Dl complex and Cdk4 alone were im-
munoprecipitated using published procedures (24 and GST-
handbook, Pharmacia). In essence, 150 Ag^ units of cells were har-
vested (either from EGY48_CDK4_GSTDl or from EGY48_CDK4) 
after a 5 h induction with galactose in SD medium. The cells were 
lysed in PBS, containing a protease inhibitor cocktail (Boehringer) 
and 0.2 mM sodium orthovanadate (Sigma), by vortexing with glass 
beads (0.45-0.5 mm diameter, Sigma). The supernatants were clar-
ified through high-speed centrifugation. GSH-Sepharose (100 /xl; 
Pharmacia) or the Cdk4 antibody (Santa Cruz Biotechnology) fol-
lowed by protein A-Sepharose (100 /xl; Pharmacia) were used for 
immunoprecipitation. 
Preparation of samples for SDS-PAGE and Western blot analysis. 
Cells in late exponential phase were harvested, washed twice with 
0.9% NaCl and were resuspended in an equal volume of medium 
containing 2% galactose. Cultures were incubated at 30°C for 5 h 
with shaking. 150 A600 units of cells were harvested and resuspended 
in 200 /xl of 2x sample buffer (4% SDS w/v, 0.1 M Tris, 4 mM EDTA, 
20% glycerol v/v, -33% bromophenol blue w/v) containing a cocktail of 
protease and phosphatase inhibitors (see above). 
1 /xl cell lysates, pretreated with 30 mM dithiothreitol, were loaded 
on 12.5 % SDS-polyacrylamide gels along with 10 ttl of prestained 
marker (SDS-PAGE broad range standard; Bio-Rad) using a Mini 
Protean chamber system (Bio-Rad). The gels were blotted onto Im-
mobilon P (Millipore) using a semi-dry electroblotter (Sartorius). 
After blotting, proteins were visualized using the ECL kit (Amer-
sham). A HA-specific polyclonal antibody raised in rabbits (Boeh-
ringer) was used to recognize the Cdk-inhibitory proteins expressed 
in yeast. The mouse monoclonal antibody (mycl-9E10.2) raised 
against the c-myc epitope was obtained from ATCC (#CRL-1729; 
kindly provided by M. Geiser; Novartis) and was used to detect 
h_Cdc37. The Cdk4 and cyclin Dl antibodies were available from 
Santa Cruz Biotechnology. 
Microscopic analysis of yeast cell morphology. A pre-culture of 
yeast cells was prepared using SD-glucose (SD-Glu) and grown over-
night to stationary phase at 30°C. An appropriate amount of the 
stationary culture was then diluted to achieve an A600 of —0.5 in 
SD-Glu after overnight growth, i.e early exponential phase growth. 
Cells were then harvested and washed three times with sterile water 
before induction with galactose. The compound flavopiridol (1 /xM or 
10 ttM) was added at this stage. The galactose-induced cells were 
analysed under a microscope using bright-field and 500-fold magni-
fication, at different time points. At each time point, a sample of cells 
were treated with methylene blue as described by Pierce (25). 
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Briefly, cells were resuspended in an appropriate volume of 0.9 M 
KC1 and were treated with the dye solution (final concentration of 
0.5 g/1). 
A minimum of 5 (usually 10) separate frames were counted. The 
Standard Error of Mean (SEM) was calculated for each cell type and 
the errors were combined so as to give a maximum and minimum 
value for each percentage. 
RESULTS AND DISCUSSION 
The S. cerevisiae yeast strains HT444 and EGY48 
were transformed with pRS416Gal/CD2f4. The plasmid 
pRS416Gal is a single-copy centromere plasmid 
(pCEN-URA3, encoding the yeast URA3 gene as selec-
tion marker). The human CDK4 gene (12) is under the 
control of the galactose-inducible GAL1 promoter. 
Transformants were spotted on minimal medium 
plates which contained either glucose or galactose. Un-
expectedly, we find that upon induction with galactose, 
yeast expressing wild type CDK4 stop growing (Fig. 
1A; the results with the strain EGY48 are not shown). 
In contrast, a catalytically inactive Cdk4 mutant has 
no effect on growth, nor has expression of Cdk4 with a 
weaker promoter (e.g. ADH1 as in the yeast-two-hybrid 
system) (results not shown). One transformant from 
each of the two strains, bearing CDK4, is referred to as 
HT444_CDK4 and EGY48_CDK4. 
In order to find if Cdk4-inhbitory proteins would 
restore cell growth, pCEN-LEU2 plasmids encoding 
the genes pl6,NK4A (18), pl8,NK4C (19), pl9*NK4D (20), 
(A) 
Cdk4 
HT444 
p21L (17), p27K1F1 (21), were transformed in 
HT444.CDK4 and EGY48_CDK4. Transformants 
grow in galactose-containing medium, implying that 
the inhibitory proteins restore growth to CDK4-
express ing cells (Fig. IB; the resu l t s wi th 
EGY48_CDK4, which are not shown, are identical). 
The presence of HA-tagged Cdk-inhibitory proteins 
and Cdk4 in these transformants is confirmed by West-
ern blotting (Fig. 1C, top and bottom panels). It can be 
concluded that pl6INK4A, pl8 INK4C , pl9 INK4D, p21CIP1, 
p27KIP1 proteins can abolish the growth-inhibitory ef-
fect of Cdk4 in yeast. 
The observed inhibition of growth induced by Cdk4 
can be due to the inactivation of a protein that is 
essential for growth. The human Cdc37 protein 
(h_Cdc37) has been recently identified as a Cdk4-
binding protein and is postulated to act as a Cdk4-
specific molecular chaperone (16, 26-27). On the other 
hand, yeast Cdc37 (a protein similar in its primary 
sequence to h_Cdc37) is known to be vital for the as-
sembly of the yeast protein kinase Cdc28, the prototype 
of all known Cdk-s (28). Moreover, a mutant yeast 
Cdc37 (therefore probably inactivated) causes a Gl 
block in the cell cycle (28 and references therein). It is 
possible that expression of Cdk4 in yeast nullifies the 
function of the endogenous Cdc37. If this were to be 
true, then overexpression of h_Cdc37 (16) would negate 
the effect of Cdk4 in yeast. Hence, HT444_CDK4 and 
SD-Glu SD-Gal 
Cdk4 
HT444_CDK4 
-+ Cdk4 
FIG. 1. Cdk4 blocks yeast cell growth whereas the Cdk-
inhibitory proteins restore growth in the presence of Cdk4. (A) The 
yeast strain HT444 was transformed with the pCEN-URA3 plasmid 
(pRS416Gal) encoding CDK4. An equal number of cells from three 
individual transformants were spotted on minimal SD medium 
plates, in the presence of glucose (Glu) or galactose (Gal), as de-
scribed under Materials and Methods. One such transformant is 
referred to as HT444_CDK4. (B) HT444_CDK4 was transformed 
with pCEN-LEU2 plasmids (pRS415Gal) encoding genes for the 
Cdk-inhibitors. An equal number of cells from three individual trans-
formants were spotted as in (A). (C) Western blot analysis of cells 
coexpressing Cdk4 and one of the Cdk-inhibitory proteins. 150 A600 
cells were harvested and lysed in 200 /J.1 of lysis buffer (Materials and 
Methods). After blotting, lp.1 of each lysate was probed either with 
the HA-antibodies (upper panel) or with the Cdk4 antibodies (lower 
panel) using the ECL kit (Amersham).'—' denotes the transformants 
of centromere plasmids which contain no expression cassette. 
EGY48_CDK4 were transformed with a plasmid encod-
ing human cdc37. Expression of h_Cdc37 does indeed 
restore cell growth (Fig. 2A and B). The growth restor-
ing ability of h_Cdc37 in HT444_CDK4 are similar 
(results not shown). 
In contrast to h_Cdc37, coexpression of cyclin Dl 
with Cdk4 continues to inhibit growth (Fig. 3A) 
whereas coexpression of cyclin Dl with catalytically 
inactive Cdk4 has no effect on yeast. Precipitation 
of the GST-cyclin_Dl/Cdk4 complex with GSH-
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h_Cdc37 
EGY48_CDK4 
SO-Glu SD-Gal 
through microscopic analysis of cells growing in liquid 
h_Cdc37 cultures. This was achieved by counting the number of 
budded cells against unbudded ones, at different time 
points of growth, in strains which express Cdk4 only. 
CdfcV Cdk4/ 
Cdc37 EGY48_CDK4 
FIG. 2. Human Cdc37 restores yeast growth blocked by Cdk4. 
(A) The yeast strain EGY48 was transformed with the pCEN-URA3 
plasmid (pRS416Gal) encoding CDK4. One such transformant is 
referred to as EGY48_CDK4 which was then transformed with a 
pCEN-LEU2 plasmid (pRS415Gal) encoding h_Cdc37. An equal 
number of cells from three individual transformants were spotted on 
minimal SD medium plates, in the presence of glucose (Glu) or 
galactose (Gal) as in Fig. 1. (B) Western blot analysis of cells coex-
pressing Cdk4 and h_Cdc37, as described above. After blotting, 1 /xl 
of each lysate was probed with either the Cdk4 antibodies (left panel) 
or the c-myc antibodies (right panel) using the ECL kit (Amersham). 
'—' denotes the transformants of centromere plasmids which contain 
no expression cassette. 
Sepharose (Fig. 3B) from cell lysates shows that an 
active enzyme is produced in yeast (Fig. 3C, lanes 5-6). 
Although pl6INft4A,
 P18 INK4C , P19 INK4D, p21 C I P \ 
p27 r a p l overcome Cdk4/cyclin_Dl mediated growth in-
hibition, h_Cdc37 is unable to do the same (Fig. 3D). 
Probably, h_Cdc37 can neither displace cyclin Dl from 
Cdk4 like pl6 INK4A nor can it act as an ATP-
competitive inhibitor like p21OIP1 or p27E Thus 
h_Cdc37 cannot inactivate active Cdk4 like the pl6 
and p21-families of Cdk-inhibitory proteins (27). 
In yeast, temperature sensitive alleles of cdc28 (that 
do not grow at the restrictive temperature of 37°C, but 
grow at the permissive temperature of 25°C) are com-
plemented at 37°C by human Cdk2 but not by human 
Cdk4 (29-30). It is also known that the mammalian 
cyclins E (which activates Cdk2) and Dl (which acti-
vates Cdk4) are similar to specific yeast cyclins (13, 
31). This may indicate that, at least in yeast, Cdk2 and 
Cdk4 may have fundamentally different properties 
(viz. only Cdk2 can be considered as a true Cdc28 
analog). 
Our results show that overexpression of Cdk4 or 
Cdk4-cyclin Dl in yeast blocks cell growth. Coexpres-
sion of pl6 INK4A nullifies this effect, as seen in plate 
assays (Fig. IB, 3D) and in liquid cultures (Fig. 4A, left 
panel; similar results are obtained when pl6 INK4A is 
coexpressed with Cdk4 and cyclin Dl). We have there-
fore attempted to corroborate these unusual findings 
cyclln_D1 
GST-cyclin_D1 
(B) 
Cdk4-
cyclin_D1 
GST-cyclin_D1 
Cdk4/ 
Cdk4GST-01 Cdk4GST-D1 
1 ? 3 f 1 2 3 4_ 
* * ^ 1 % -w • GST-D1 
Cdk4_ Cdk4-GSIJ>1 
(C) 1 2_ 
mm wlm wk •+- GST-Rb 
EGY48_CDK4_GSTD1 
FIG. 3. Coexpression of cyclin Dl with Cdk4 forms an active 
kinase and blocks yeast cell growth that is relieved by the Cdk-
inhibitory proteins but not h_Cdc37. (A) The yeast strain 
EGY48_CDK4 was transformed with a pCEN-LEU2 plasmid 
(pRS415Gal) encoding cyclin Dl and GST-cyclin Dl. An equal num-
ber of cells from three individual transformants were spotted on 
minimal SD medium plates, in the presence of glucose (Glu) or 
galactose (Gal) as in Fig. 1. (B) Western blot analysis of cells express-
ing Cdk4 alone or coexpressing Cdk4 and GST-cyclin Dl, After 
blotting, niters were probed either with Cdk4 antibodies (left panel) 
or with cyclin Dl antibodies (right panel), as in Fig. 1. Lane 1, 500 ng 
E. coli expressed His-tagged Cdk4 (left panel) or 500 ng E. coli 
expressed GST-tagged cyclin Dl (right panel); lane 2, 10 fi\ of protein 
A-Sepharose beads after immunoprecipitating cell lysates from 
EGY48_CDK4 with Cdk4 antibodies (see Materials and Methods); 
lane 3, 10 /xl of GSH-Sepharose beads used for precipitating GST-
cyclin Dl/Cdk4 complex from EGY48_CDK4:: pCENLEU2/GST-
cyclin Dl (see Materials and Methods); lane 4, 1 /xl of GSH-
Sepharose beads used for precipitating GST-cyclin Dl/Cdk4 from 
~2 x 107 Sf9 insect cells. (C) Kinase assay using 10 (xl of beads with 
GST-Rb (Rb = C-terminal 773-924 amino-acid residues of human 
pRb) as substrate (24). (D) The yeast strain EGY48_CDK4 trans-
formed with a pCEN-LEU2 plasmid encoding GST-cyclin Dl is re-
ferred to as EGY48_CDK4_GSTD1. This strain is transformed with 
pCEN-TRPl plasmids encoding the Cdk-inhibitors or h_Cdc37. An 
equal number of cells from three individual transformants were 
spotted on minimal SD medium plates, in the presence of glucose 
(Glu) or galactose (Gal) as in Fig. 1.'—' denotes the transformants of 
centromere plasmids which contain no expression cassette. 
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Effect of Flavopiridol 
FIG. 4. Expression of Cdk4 and coexpression of Cdk4/GST-cyclin Dl cause cell cycle arrest in yeast, whereas pl6 I N K 4 A and flavopiridol 
restore cell division. (A) Left panel, restoration of cell division as monitored by A600 measurements at different time points. Right panel, 
analysis of bud formation through microscopic analysis (see Materials and Methods). (B) Left panel, an example of the unbudded phenotype 
of Cdk4-expressing cells; right panel, during restoration of cell division by pl6 INK4A, bipolar buds form. Cells with a bipolar bud pattern are 
indicated by arrows. Such a budding pattern is not normally seen with haploid yeast nor is it seen in any of the other cultures described here. 
(C) Effect of flavopiridol on cells whose growth is arrested by Cdk4. 
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The majority of living cells are unbudded, as clearly 
visualized in Fig. 4B (left panel; the figure depicts 
HT444_CDK4 after 10 h of induction with galactose). 
The phenomenon of cell cycle arrest observed in a 
strain expressing Cdk4 alone is compared with strains 
which either coexpress Cdk4 and GST-cyclin D l or 
Cdk4 and p l 6 I N K 4 A (Fig. 4A, right). Although no sig-
nificant change in A6 0 0 is seen with cells lacking 
p l 6 i N K 4 A ( F i g 4 A ; l e f t ) > c e l l g w i t h o r ^thout c y c l i n D i 
were able to complete mitosis. This is shown by the 
accumulation of unbudded cells in the 2 upper curves 
(Fig. 4A, right). Cells with p l6 I N K 4 A , as would be ex-
pected from growing cells, maintain a high level of 
budding. Even though coexpression of cyclin D l makes 
no significant difference to the final percentage of cells 
which undergo mitosis there is a significant kinetic 
difference. While in the absence of cyclin D l there is an 
immediate decrease in budding, budding levels with 
cyclin D l remain constant for the first 8 hours. This 
delay could be due to an immediate effect of the Cdk4-
cyclin D l complex inhibiting mitosis whereas the less 
severe effect of Cdk4 is probably manifested only after 
mitosis. Cdk4 on its own prevents further bud forma-
tion but allows cells in G2/M to complete their cell cycle 
unhindered. It seems tha t simultaneous induction of 
cyclin D l only accentuates the growth-inhibitory effect 
of Cdk4 at early time points of induction and imposes a 
delay in the cells' entry into mitosis. In s tark contrast, 
when galactose induces p l 6 I N K 4 A levels in Cdk4-
containing yeast, the percentage of unbudded cells re-
mains unaltered during growth which is typical of an 
exponentially growing culture. This also corresponds 
with the observed increase in cell density (Fig. 4A, left 
panel). Identical observations on budding have been 
made when p l 6 I N K 4 A is coexpressed in a yeast cell 
along with Cdk4 and cyclin D l . 
Interestingly, during pl6 I N K 4 A-mediated restoration 
of growth, a significant percentage (>13% of cells) of 
dividing cells form bipolar buds (Fig. 4B, right panel). 
Yeast cells display either an axial (for haploid Mata or 
Mata cells) or bipolar (for diploid Mata/a cells) pat tern 
of bud-site selection. Choice of bud site is controlled by 
a series of genes, notably BUD1 to BUD5 and AXL1 
and AXL2. Mutations in BUD3, BUD4, AXL1 and 
AXL2 all cause the budding pat tern to be altered from 
axial to bipolar (32-34). BUD3, BUD4 and AXL2 have 
a cellular localisation a t the bud site and are possibly 
all involved in recruitment of other proteins to tha t 
site. AXL1 encodes a protein similar in sequence to the 
human and Drosophila insulin-degrading enzymes 
(33). It could be speculated that p l 6 I N K 4 A not only 
inactivates Cdk4 in yeast but may also inhibit the 
AXL1 gene product thereby causing bipolar bud forma-
tion. Further studies should reveal if p l 6 I N K 4 A is in-
deed an inhibitor of the human insulin-degrading en-
zyme. 
Flavopiridol is an inhibitor of Cdk4 and Cdk2 ki-
nases and in mammalian cells can inhibit cell cycle 
progression in either G l or G2 (35-36). We have en-
quired if this compound would have any effect on yeast 
cell cycle arrest induced by Cdk4 and Cdk4-cyclin D l 
at 1 and 10 /u.M concentrations (Fig. 4C; although re-
sults for a strain expressing Cdk4 are only shown, 
similar observations have been made with strains ex-
pressing Cdk4-cyclin Dl) . Using pRb as substrate, we 
find t h a t flavopiridiol (the racemic form) may be an 
equipotent inhibitor of Cdk4/GST-cyclin D l and Cdk2/ 
GST-cyclin A (the active kinases are produced from 
insect cells; unpublished observations). An increase in 
budding is clearly observed in the presence of 10 JAM 
concentrations of flavopiridol (Fig. 4C). This suggests 
that , for a limited time period (5 h), the cells are able to 
continue dividing normally. This is in contrast to (a) 
the sharp decrease in budding which is typical for 
Cdk4-expressing yeast, and (b) to the initial delay fol-
lowed by more rapid accumulation of unbudded cells 
seen in Cdk4-cyclin D l expressing cells (Fig. 4A, right). 
Even after 20 h of flavopiridol treatment, the level of 
budding remains higher than in the absence, or with 
low levels, of the compound. Since the effects of the 
compound are observed only at 10 /LIM concentrations, 
it may be that flavopiridol is efficiently metabolized by 
yeast and therefore its growth stimulatory effect is not 
clearly perceived at lower concentrations. It is also 
possible tha t flavopiridol does not induce more pro-
nounced cell division because it is a Cdk2 inhibitor too, 
and therefore can inhibit yeast Cdc28 whose activity is 
critical for growth. It is very likely that a compound 
which inhibits Cdk4 but not Cdk2 (and therefore also 
not Cdc28) will be able to restore growth fully, possibly 
like p l6 I N K 4 A . 
We have shown in this communication that Cdk4-
cyclin D l complex in yeast forms an active enzyme, and 
its activity blocks cell growth indicating tha t active 
Cdk4 is toxic to yeast. The block is relieved by coex-
pression of p 2 1 c , p 2 7 r a p i (proteins belonging to the 
p21-family of Cdk-inhibitors), and p l6 I N K 4 A , p l 8 I N K 4 c 
and p l 9 I N K 4 d (proteins belonging to the p l6 I N K 4 A -
family of Cdk-inhibitors) (1). We also observe tha t ex-
pression of Cdk4 without its activating partner stops 
cell growth. However, overexpression of human Cdc37 
(16) relieves these cells from growth arrest. Cdk4-
mediated inhibition of growth can be also abrogated by 
expression of the same kinase inhibitors (p l6 I N K 4 A , 
p l 8 I N K 4 C , p l 9 I N K 4 D , and p21 C I P 1 , p27 l a P 1 ) which nul-
lify the effect of the Cdk4-cyclin D l complex. Perhaps 
even more significantly, flavopiridol (35-36), a com-
pound which inhibits Cdk4, can restore growth to 
Cdk4-cyclin D l inhibited cells. 
It can be considered anomalous that Cdk4 should 
inhibit cell growth in yeast yet cause proliferation in 
mammalian cells. However, it must be remembered 
that the main target for Cdk4 in mamalian cells is pRb 
which is clearly absent in yeast cells. Furthermore, 
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unlike mammalian cells, yeast cells pass through con-
tinuous cycles of mitosis unless acted upon by a specific 
"anti-mitogenic signal" like the a-factor (37). There-
fore, Cdk4 activity in normally dividing yeast is prob-
ably inappropriate and may thus have catastrophic 
consequences. We suspect that expression of Cdk4 
alone gives rise to an active enzyme (Fig. 3C, lanes 3-4) 
I which may imply that there is a cyclin D-like molecule 
! in yeast (may be Cln3) that activates Cdk4 (16). Fur-
thermore coexpression of Cdk4 with cyclin Dl clearly 
! yields an active kinase (Fig. 3C, lanes 5-6). We expect 
\ that compounds which destroy this activity in yeast 
would permit growth again. These chemical entities 
would behave either like pl6 INK4A or would be novel 
i ATP-competitive inhibitors. Such compounds would 
not inhibit Cdk2 because, if it did so, it would inacti-
; vate yeast Cdc28 and would cause cell cycle arrest. 
| This leads us to believe that true mimics of pl6 INK4A, 
unable to inhibit Cdk2, would be identified using this 
simple cellular system. This new class of compounds 
would compensate for the functionally inactive 
VW" present in a variety of known tumors. 
It seems that this speculation can be aptly corrobo-
rated (Lionel Muller, Rajeev Soni and B.C.; unpub-
lished observations). An inhibitor has been identified 
using this system that also inhibits the recombinant 
enzyme produced in baculovirus infected insect cells 
(24). The compound does not inhibit Cdk2. The inhib-
itor also blocks growth of mammalian pRb-positive 
cancer cells in early Gl. The identified compound is 
currently undergoing further preclinical tests. These 
results definitely confirm that this simple yeast-based 
system devised for identifying Cdk4-specific inhibitors 
could be an invaluable addition to the very difficult 
protocols (i.e. baculovirus-produced recombinant en-
zyme assay or an ELISA, based on the interaction of 
Cdk4 and cyclin Dl) currently used for identifying 
Cdk4 antagonists in a high throughput format. 
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Abstract Progress in the cell cycle is governed by the activity of 
cyclin dependent kinases (Cdks). Unlike other Cdks, the CdkS 
catalytic subunit is found mostly in differentiated neurons. 
Interestingly, the only known protein that activates CdkS (i.e. 
p35) is expressed solely in the brain. It has been suggested that, 
besides its requirement in neuronal differentiation, Cdk5 activity 
is induced during myogenesis. However, it is not clear how this 
activity is regulated in the pathway that leads proliferative cells 
to differentiation. In order to find if there exists any CdkS-
interacting protein, the yeast two-hybrid system was used to 
screen a HeLa cDNA library. We have determined that a C-
terminal 172 amino acid domain of the DNA binding protein, 
dbpA, binds to CdkS. Biochemical analyses reveal that this 
fragment (dbpA(CA)) strongly inhibits p3S-activated Cdk5 
kinase. The protein also interacts with Cdk4 and inhibits the 
Cdk4/cyclin Dl enzyme. Surprisingly, dbpA(CA) does not bind 
Cdk2 in the two-hybrid assay nor does it inhibit Cdk2 activated 
by cyclin A. It could be that dbpA's ability to inhibit CdkS and 
Cdk4 reflects an apparent cross-talk between distinct signal 
transduction pathways controlled by dbpA on the one hand and 
CdkS or Cdk4 on the other. 
© 1999 Federation of European Biochemical Societies. 
Key words: Cyclin dependant kinase 5; 
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1. Introduction 
Cyclin dependent kinases (Cdks) are a class of serine/threo-
nine protein kinases which regulate important transitions in 
the cell cycle. Cdk5 was initially identified on the basis of its 
sequence similarity to the family of cyclin dependent kinases 
[1,2]. However, Cdk5 is thought be a cyclin dependent kinase 
with neuron-specific function only, since its catalytic subunit 
is predominantly expressed in post-mitotic cells of the nervous 
system, cells which have permanently exited the cell cycle [2,3]. 
Moreover, the protein p35 which activates the Cdk5 enzyme is 
exclusively expressed in the central nervous system (CNS) 
[3,4]. 
Nevertheless, the catalytic subunit of Cdk5 is widely ex-
pressed at basal levels, in both cycling and non-cycling cells, 
in most human tissues [2,3]. Interestingly, cyclins D and E, 
activator molecules which regulate Cdk activity in proliferat-
"Corresponding author. Fax: (41) (61) 696 38 35. 
E-mail: bob.chaudhuri@pharma.novartis.com 
Abbreviations: P-gal, fj-galactosidase; Cdk, human cyclin dependent 
kinase; CSD, cold shock domain; DBD, DNA binding domain; GSH-
Sepharose, glutathione Sepharose; GST, glutathione 5-transferase; 
p35, 35 kDa protein which activates Cdk5; PCR, polymerase chain 
reaction; pRb. human retinoblastoma protein; RT. room temperature; 
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ing cells, bind Cdk5 ([5,6]; our own observations). It could be 
argued that Cdk5 bound to cyclin D or cyclin E phospho-
rylates substrates which are not yet known. 
The 35 kDa p35 protein, the only known activator of Cdk5, 
which was originally isolated as a smaller 25 kDa proteolytic 
product, bears no significant homology to the family of cy-
clins [3,4]. As a Cdk activator, p35 is unique since it has no 
influence on the activity of other Cdks [2,3]. 
Histone HI and the retinoblastoma protein (pRb) are sub-
strates that are frequently used to confirm in vitro activity of 
the Cdks. Heterodimeric Cdk5/p35 and Cdk5/p25 complexes 
can phosphorylate both histone HI and pRb [3,7]. Activated 
Cdk5 also phosphorylates its activating partner p35 [8]. Be-
sides, Cdk5 is known to phosphorylate in vitro a number of 
neuron-specific cytoskeletal proteins that includes the neuro-
filament proteins NF-M, NF-H, the microtubule associated 
protein tau and the actin binding protein caldesmon [2,3], 
Phosphorylation of cytoskeletal proteins is thought to play 
an important role in the polymerization and assembly of cy-
toskeletal elements which, in turn, may affect growth of neu-
rites. Indeed, Cdk5 activity has been demonstrated to play a 
key role in neurite outgrowth [9] and neuronal migration dur-
ing differentiation of neurons [10]. Recently, Cdk5 has been 
shown to participate in the regulation of myogenesis in the 
early embryo [11,12]. These observations may provide new 
insight into the possible function of Cdk5 during differentia-
tion. 
Cdk5 is known to phosphorylate neurofilament proteins 
exclusively at sites phosphorylated in Lewy body pathologies, 
i.e. diffuse Lewy body disease (dementia), Parkinson's disease 
[13,14] and amyotrophic lateral sclerosis [2,15], and tau pro-
tein at sites phosphorylated in Alzheimer's disease [2,3,16,17]. 
Moreover, it has been reported that the kinase activity of 
Cdk5 correlates with the extent of differentiation of neuronal 
cells [2,3,18] and colocalizes with neurofilament tracts in the 
axons of neuronal cells in culture. 
It is therefore possible that Cdk5 activity is tightly regulated 
in pathways that lead from cell proliferation towards differ-
entiation. Hence, we have inquired whether if there are any 
proteins that could be involved in the regulation of Cdk5 (i.e. 
may activate or inhibit the kinase) in cycling cells. With this in 
mind, a cDNA library, constructed from total RNA obtained 
from HeLa cells, was screened using the yeast two-hybrid 
system. Amongst other proteins (unpublished observations), 
we find that a C-terminal fragment of the DNA binding pro-
tein dbpA (in this communication referred to as dbpA(CA)) 
interacts with the bait protein Cdk5, in the two-hybrid assay. 
Conversely, when dbpA(CA) was used as bait, the interaction 
between dbpA(CA) and Cdk5 was equally efficient. The val-
idity of these interactions was corroborated using the Esche-
richia colt expressed GST-dbpA(CA) fusion protein. The pu-
rified protein precipitates not only in vitro transcribed/ 
translated Cdk5 but also the protein which is expressed in 
0014-5793/99520.00 © 1999 Federation of European Biochemical Societies. All rights reserved. 
PII: S 0 0 1 4 - 5 7 9 3 ( 9 9 ) 0 0 2 4 8 - 3 
65 
344 M. Moorthamer et aLIFEBS Letters 446 (1999) 343-350 
COS-1 cells. Similar experiments reveal that dbpA(CA) can 
bind Cdk4 as well, but not Cdk2 or Cdkl. Surprisingly, 
dbpA(CA) appears to be an efficient inhibitor of Cdk5/p35 
and Cdk4/cyclin Dl kinase activities but fails to inhibit 
Cdk2/cyclin A. 
2. Materials and methods 
2.1. Plasmid constructs for yeast expression 
EcoRl-BgUl PCR fragments of human Cdkl, Cdk2 and Cdk4 and 
EcoRl-Sall PCR fragments of bovine Cdk5 and human p35 were 
cloned in the pLEX-a vector [19] downstream of the LEX-a DNA 
binding domain (DBD). Expression in yeast from pLEX-a plasmids 
is controlled by the constitutive alcohol dehydrogenase promoter 
(ADH1), and the plasmid encodes the TRP1 and ADE2 genes for 
stable propagation in yeast. Furthermore, the EcoRl-Sall fragments 
of Cdk5 and p35 were also cloned in the vector pGAD424 (Clontech) 
in such a way that they lie directly downstream of the GAL4 tran-
scriptional activation domain (TAD). Expression from the pGAD424 
plasmid, which encodes LEU2 as a marker gene, is also driven by the 
ADH1 promoter. 
A BamHl-Sall PCR fragment of dbpA(CA) (the isolated HeLa 
cDNA) was cloned in pLEX-a for expression in yeast. Furthermore, 
a BamHI-Xhol fragment of the dbpA(CA) was cloned in pACT2 
(Clontech) whereas a BamHl-Notl fragment was cloned in pVP16 
[19]. The pACT2 plasmid encodes GAL4TAD whereas the pVPI6 plas-
mid encodes VP16TAD- The TADs in both plasmids are under the 
control of the constitutive ADH1 promoter. The plasmids encode 
LEU2 for selection in yeast. The dbpA(CA) fragment has been cloned 
directly downstream of GALAJAD and VP16TAD-
Plasmids pLEX-a/lamin and pLEX-a/MyoD were gifts from S.M. 
Hollenberg [19]. 
2.2. Plasmid constructs for E. coli expression 
A BamHl-Sall fragment of the dbpA(CA) cDNA was cloned in (a) 
pGEX4T-l (Amersham-Pharmacia Biotech) for expression of a GST-
dbpA(CA) fusion protein and (b) pQE32 (Qiagen) for expression of a 
His-tagged dbpA(CA) protein. 
2.3. Plasmid constructs for COS-I cell expression and in vitro 
transcription/translation 
A BamHl-Sall fragment of Cdk5 was cloned in pcDNA3.1— (In-
vitrogen). The EcoRl-Xhol fragments of Cdkl, Cdk2 and Cdk4 were 
cloned into pcDNA3.1+ (Invitrogen). The plasmid pcMV-p-gal was 
obtained from H.-J. Keller (Novartis). 
2.4. Plasmid constructs for insect cell expression 
A BamHl-Sall fragment of Cdk5 was cloned in pFastBacl (Gibco 
BRL) for construction of a recombinant baculovirus. The pFastBacl 
vector has a baculovirus-specific promoter from Autographa califor-
nica nuclear polyhidrosis virus (AcNPV) for heterologous expression 
of proteins in insect cells. Similarly, BamHl-EcoRl fragments of hu-
man Cdkl and Cdk4 were cloned in pFastBacl for construction of 
recombinant baculoviruses. 
EcoRl-Sall fragments of human p35, human cyclin A, murine cyclin 
D2 and murine cyclin D3 were cloned in pFastBacl downstream of a 
BgRl-EcoRl fragment of GST (PCR fragment from pGEX4T-l; 
Amersham-Pharmacia Biotech) for construction of recombinant ba-
culoviruses. Similarly, an EcoRl-Xhol fragment of human cyclin Dl 
and a BamHl-Sall fragment of dbpA(CA) were cloned as GST fusions 
in pFastBacl. 
2.5. Yeast strains and media 
The Saccharomyces cerevisiae strains L40 (Mata, his3>A200, trpl-
901, /ew2-3,l 12, adel, /ys2-80Iam, URA3: :(lexAop)g-\acZ, 
LYS:;(lexAop)4-hisl) and AMR70 (Mata, his3A100, trpl-901, leul-
3,112, adel, />>52-801am, URA3::(lexAop)8-lacZ) [19] were used for 
yeast transformation and for mating assays. In order to perform the 
yeast two-hybrid screen, L40 was transformed sequentially with (a) 
pLEX-a/cdk5 and (b) a human HeLa S3 Matchmaker cDNA library 
cloned unidirectionally into the EcoRl and Xhol sites of pGADGH 
(Clontech, HL4000AA). The pGADGH vector contains the GAL4TAD 
under the control of the ADH1 promoter and also encodes LEU2 as a 
marker gene. In order to mate a L40 strain that was cured of bait 
plasmid but still contains the prey plasmid (from the cDNA library), 
transformants of AMR70 (bearing plasmids pLEX-a/cdk5 or pLEX-a/ 
lamin) were used. Both L40 and AMR70 contain the lacZ reporter 
gene linked to the lexA operon. Besides, L40 also contains the HIS3 
reporter gene downstream of the lexA operon. Untransformed yeast 
strains were grown in YPAD whereas transformed yeast strains were 
grown in minimal medium that allow maintenance of plasmids in a 
particular strain. 
The S. cerevisiae strain L40 was also used for transformation of 
pLEX-a plasmids that encode Cdkl, Cdk2, Cdk4, Cdk5, p35, 
dbpA(CA), lamin or MyoD. A pACT2 or pVP16 plasmid that encodes 
dbpA(CA) or pGAD424 plasmids that encode CdkS and p35 were used 
to perform yeast two-hybrid assays on selected transformants. 
2.6. Yeast two-hybrid screen 
A pLEX-a/cdk5 plasmid-bearing strain of L40 was transformed 
with the HeLa cDNA library (Clontech) and transformants were se-
lected exactly as described earlier [19]. His+ colonies were lysed in 
liquid nitrogen and assayed for |5-galactosidase activity on filters. 
Only those colonies, which do not express p-galactosidase after loss 
of the pLEX-a/cdk5 bait plasmid, were selected for further analysis. 
The plasmids pLEX-a/cdk5 or pLEX-a/lamin were reintroduced into 
L40 (a) by direct transformation of L40 strains that already contain 
the prey plasmid or (b) by mating prey plasmid-containing L40 strains 
with AMR70 transformants of pLEX-a/cdk5 or pLEX-a/lamin. Later, 
the prey plasmids were isolated by transforming total yeast DNA into 
HB10I and by selecting for leucine prototrophy on minimal medium 
plates (manufacturer's protocol; Clontech). Plasmids, that contain 
defined inserts, were then retransformed into L40 strains that already 
harbor pLEX-a/cdk5 or pLex-a/lamin. Plasmids, which express pro-
teins that do not bind lamin but reproducibly interact with Cdk5, 
were sequenced using an automated DNA sequencer (LiCor). Inserts 
were identified by comparing translated DNA sequences with the 
SWISS PROT database. 
2.7. Pull-down assay with [35S]methionine-labeled Cdkl, Cdk2, Cdk4 
and Cdk5 
The pcDNA3.1 plasmids (1 ug) carrying the genes Cdkl, Cdk2, 
Cdk4 or Cdk5 were linearized uniquely at the 3 -end of the gene 
inserts. The linearized plasmids were used as templates for in vitro 
transcription/translation. The Cdk proteins were radioactively labeled 
with [3GS]methionine (20 uCi of an in vivo cell labeling grade; Amer-
sham-Pharmacia Biotech). The transcription and translation was per-
formed using the TNT-T7 in vitro transcription/translation kit (Prom-
ega). 
Bacterially expressed glutathione 5-transferase (GST) and GST-
dbpA(CA) fusion protein were bound to glutathione Sepharose 4B 
(Amersham-Pharmacia Biotech) by incubating protein and beads at 
RT for I h. After four washing steps with 10 volumes of ice-cold PBS, 
the beads were resuspended in 200 \i\ 1% w/v BSA-PBS solution and 
kept on ice. 5 u1 of the [35S]methionine-labeled Cdk proteins (from 
100 (4.1 of an in vitro transcribed/translated product) diluted in 200 ul 
1% w/v BSA-PBS solution, which contained 4 ul of a 100X solution 
of universal protease inhibitors (tablet dissolved in redistilled H2O; 
Boehringer Mannheim), was kept on ice for 15 min. GSH-Sepharose 
4B beads, bound to GST or GST-dbpA(CA), were incubated with 
labeled Cdks at 4°C for 2 h with gentle mixing. The beads were 
washed three times with 1 ml of bead-binding buffer (50 mM potas-
sium phosphate pH 7.5, 150 mM KCl, 1 mM MgCl2, 10% v/v glyc-
erol, 1% v/v Triton X-100) containing universal protease inhibitors 
(Boehringer Mannheim). The pelleted bead-bound protein complexes 
were denatured by boiling in Laemmli sample buffer (4% w/v SDS, 0.1 
M Tris, 4 mM EDTA, 20% v/v glycerol, 33% w/v bromophenol blue) 
containing 50 mM DTT, and were analyzed by 12.5% SDS-PAGE. 
The gels were fixed (10% v/v glacial acetic acid, 30% v/v methanol 
solution) for 10 min, and the signal was enhanced by soaking the gel 
in EN:iHANCE (NEN) for 1 h at RT. The dried gel was exposed to 
Kodak X-OMAT AR film. 
2.8. Transfection of pcDNA 3.1 +tcdk2, pcDNA 3.1 +Icdk4 and pcDNA 
3.1-lcdk5 in COS-1 cells and precipitation of COS-1 expressed 
Cdks by GST-dbpA(CA) 
COS-1 cells in six-well plates, grown in Dulbecco's modified Eagle's 
medium (DMEM, Gibco BRL) that contained 10% v/v fetal bovine 
serum (FBS, Gibco BRL), were transfected with 2 ug of pcDNA 3.1 
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plasmids that carry Cdk2, Cdk4 or Cdk5, using calcium phosphate. In 
order to control transformation efficiency, pcMV-fi-gal was used. 
Harvested cells ( ~ 5 x 105) were washed once with PBS and then 
lysed in 1 ml of hypotonic lysis buffer (10 mM Tris-HCl pH 7.4, 10 
mM NaCl, 3 mM MgCI2, 0.5% v/v Nonidet P-40) that contained 
1 mM DTT and universal protease inhibitors (Boehringer Mann-
heim). Total protein in cell lysates was measured by the Bradford 
assay (Bio-Rad) and was stored at —70°C before use. 
400 ul of a COS-1 cell lysate was first preincubated for 2 h at 4°C 
with 30 ul of Sepharose 4B (to remove unspecific binding of proteins 
to beads). This was followed by incubation with 30 u.1 of GSH-
Sepharose 4B that was already bound to bacterially expressed GST-
dbpA(CA). Pull-down of the Cdks in COS-1 cell lysates was per-
formed as described above for the [35S]methionine-labeled Cdks. 
The pelleted bead-bound protein complexes were denatured by boiling 
in Laemmli sample buffer and were analyzed by Western blotting. The 
blots were probed with polyclonal antibodies raised against Cdk2 and 
N-terminal fragments of Cdk4 and Cdk5 and were detected by ECL 
(Amersham-Pharmacia Biotech). 
2.9. Northern blotting 
25 ng of pcDNA3.1+ encoding the dbpA(CA) gene was used to 
make a labeled probe for Northern blotting (1.9X 10° dpm/ug) using 
the rediprime DNA labeling system (Amersham-Pharmacia Biotech, 
RPN1633) with Redivue fl2P]dCTP (specific activity = 3000 Ci/mmol; 
Amersham-Pharmacia Biotech). The probe was used to hybridize a 
human multiple tissue Northern blot according to the manufacturer's 
protocol (Clontech). The blot was quantified using a phosphorimager 
(Molecular Devices). 
2.10. Expression of baculoviruses 
Recombinant baculoviruses encoding different genes were con-
structed using protocols provided by the manufacturer (Gibco 
BRL). The viruses were harvested and amplified until a desired titer 
was reached (viz. 1 X 10s pfu/ml). 
2X 107 Sf9 cells were used to co-infect baculoviruses carrying Cdk5, 
Cdk4 or Cdk2 with GST-p35, GST-cyclin A, GST-cyclin Dl, GST-
cyclin D2 or GST-cyclin D3 in 25 ml of SF900 II SFM medium 
(Gibco BRL). Triple infections were performed with the above men-
tioned viral combinations and baculoviruses carrying GST-dbpA(CA). 
After 72 h, cells were harvested and lysed by sonication in NETN 
buffer (20 mM Tris-HCl pH 8.0, 100 mM NaCl, 1 mM EDTA, 05% 
v/v NP-40, 5 mM NaF, 30 mM p-NPP, 1 mM PMSF, 1 ug/ml anti-
pain) that contained universal protease inhibitors (Boehringer Mann-
heim). HBT buffer (50 mM HEPES pH 7.6, 150 mM NaCl, 1 mM 
EDTA, 2.5 mM EGTA, 0.1% v/v Tween 20, 1 mM DTT, 5 mM NaF, 
30 mM p-NPP, 25 mM p-glycerolphosphate, 1 mM PMSF, 1 ug/ml 
antipain) was used to lyse cells that were co-infected with GST-cyclin 
Dl, D2 or D3 viruses. Heterodimeric enzyme complexes were isolated 
by binding to 100 ul of GSH-Sepharose 4B, overnight at 4°C. The 
beads were washed seven times with ice-cold NETN buffer (or HBT 
buffer) and three times with ice-cold kinase buffer (20 mM Tris-HCl 
pH 7.5, 10 mM MgCL). The beads were resuspended in 100 ul kinase 
buffer and kept on ice before a kinase assay was performed. 
2.11. Kinase assays 
Phosphorylation of 0.1 ug histone HI (type III-S: from calf thy-
mus, Sigma H-5505) or 0.25 ug GST-RM52 (i.e. C-terminal 152 ami-
no acid residues of pRb covalently linked to GST; Santa Cruz Bio-
technology) was performed in kinase buffer for 40 min at 30°C using 
2 ul of beads, 10 uM ATP and 3 uCi [>:"P]ATP (specific activ-
ity =3000 Ci/mmol; Amersham-Pharmacia Biotech) in a total volume 
of 10 ul. The reactions were boiled in Laemmli sample buffer and were 
analyzed by 12.5% SDS-PAGE. The gel was fixed and the phospho-
rylation was quantified using a phosphorimager (Molecular Devices). 
3. Results 
3.1. A C-terminal fragment of dbpA binds to Cdk5 in a yeast 
two-hybrid screen 
Cdk5 has been used as a bait in the yeast two-hybrid system 
to screen for proteins that may interact with Cdk5. Since 
Cdk5 is expressed hi both cycling and non-cycling cells, we 
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thought it would be interesting to know if there are any Cdk5 
binding proteins in cycling cells. Hence, a HeLa cDNA library 
in the yeast vector pGADGH was transformed into the yeast 
strain L40 [19] that already contained the bait plasmid pLEX-
a/cdk5 (which encodes LexaDBD-Cdk5). Genes encoding inter-
acting proteins were identified by selecting for His+ proto-
trophs and subsequently through induction of (S-galactosidase 
(P-gal) activity. Colonies that were His+ and blue were con-
sidered positive and were used for further analysis (results not 
shown). It was later found that one such positive yeast colony 
harbored a cDNA library plasmid (i.e. the prey plasmid) en-
coding GAL4TAD fused to a C-terminal fragment of the hu-
man gene for the DNA binding protein, dbpA (in this com-
munication referred to as dbpA(CA); Fig. 2A). 
In order to eliminate the possibility that an identified pos-
itive colony was an artifact of the two-hybrid system (fre-
quently referred to as 'false positives') [20], the yeast strain 
was cured of the bait plasmid pLEX-a/cdk5 by growing the 
strain in a non-selective medium (50 generations of growth in 
minimal medium that contained tryptophan and adenine but 
lacked leucine; the prey plasmid contains LEU2). The result-
ing L40 strain (MATa) that contains the prey plasmid, 
pGADGH/dbpA(CA), was mated with strains of AMR70 
(MATa) that had been transformed either with pLEX-a/ 
cdk5 or with pLEX-a/lamin. [J-Gal assays performed on 
mated diploid strains showed that dbpA(CA) specifically in-
teracts with Cdk5 but not with lamin (Fig. 1A). 
At this stage, the pGADGH/dbpA(CA) plasmid was iso-
lated from yeast (via transformation of total yeast DNA in 
E. colt; see Section 2). The insert was sequenced and it re-
vealed that the cloned gene encoded 172 amino acids of the C-
terminal fragment of human dbpA (Fig. 2A). The dbpA(CA) 
cDNA was amplified by PCR from the pGADGH plasmid 
and was subcloned into pACT2, another yeast vector often 
used for two-hybrid assays. The plasmid pACT2/dbpA(CA) 
(which encodes GAL4TAD-dbpA(CA) fusion protein) was 
transformed into the strain L40 that already contained 
pLEX-a/cdk5, pLEX-a/lamin, pLEX-a/MyoD or pLEX-a/ 
p35 (all plasmids code for LexaDBD fusion proteins). The re-
sults reiterate that, at least in the two-hybrid system, Cdk5 
not only binds p35 (Cdk5's known activator) but also inter-
acts with dbpA(CA) (Fig. IB, left and right panels). It was 
also found that interaction of dbpA(CA) with Cdk5 does not 
depend on the specific TAD to which dbpA(CA) is linked. 
This was supported by the observation that a V P 1 6 T A D -
dbpA(CA) fusion protein binds as well as GAL4TAD-dbpA(CA) 
to LexaDBD-Cdk5, in the two-hybrid assay (data not shown). 
Furthermore, the dbpA(CA) was cloned in pLEX-a and cdk5 
in pGAD424. It was seen that interchanging the two domains, 
TAD and DBD, did not affect the interaction between 
dbpA(CA) and Cdk5 (i.e. Lexara)D-dbpA(CA) fusion protein 
bound strongly to GAL4-,,\D-Cdk5; Fig. 1C). All these obser-
vations prove beyond doubt that neither a TAD nor a DBD 
has any influence on the Cdk5-dbpA(CA) interaction. 
We also wanted to find out if Cdk5 was the only Cdk to 
which dbpA(CA) has affinity. In order to test this, yeast strain 
L40 was first transformed with pLEX-a/cdk5, pLEX-a/cdk4, 
pLEX-a/cdk2 or pLEX-a/cdkl. The plasmid pACT2/dbpA(CA) 
(which encodes GAL4TAD-dbpA(CA)) was then transformed 
into L40 strains that already had the ability to express Lexa-
Cdk5, Lexa-Cdk4, Lexa-Cdk2 or Lexa-Cdkl fusion proteins. 
A |3-gal assay (Fig. ID) depicts that, in the yeast-two-hybrid 
<A) 
Mating 
Assay 
GAU™-
dbpA(CA) 
GAL^.n-dbpAICA) 
M. Moorthamer et al.lFEBS Letters 446 (1999) 343-3S0 
GAIA.O-P35 (B) 
Transformation 
(C) 
Transformation 
after 
Interchanging 
Domains 
(D) 
Transformation 
Fig. 1. In a yeast two-hybrid assay the C-terminal fragment of DNA binding protein dbpA binds to Cdk5 and Cdk4. Interactions were moni-
tored by analyzing six individual colonies by colorimetric fj-galactosidase assays. A: After curing the bait plasmid. a L40 strain that retains the 
prey plasmid (which encodes GAL4i
 An-dbpA(CA) fusion protein) was mated with strain AMR70 that had already been transformed with 
pLEX-a/lamin or pLEX-a/Cdk5 (these plasmids express Lex-a-lamin and Lex-a-Cdk5 fusion proteins, respectively). The results show that 
dbpA(CA) interacts with Cdk5 but not with the unspecific protein, lamin. B: Left panel, plasmid pACT2/dbpA(CA) (which expresses 
GAL4TAD-dbpA(CA)) was transformed in strain L40 that already contains pLEX-a/Iamin, pLEX-a/MyoD. pLEX-a/Cdk5 or pLEX-a/p35. The 
results show that dbpA(CA) interacts specifically with Cdk5. Right panel, plasmid pGAD424/p35 (expressing GAL4TAirp35) was transformed 
in the same L40 yeast strains (see left panel), as a control. C: Plasmids pGAD424/Cdk5 (left panel) and pGAD424/p35 (right panel, as negative 
control) were transformed into L40 strains that already harbor pLEX-a/dbpA(CA) or pLEX-a/p35. Results show that Cdk5 and dbpA(CA) can 
still interact with each other even after interchanging the two domains (GAL4,An and Lex-aoRo) which has to be linked to two putative inter-
acting proteins, in the two-hybrid assay. D: Plasmids pACT2/dbpA(CA) (left panel) and pACT2/p35 (right panel, as control), which express 
GAL4TAD-dbpA(CA) and GAL4TAo-p35 respectively, were transformed in L40 strains that already harbor pLEX-a/Cdk5, pLEX-a/Cdk4, 
pLEX-a/Cdk2 or pLEX-a/Cdkl. Results show that dbpA(CA) interacts specifically with Cdk5 and Cdk4. 
system, dbpA(CA) can interact with Cdk5 and Cdk4 but not 
with Cdk2 and Cdkl. 
3.2. The dbpA(CA) protein precipitates <0S-labeled CdkS and 
Cdk4 
In order to confirm some of the yeast two-hybrid data, a set 
of in vitro pull-down experiments were employed. We found 
that bacterially expressed GST-dbpA(CA) fusion protein (Fig. 
2B) was able to pull down [''SJmethionine-labeled Cdk5 and 
Cdk4 but not Cdk2 and Cdkl (all proteins were transcribed/ 
translated in vitro). We were sure that the GST moiety in 
GST-dbpA(CA) did not play a role in the precipitation of 
Cdk5 or Cdk4 since the GST protein alone is not able to 
pull down Cdk5 (Fig. 2C). 
3.3. The dbpA(CA) protein precipitates Cdk5 and Cdk4 
expressed in COS-1 cells 
As an alternative to the in vitro transcription/translation 
procedure to obtain desired proteins, Cdk5, Cdk4 and Cdk2 
were expressed in COS-1 cells. Lysates from transfectants 
were incubated with the E. coli expressed GST-dbpA(CA) fu-
sion protein. The bound proteins were detected by Western 
blotting, using antibodies specific to Cdk5, Cdk4 or Cdk2. 
Similar to our earlier observations with labeled proteins, we 
observed that GST-dbpA(CA) was able to bind COS-1-ex-
pressed Cdk5 and Cdk4 whereas it was unable to pull-down 
Cdk2 (Fig. 2D). 
3.4. Tissue specific expression of dbpA 
The dbpA(CA) cDNA was labeled with 32P and a human 
multiple tissue Northern blot was probed. The dbpA mRNA 
was relatively abundant in skeletal muscle tissue and the heart 
(Fig. 3), corroborating earlier findings of Kudo et al. [21]. 
Since Cdk5 has been demonstrated to play a role in muscle 
differentiation [11,12] we were interested to find out what 
effect dbpA(CA) would have on the Cdk5 kinase. 
3.5. Inhibition of the CdkS kinase by bacterially expressed 
GST-dbpA(CA) and His-dbpA(CA) 
The Cdk5/GST-p35 heterodimeric complex was expressed 
in insect cells using the baculovirus expression system. The 
enzyme was purified by binding to GSH-Sepharose 4B. The 
bead-bound enzyme was tested for activity (see Section 2) 
using histone HI as a substrate. Fig. 4A (lane 1) portrays 
the phosphorylation of histone HI by GST-p35 activated 
Cdk5 kinase. Kinase assays performed on GST-dbpA(CA) 
demonstrate that dbpA(CA) is not phosphorylated by Cdk5 
and therefore cannot be a Cdk5 substrate (Fig. 4A, lane 3). 
We then asked if dbpA(CA) could be an inhibitor of Cdk5. 
Fig. 4B shows a dose-dependent inhibition of Cdk5 by GST-
dbpA(CA). It should be noted that, whereas 10 ug of GST did 
not have any effect on the kinase (Fig. 4B, lane 8), 0.4 ug of 
GST-dbpA(CA) distinctly inhibited the complex ( > 50%; Fig. 
4B, lane 5). Staurosporine (CGP39360. Novartis), which 
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B: Coomassie stain of 0.1 ug E. coli and 1 ug insect cell (Sf9) expressed GST-dbpA(CA) and Western blot of 0.1 u,g E. coli and 0.1 u.g insect 
cell (Sf9) expressed GST-dbpA(CA) using a monoclonal antibody against GST (Clontech). C: GST-dbpA(CA) (referred to as (CA)) binds to 
35S-labeled Cdk4 and Cdk5 and not to 35S-labeled Cdkl and Cdk2. Lane 1, 10% of the 35S-labeled Cdkl input used for the pull-down assay 
with (CA) (as in lane 2); lane 3, 10% of the 35S-labeled Cdk2 input used for the pull-down assay with (CA) (as in lane 4); lane 5, 10%> of the 
35S-labeled Cdk4 input used for the pull-down assay with (CA) (as in lane 6); lane 7, 10% of the ;!5S-labeled Cdk5 input used for the pull-
down assay with (CA) (as in lane 8) and the pull-down assay with GST alone (as in lane 9). D: GST-dbpA (CA) binds to Cdk4 and Cdk5 and 
not to Cdk2 overexpressed in COS-1 cells. Each lane shows a Western blot of proteins fractionated on a 10%o SDS-polyacrylamide gel. Polyclo-
nal antibodies raised against Cdk2 and the N-termini of Cdk4 and Cdk5 were used to detect the respective proteins. Lanes 1, 3 and 5, 15 ul of 
lysates from COS-1 cells expressing Cdk2, Cdk4 or Cdk5. Lanes 2, 4 and 6, 400 ul of same cell lysates, used in pull-down assays with GST-
dbpA(CA) (referred to as (CA)). 
strongly inhibits most Cdks including Cdk5, was used as a 
control inhibitor [22]. 
It can be argued that the relatively large GST moiety causes 
a steric hindrance in the fusion protein so that it interferes 
with dbpA(CA)'s ability to act as a substrate for Cdk5 or that 
the presence of GST causes an artifactual inhibition of Cdk5. 
Therefore, dbpA(CA) was expressed in £. coli as a His-tagged 
protein (six consecutive histidines attached to the protein at its 
N-terminus, as in pQE32; see Section 2). His-dbpA(CA) was 
used to probe if it is a substrate or an inhibitor of the Cdk5/ 
p35 kinase. Like GST-dbpA(CA), His-dbpA(CA) is not phos-
phorylated by Cdk5/GST-p35 (Fig. 4D, right panel, lane 4). 
Again similar to GST-dbpA(CA), His-dbpA(CA) inhibits the 
Cdk5/GST-p35 complex in a dose-dependent manner. His-
dbpA(CA) completely abolishes the Cdk5-mediated phospho-
rylation of histone HI (Fig. 4C, left panel). The His-tagged 
protein can also completely inhibit the phosphorylation of 
GST-RM52 by the Cdk5/GST-p35 complex (Fig. 4C, right 
panel, lane 4 and 5). Kinase assays performed with Cdk5/ 
GST-p35 enzyme eluted from the GSH-Sepharose 4B beads 
gave identical results (results not shown). 
3.6. Activation of Cdk5 with D-lype cyclins 
Since D-type cyclins are reported to bind Cdk5 [5], we 
wanted to find out if cyclin D formed a complex with Cdk5 
when both proteins are expressed in insect cells, and if it did, 
whether the complex formed an active kinase by phosphoryl-
ating either histone HI or GST-Rbl52. One could speculate 
that an active cyclin D/Cdk5 enzyme, with no known cellular 
substrate, may phosphorylate the Cdk5 binding protein, 
dbpA(CA). Hence, Sf9 insect cells were co-infected with bacu-
loviruses encoding Cdk5 and GST-cyclin Dl , GST-cyclin D2 
or GST-cyclin D3. The cyclin D-bound Cdk5 proteins ob-
tained from insect cells were precipitated with GSH-Sepharose 
4B and the bead-bound complexes (as confirmed by Western 
blotting using antibodies specific for Cdk5 and D-type cy-
clins; results not shown) were used directly for kinase assays. 
We observed that neither GST-cyclin Dl nor GST-cyclin D3 
can activate Cdk5 (results not shown). Surprisingly, like cyclin 
D2-activated Cdk2 (Fig. 4D, left panel, lane 2) and Cdk4 
(Fig. 4D, left panel, lane 4), kinases that are known to phos-
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Fig, 3. Tissue-specific expression of dbpA. Human multiple tissue 
Northern blot (Clontech) hybridized with dbpA(CA). 
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sponse to His-dbpA(CA) in the inhibition of Cdk5-mediated phosphorylation of histone HI (0.1 ug). Lane 1, Cdk5/GST-p35+no substrate; 
lane 2, Cdk5/GST-p35+substrate; lane 3, Cdk5/GST-p35+substrate+0.5 ug His-dbpA(CA); lane 4, Cdk5/GST-p35+substrate+l ug His-
dbpA(CA); lane 5, Cdk5/GST-p35+substrate+3 ug His-dbpA(CA); lane 6, Cdk5/GST-p35+substrate+6 ug His-dbpA(CA). Right panel, dose re-
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GST-p35+no substrate; lane 2, Cdk5/GST-p35 incubated with 1 ug histone HI; lane 3, Cdk5/GST-p35 kinase incubated with 0.25 ug GST-
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5 jig His-dbpA(CA). 
phorylate pRb, cyclin D2-activated Cdk5 also has the ability 
to phosphorylate GST-Rbl52 (Fig. 4D, left panel, lane 6). 
However, His-dbpA(CA) is not phosphorylated by cyclin D2 
and p35 activated Cdk5 (Fig. 4D, right panel, lanes 4 and 8). 
GST-cyclin A is not affected at all (Fig. 5B, compare lanes 1 
and 2). This seems to corroborate our earlier two-hybrid data 
which indicated that dbpA(CA) does not interact with Cdk2 
but binds Cdk4 and Cdk5. 
3.7. Inhibition of the Cdk4 kinase by bacterially expressed 
His-dbpA(CA) 
Since dbpA(CA) interacts not only with Cdk5 but also with 
Cdk4 in both two-hybrid and in vitro binding assays, the 
effect of His-dbpA(CA) on active Cdk4/cyclin Dl complex 
was investigated. We see that the His-tagged protein com-
pletely inhibits Cdk4/GST-cyclin Dl mediated phosphoryla-
tion of GST-RM52 (Fig. 5A, lane 4). Furthermore, dbpA(CA) 
is definitely not a substrate for the Cdk4/GST-cyclin Dl en-
zyme (Fig. 5A, lane 5). 
3.8. Specificity of inhibition of the CdkS kinase compared to the 
Cdk2 kinase 
Although His-dbpA(CA) inhibits the Cdk5/GST-p35 medi-
ated phosphorylation of histone H1 (there is at least a 20-fold 
decrease in activity; compare lanes 3 and 4 in Fig. 5B), it 
seems that phosphorylation of the same substrate by Cdk2/ 
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3.9. Triple infections with GST-DbpA(CA) baculoviruses 
do not yield active Cdk5 or Cdk4 kinases 
Sf9 insect cells were infected with three baculoviruses en-
coding (a) Cdk5, GST-p35 and GST-dbpA(CA), (b) Cdk4, 
GST-cyclin Dl and GST-dbpA(CA), or (c) Cdk2, GST-cyclin 
A and GST-dbpA(CA). Proteins were precipitated using GSH-
Sepharose. Western blot analysis showed that all three pro-
teins were expressed in each precipitate. Kinase assays per-
formed on the GSH-Sepharose purified enzymes (according 
to Section 2) yielded inactive kinases for Cdk5 and Cdk4 
whereas the Cdk2 kinase was still active (results not shown). 
3.10. Inhibition of the CdkS and Cdk4 kinase by insect cell 
expressed GST-DbpA(CA) 
GST-dbpA(CA) was purified from Sf9 insect cells using the 
baculovirus expression system (Fig. 2B) and used in Cdk5/ 
GST-p35, Cdk4/GST-cyclin Dl and Cdk2/GST-cyclin A kin-
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Fig. 5. His-dbpA(CA) is not a substrate for Cdk4/GST-cyclin Dl 
but instead inhibits the kinase. Comparison of the inhibition of 
Cdk5/GST-p35 and Cdk2/GST-cyclin A kinases by His-dbpA(CA). 
A: His-dbpA(CA) inhibits Cdk4/GST-cyclin Dl-mediated phospho-
rylation of GST-RM52 (0.5 ug) and is not phosphorylated by the 
kinase. Lane 1, Cdk4/GST-cyclin Dl+no substrate; lane 2, Cdk4/ 
GST-cyclin Dl+substrate (the lower band is a breakdown product 
of GST-RM52); lane 3, Cdk4/GST-cyclin Dl+substrate+1 ug His-
dbpA(CA); lane 4, Cdk4/GST-cyclin D1+substrate+6 ug His-
dbpA(CA); lane 5, Cdk4/GST-cyclin Dl+6 ug His-dbpA(CA). B: 
Comparison of inhibition of the Cdk5/GST-p35 and Cdk2/GST-cy-
clin A-mediated phosphorylation of histone HI (1 ug) by His-
dbpA(CA). Lane 1, Cdk2/GST-cyclin A+substrate; lane 2, Cdk2/ 
GST-cyclin A+substrate+0.5 ug His-dbpA(CA); lane 3, Cdk5/GST-
p35+substrate; lane 4, Cdk5/GST-p35+substrate+0.5 u.g His-
dbpA(CA); lane 5, Cdk5/GST-p35+substrate+6 ug His-FKBP12 (an 
unspecific protein). The results show that His-dbpA(CA) inhibits 
Cdk5/GST-p35 but not the Cdk2/GST-cyclin A kinase. 
ase assays. The insect cell expressed GST-dbpA(CA) protein 
gave the same results as the bacterially expressed GST-
dbpA(CA) in its inhibition of the Cdk5/GST-p35 and the 
Cdk4/GST-cyclin Dl kinase and not the Cdk2/cyclin A kin-
ase, whereas it was not a substrate for any of the kinases 
tested (results not shown). Eukaryotic expression of GST-
dbpA(CA) did therefore not give any drastic difference in 
the folding or post-translational modification of the polypep-
tide. 
4. Discussion 
DNA binding protein DbpA belongs to the Y-box protein 
family. These proteins contain three domains: N-terminal do-
main, cold shock domain (CSD) and C-terminal domain. The 
cold shock domain, comprising of 70 amino acids, is highly 
conserved from prokaryotes to eukaryotes [23] and can bind 
so called Y-boxes on DNA. The DNA binding depends on the 
presence of inverted CCAAT motifs and flanking bases in 
these Y-boxes. The N-terminal region of dbpA is rich in pro-
line and alanine residues which could potentially function as a 
transcriptional regulation domain [24]. Several eukaryotic 
genes contain a Y-box in their regulatory region. Ishii and 
colleagues were the first to isolate dbpA via interaction with 
the enhancer of the human epidermal growth factor receptor 
gene and the promoter of the human c-erbB-2 gene [25]. The 
dbpA protein has also been found to bind to the promoter 
sequence of the leukosialin gene [21]. Furthermore, the dbpA 
protein represses the expression of the I-A$ gene of the major 
histocompatibility complex [24] and the expression of the 
stress-inducible gene grp78 [26]. The C-terminal domain of 
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dbpA is hydrophilic due to an alteration of groups of basic 
and acidic amino acids, termed the charged zipper domain, 
that presumably contributes to interactions with other pro-
teins [24]. This is the region we have isolated using the yeast 
two-hybrid system (Fig. 2A). Surprisingly, it inhibits both 
Cdk5 and Cdk4 activity. Further experiments should reveal 
whether full length dbpA has the same effect on Cdk5 and 
Cdk4 as its C-terminal fragment. 
We have not found the consensus sequence (X-S/T-P-X-K/ 
R-X-) [27], which is typical of a site phosphorylated by a Cdk, 
in dbpA(CA) (EMBL-PROSITE database). Our data confirm 
that dbpA(CA) is neither a substrate for Cdk5 nor for Cdk4 
(Fig. 4D, right panel, lane 4 and Fig. 5A, lane 5 respectively). 
However, it should be noted that the protein has three poten-
tial protein kinase C phosphorylation sites. We do not know if 
these sites are utilized at all. 
Although Cdk5 is expressed in both proliferative and differ-
entiated cells, its expression is relatively abundant in nerve 
and muscle cells. Since dbpA mRNA is present in HeLa cells, 
the dbpA protein must also be present in proliferating cells. 
DbpA may therefore play a role in inhibiting Cdk5 during the 
cell cycle. 
The p35 protein, the only known activator of Cdk5, is 
solely expressed in differentiated nerve cells. Cdk5 kinase ac-
tivity (with p35 as its activator) could therefore be responsible 
for the onset of differentiation of nerve cells and possibly of 
muscle cells [9-12]. However, Cdk5 kinase activity should be 
blocked during terminal differentiation. Since both Cdk5 and 
p35 are present in terminally differentiated cells, other pro-
teins should be involved in preventing this complex to be 
active in these cells. We would like to propose that dbpA is 
probably a specific inhibitor of Cdk5. This assumption is 
supported by results from Northern blot analyses which 
show that dbpA is highly expressed in skeletal muscle and 
heart as compared to other tissues ([21]; and our results, 
Fig. 3). Cdk5 is reported to phosphorylate neurofilament pro-
teins and tau protein in vitro. Neurofilament proteins are also 
hyperphosphorylated in patients suffering from Lewy body 
pathologies, whereas the tau protein is hyperphosphorylated 
in patients suffering from Alzheimer's disease. Since the dbpA 
transcript was not detected in the brain ([21]; and our results, 
Fig. 3) other proteins may be responsible for inhibition of 
Cdk5 in the brain. It is also possible that dbpA is expressed 
in a particular section of the brain whose mRNA was not 
present in the commercial blot used for Northern analysis. 
It is known that the Cdk4 kinase is responsible for phos-
phorylation of pRb early in the Gl phase of the cell cycle and 
has a very important function in cycling cells [28]. One can 
speculate that binding of dbpA to the Cdk4 protein allows 
inhibition of its kinase activity which thereby causes cell cycle 
arrest. Probably, this is what occurs in differentiated cells 
where it is essential that Cdk4 activity is inhibited. In cycling 
cells however, dbpA should be bound to Cdk5 to prevent the 
premature onset of differentiation. When Cdk5 is activated 
during differentiation, dbpA may switch its binding allegiance 
to Cdk4, resulting in the latter's inhibition and causing a cell 
cycle block. Later, terminally differentiated cells may again 
have dbpA bound to Cdk5 to maintain the kinase in its in-
active form. 
It has been reported that dbpA activates the transcription 
of thymidine kinase [29]. This may also suggest that dbpA is 
expressed at the beginning of S phase of the cell cycle and 
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may thus block Cdk4 activity at a point in the cell cycle where 
Cdk4 activity is no longer needed. This assumption may be 
equally valid if Cdk5 were to be responsible for the onset of 
differentiation. It is noteworthy that interactions between 
dbpA and Cdk5 or Cdk4 provide a link between unique signal 
transduction pathways and allow for alteration in gene ex-
pression. However, the true role of dbpA in cycling and 
post-mitotic cells needs to be evaluated through further cellu-
lar analyses. 
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The cell cycle is regulated by sequential activation, 
(nactivation of cyclin dependent kinases (Cdk-s). Like 
ftll other Cdk-s, the catalytic sublimit of Cdk5 is 
present in cycling cells. However, its highest concen-
trat ion is found in differentiated neurons, and the 
knly known protein tha t activates CdkS (i.e., p35) is 
Expressed solely in the brain. Active Cdk5 is thought 
to be involved in the in vivo phosphorylation of the 
Neurofilament proteins and tau which a re hyperphos-
tohorylated in neurodegenerative diseases. Recent re-
Cr ts suggest that CdkS may also contr ibute to cellu-* differentiation. Therefore, it would not be unusual 
t o surmise tha t there exist specific proteins tha t reg-
ulate Cdk5 activity in cycling cells. In order to find if 
{this was t rue, a cDNA library prepared from HeLa 
Bells was screened using the yeast-two-hybrid system. 
(The 60S ribosomal protein, L34, was identified as a 
Cdk5-interacting protein. Biochemical analyses reveal 
tha t L34 cannot activate CdkS but potently inhibits 
t he p35-activated kinase. L34 also interacts with Cdk4 
|and, in parallel, inhibits the Cdk4/cyclin Dl activity. 
Interestingly, L34 does not interact with Cdk2 in the 
two-hybrid assay nor does it inhibit the Cdk2/cyclin A 
Enzyme. The fact that a ribosomal protein inhibits IdkS and Cdk4 may suggest that these two kinases 
have a cellular role in translational regulation, c 1999 
jAcademic Press 
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Bmide gel electrophoresis; TAD, transcriptional activation domain. 
Cyclin dependent kinase 5 (Cdk5) was initially iden-
tified on the basis of its sequence similarity to the 
family of cyclin dependent kinases (Cdk-s), a class of 
serine/threonine kinases which regulate important 
transitions in the cell cycle (1, 2). However, Cdk5 is an 
unusual member of the Cdk-family. Its catalytic sub-
unit is predominantly expressed in post-mitotic cells of 
the nervous system, cells which have permanently ex-
ited the cell cycle (2, 3). Moreover, the protein p35 
which activates the Cdk5 enzyme is exclusively ex-
pressed in the central nervous system (CNS) (3, 4). 
These observations have led to the belief tha t Cdk5 
may be a cyclin dependent kinase with only neuron-
specific function. 
Nevertheless, the catalytic subunit of Cdk5 is widely 
expressed at basal levels in most human tissues, tha t 
is, in both cycling and non-cycling cells (2, 3). Interest-
ingly, cyclins D and E, activator molecules which reg-
ulate Cdk activity in proliferating cells', bind Cdk5 (5, 
6; our own observations). It could be argued tha t Cdk5 
bound to cyclin D or cyclin E phosphorylates substrates 
which are not yet known. 
The p35 protein, the only known activator of Cdk5, 
bears no significant homology to the family of cyclins 
(3, 4). As a Cdk-activator, p35 is unique since it has no 
influence on the activity of other Cdk-s (2, 3). The 35 
kDa p35 protein was originally isolated as a smaller 25 
kDa proteolytic product. 
Not only can heterodimeric Cdk5/p35 and Cdk5/p25 
complexes phosphorylate histone H I but they also 
phosphorylate the retinoblastoma protein (pRb). His-
tone H I and pRb are substrates that are frequently 
used to confirm in vitro activity of the Cdk-s (3, 7). 
Activated Cdk5 also phosphorylates its activating part-
ner p35 (8). Besides, Cdk5 is known to phosphorylate 
in vitro a number of neuron-specific cytoskeletal pro-
teins tha t includes the neurofilament proteins NF-M, 
NF-H, the microtubule associated protein t au and the 
actin binding protein caldesmon (2, 3). Phosphoryla-
tion of cytoskeletal proteins is thought to play an im-
portant role in the polymerization and assembly of 
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cytoskeletal elements which, in turn, may affect 
growth of neurites. Indeed, Cdk5 activity has been 
demonstrated to play a key role in neurite outgrowth 
(9) and neuronal migration during differentiation of 
neurons (10). Recently, Cdk5 has been shown to par-
ticipate in the regulation of myogenesis in the early 
embryo (11, 12). These observations may provide new 
insight into the possible function of Cdk5 during dif-
ferentiation. 
Cdk5 is known to phosphorylate neurofilament pro-
teins exclusively at sites phosphorylated in Lewy body 
pathologies, i.e., diffuse Lewy body disease (dementia), 
Parkinson's disease (13, 14) and amyothrophic lateral 
sclerosis (2, 15), and tau protein at sites phosphory-
lated in Alzheimer's disease (2, 3, 16, 17). Moreover, it 
has been reported that the kinase activity of Cdk5 
correlates with the extent of differentiation of neuronal 
cells (2,3,18) and colocalizes with neurofilament tracts 
in the axons of neuronal cells in culture. 
It is therefore possible that Cdk5 activity is tightly 
regulated in pathways that lead from cell proliferation 
towards differentiation. Hence, we have inquired if 
there are any proteins that could be involved in the 
regulation of Cdk5 (i.e., may activate or inhibit the 
kinase) in cycling cells. With this in mind, a cDNA 
library, constructed from total RNA obtained from 
HeLa cells, was screened using the yeast-two-hybrid 
system. Amongst other proteins (unpublished observa-
tions), we find that the 60S ribosomal protein L34 
interacts with the bait protein Cdk5, in the two-hybrid 
assay. Conversely, when L34 was used as bait, the 
interaction between L34 and Cdk5 was equally effi-
cient. The validity of these interactions were corrobo-
rated by using the Escherichia coli expressed GST-L34 
fusion protein. The purified protein precipitates not 
only in vitro transcribed/translated Cdk5 but also the 
protein which is expressed in COS-1 cells. Similar ex-
periments reveal that L34 can bind Cdk4 as well, but 
not Cdk2 or Cdkl. Surprisingly, L34 appears to be an 
efficient inhibitor of Cdk5/p35 and Cdk4/cyclin Dl ki-
nase activities but fails to inhibit Cdk2/cyclin A. 
MATERIALS AND METHODS 
Plasmid constructs for yeast expression. EcoRi-Bglll fragments 
of human Cdkl, Cdk2 and Cdk4 and EcdBi-Sall PCR fragments of 
bovine Cdk5 and human p35 were cloned in the pLEX-a vector (19) 
downstream of the LEX-a DNA-binding domain (DBD). Expression 
in yeast from pLEX-a plasmids is controlled by the constitutive 
alcohol dehydrogenase promoter (ADHD, and the plasmid encodes 
the TRP1 and ADE2 genes for stable propagation in yeast. Further-
more, the EcoRI-Sall fragments of Cdk5 and p35 were also cloned in 
the vector pGAD424 (Clontech) in such a way that they lie directly 
downstream of the GAL4 transcriptional activation domain (TAD). 
Expression from the pGAD424 plasmids, that encodes LEU2 as a 
marker gene, is also driven by the ADH1 promoter. 
A BamUI-Sall fragment of the L34 ORF was cloned in pLEX-a for 
expression in yeast. Furthermore, a BamHl-Xhol fragment of L34 
was cloned in pACT2 (Clontech) whereas a BamHI-Kpnl fragment 
was cloned in pVP16 (19). The pACT2 plasmid codes for GAL4TA0 
whereas the pVP16 plasmid codes for VP16TAD. The TAD-s in both 
plasmids are under the control of the constitutive ADH1 promoter. 
The plasmids encode LEU2 for selection in yeast. The L34 gene has 
been cloned directly downstream of GAL4TAD and VP16TAD. 
Plasmids pLEX-a/lamin and pLEX-a/MyoD were gifts from S. M. 
Hollenberg (19). 
Plasmid constructs for E. coli expression. A BamHISall frag-
ment of the L34 open reading frame (ORF) was cloned in (a) 
pGEX4T-l (Amersham Pharmacia Biotech) for expression of GST-
L34 fusion protein and (b) pQE32 (Qiagen) for expression of a His-
tagged L34 protein. 
Plasmid constructs for COS-1 cell expression and in vitro 
transcription/translation. A BamHISall fragment of Cdk5 was 
cloned in pcDNA3.1- (Invitrogen). Similarly, EcoRI-XhoI fragments 
of Cdkl, Cdk2 and Cdk4 were cloned into pcDNA3.1+ (Invitrogen). 
The plasmid pcMV-0gal was obtained from H.-J. Keller (Novartis). 
Plasmid constructs for insect cell expression. A BamHISall frag' 
ment of Cdk5 was cloned in pFastBacl (Gibco-BRL) for construction 
of a recombinant baculovirus. The pFastBacl vector has a 
baculovirus-specific promoter from Autographa californica nuclear 
polyhedrosis virus (AcNPV) for heterologous expression of proteins 
in insect cells. Similarly, BamHl-EcoRl fragments of human Cdk2 
and Cdk4 were cloned in pFastBacl for construction of recombinant 
baculoviruses. 
EcoRI-Sall fragments of human p35, human cyclin A, murine 
cyclin D2 and murine cyclin D3 were cloned in pFastBacl down-
stream of a Bglll-EcoRI fragment of GST (PCR fragment from 
pGEX4T-l; Amersham Pharmacia Biotech) for construction of re-
combinant baculoviruses. Similarly, an EcoRI-XhoI fragment of hu-
man cyclin Dl was cloned as a GST fusion in pFastBacl. 
Yeast strains and media. The S. cerevisiae strains L40 (Mat a, 
Ais3A200, trpl-901, feu2-3,112, ade2, /ys2-801am, URA3::(lexAop)a-
lacZ, LYS::(lexAop)i-his3 and AMR70 (Mat a, Ais3A200, irpl-901, 
fe«2-3,112, ade2, Zys2-801am, URA3::(lexAop)s-lacZ (19) were used 
for yeast transformation and for mating assays. In order to perform 
the yeast-two-hybrid screen, L40 was transformed sequentially with 
(a) pLEX-a/cdk5 and (b) a human HeLa S3 Matchmaker cDNA 
library cloned unidirectionally into the EcoRI and Xhol sites of 
pGADGH (Clontech, HL4000AA). The pGADGH vector contains the 
GAL4TiD under the control of the ADH1 promoter and also encodes 
LEU2 as a marker gene. In order to mate a L40 strain that was cured 
of bait plasmid but still contains the prey plasmid (from the cDNA 
library), transformants of AMR70 (bearing plasmids pLEX-a/cdk5 or 
pLEX-a/lamin) were used. Both L40 and AMR70 contain the lacZ 
reporter gene linked to the lexA operon. Besides, L40 also contains 
the HIS3 reporter gene downstream of the lexA operon. Untrans-
formed yeast strains were grown in YPAD whereas transformed 
yeast strains were grown in minimal medium that allow mainte-
nance of plasmids in a particular strain. 
The & cerevisiae strain L40 was also used for transformation of 
pLEX-a plasmids that encode Cdkl, Cdk2, Cdk4, Cdk5, p3S, L34, 
lamin or MyoD. A pACT2 or pVP16 plasmid that encodes L34 or 
pGAD424 plasmids that encode Cdk5 and p35 were used to perform 
yeast-two-hybrid assays on selected transformants. 
Yeast-two-hybrid screen. A pLEX-a/cdk5 plasmid-bearing strain 
of L40 was transformed with the HeLa cDNA library (Clontech) 
and transformants were selected exactly as described earlier (19). 
His* colonies were lysed in liquid nitrogen and assayed for 
0-galactosidase activity on niters. Only those colonies, which do not 
express |3-galactosidase after loss of the pLEX-a/cdk5 bait plasmid, 
were selected for further analysis. The plasmids pLEX-a/cdk5 or 
pLEX-a/lamin were reintroduced into L40 (a) by direct transforma-
tion of L40 strains that already contain the prey plasmid or (b) by 
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(Dating prey plasmid-containing L40 strains with AMR70 transfor-
Inants of pLEX-a/cdk5 or pLEX-a/lamin. Later, the prey plasmids 
fcrere isolated by transforming total yeast DNA into HB101 and by 
Selecting for leucine prototrophy on minimal medium plates (manu-
facturer's protocol; Clontech). Plasmids, that contain denned inserts, 
*rere then retransformed into L40 strains that already harbor pLEX-
i/cdk5 or pLex/lamin. Plasmids, which express proteins that do not 
pind lamin but reproducibly interact with Cdk5, were sequenced 
Rising an automated DNA sequencing machine (LiCor). Inserts were 
Identified by comparing translated DNA sequences with the SWISS 
PROT database. 
xS-methionine labeling of Cdkl, Cdk2, Cdk4 and Cdk5. 1 ng of 
the pcDNA3.1 plasmids carrying the genes Cdkl, Cdk2, Cdk4 or 
Cdk5 were linearized uniquely at the 3'-end of the gene inserts. The 
linearized plasmids were used as templates for in vitro transcription/ 
translation. The Cdk proteins were radioactively labeled with 3SS-
iaethionine (20 jiCi of an in vivo cell labeling grade; Amersham 
Pharmacia Biotech). The transcription and translation was per-
formed using the TNT-T7 in vitro transcription/translation kit (Pro-
Jnega). 
Pull-down assay with 3SS labeled Cdk proteins. Bacterially ex-
pressed glutathione-S-transferase (GST) and GST-L34 fusion pro-
^ i n were bound to gluthathione Sepharose 4B (Amersham Pharma-
cia Biotech) by incubating protein and beads at RT for 1 h. After 4 
trashing steps with 10 volumes of ice-cold PBS, the beads were 
Iresuspended in 200 nl 1% w/v BSA-PBS solution and kept on ice. 5 /xl 
pf the ^S-methionine labeled Cdk proteins (from 100 fil of an in vitro 
transcribed/translated product) diluted in 200 /d 1% w/v BSA-PBS 
solution, that contains 4 /i\ of a lOOx solution of universal protease 
Inhibitors (tablet dissolved in redist. H20; Boehringer Mannheim), 
*?as kept on ice for 15 min. GSH-Sepharose 4B beads, bound to GST 
tor GST-L34, were incubated with labeled Cdk-s at 4°C for 2 h with 
entle mixing. The beads were washed three times with 1 ml of 
ead-binding buffer (50 mM potassium phosphate pH 7.5, 150 mM 
KC1, 1 mM MgClj, 10% v/v glycerol, 1% v/v Triton X-100) that 
ontain universal protease inhibitors (Boehringer Mannheim). The 
elleted bead-bound protein complexes were denatured by boiling in 
aemmli sample buffer (4% w/v SDS, 0.1 M Tris, 4 mM EDTA, 20% 
Wv glycerol, 33% w/v bromophenol blue) that contains 50 mM DTT, 
fcnd were analyzed by 12.5% SDS-PAGE. The gels were fixed (10% 
fr/v glacial acetic acid, 30% v/v methanol solution) for 10 min, and the 
signal was enhanced by soaking the gel in EN3HANCE (NEN) for an 
pour at RT. The dried gel was exposed to Kodak X-OMAT AR film. 
, Transfection ofpcDNA 3.1 + Icdk2, pcDNA 3.1 + Icdk4 and pcDNA 
B.l-/cdk5 in COS-1 cells. COS-1 cells in six-well plates, grown in 
Pulbecco's modified Eagle Medium (DMEM, Gibco BRL) that con-
tained 10% v/v fetal bovine serum (FBS, Gibco BRL), were trans-
l a t ed with 2 ^ of pcDNA 3.1 plasmids that carry Cdk2, Cdk4 or 
<Cdk5, using calcium phosphate. In order to control transformation 
jefficiency, pcMV-/3gal was used. 
Precipitation of COS-1 expressed Cdk-s by GST-L34. Harvested 
jeells (~5 x 105) were washed once with PBS and then lysed in 1 ml 
Sf hypotonic lysis buffer (10 mM Tris/HCl pH 7.4,10 mM NaCl, 3 mM IgCl2, 0.5% v/v Nonidet P-40) that contained 1 mM DTT and uni-
versal protease inhibitors (Boehringer Mannheim). Total protein in 
(cell lysates was measured by the Bradford assay (Bio-Rad) and was 
(stored at -70°C before use. 
i 400 jj.1 of a COS-1 cell lysate was first preincubated for 2 h at 4°C 
ath 30 fil of Sepharose 4B (to remove unspecific binding of proteins 
beads). This was followed by incubation with 30 pi of GSH-
epharose 4B that was already bound to bacterially expressed GST-
34. Pull-down of the Cdk-s in COS-1 cell lysates was performed as 
described above for the 35S-methionine labeled Cdk-s. The pelleted 
fcead-bound protein complexes were denatured by boiling in Laemmli 
JBample buffer and were analyzed by Western blotting. The blots were 
|>robed with polyclonal antibodies raised against Cdk2 and 
N-terminal fragments of Cdk4 and Cdk5 and were detected by ECL 
(Amersham Pharmacia Biotech). 
Expression of baculoviruses. Recombinant baculoviruses encod-
ing different genes were constructed using protocols provided by the 
manufacturer (Gibco-BRL). The viruses were harvested and ampli-
fied until a desired titer was reached (viz. 1 X 10s pfu/ml). 
2 X 107 Sf9 cells were used to coinfect bacoluviruses carrying 
Cdk5, Cdk4 or Cdk2 with GST-p35, GST-cyclin A, GST-cyclin Dl, 
GST-cyclin D2 or GST-cyclin D3 in 25 ml of SF900 II SFM medium 
(GibcoBRL). After 72 h, cells were harvested and lysed by sonication 
in NETN buffer (20 mMTris/HCl pH 8.0,100 mM NaCl, 1 mM EDTA, 
05% v/v NP-40, 5 mM NaF, 30 mM p-NPP, 1 mM PMSF, 1/xg/ml 
Antipain) that contained universal protease inhibitors (Boehringer 
Mannheim). HBT buffer (50 mM Hepes pH 7.6,150 mM NaCl, 1 mM 
EDTA, 2.5 mM EGTA, 0.1% v/v Tween 20,1 mM DTT, 5 mM NaF, 30 
mM p-NPP, 25 mM 0-glycerolphosphate, 1 mM PMSF, 1 /ig/ml 
Antipain) was used to lyse cells that were co-infected with GST-
cyclin Dl, D2 or D3 viruses. Heterodimeric enzyme complexes were 
isolated by binding to 100 /il of GSH-Sepharose 4B, overnight at 4°C. 
The beads were washed 7 times with ice-cold NETN buffer (or HBT 
buffer) and 3 times with ice-cold kinase buffer (20 mM Tris/HCl, pH 
7.5, 10 mM MgCl2). The beads were resuspended in 100 jul kinase 
buffer and kept on ice before a kinase assay was performed. 
Kinase assays. Phosphorylation of 0.1 fig histone HI (Type III-S: 
from calf thymus, Sigma H-5505) or 0.25 jig GST-Rbl52 (i.e., 
C-terminal 152 amino acid residues of pRb covalently linked to GST; 
Santa Cruz Biotechnology) was performed in kinase buffer for 40 min 
at 30°C using 2 (U of beads, 10 /xM ATP and 3 /xCi [ r^Pl ATP 
(specific activity = 3000 Ci/mmol; Amersham Pharmacia Biotech) in 
a total volume of 10 fil. The reactions were boiled in Laemmli sample 
buffer and were analyzed by 12.5% SDS-PAGE. The gel was fixed 
and the phosphorylation was quantified using a phosphorimager 
(Molecular Devices). 
RESULTS AND DISCUSSION 
Cdk5 has been used as a bait in the yeast-two-hybrid 
system to screen for proteins that may interact with 
Cdk5. Since Cdk5 is expressed in both cycling and 
non-cycling cells, we thought it would be interesting to 
know if there are any Cdk5-binding proteins in cycling 
cells. Hence, a HeLa cDNA library in the yeast vector 
pGADGH was transformed into the yeast strain L40 
(19) that already contained the bait plasmid pLEX-a/ 
cdk5 (which codes for LexaDBD-Cdk5). Genes coding for 
interacting proteins were identified by selecting for 
His+ prototrophs and subsequently through induction 
of /3-galactosidase (/3-gal) activity. Colonies that were 
His+ and blue were considered positives and were used 
for further analysis (results not shown). It was later 
found that one such positive yeast colony harbored a 
cDNA library plasmid (i.e. the prey plasmid) encoding 
GAL4TAD fused to the human gene for the 60S ribo-
somal protein, L34. 
In order to negate the possibility that an identified 
positive colony was an artifact of the two-hybrid 
system (frequently referred to as 'false positives') 
(20), the yeast strain was cured of the bait plasmid 
pLEX-a/cdk5 by growing the strain in a non-selective 
medium (50 generations of growth in minimal me-
dium that contained tryptophan and adenine but 
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FIG. 1. In a yeast-two-hybrid assay the 60S ribosomal protein L34 binds to Cdk5 and Cdk4. Interactions were monitored by analyzing 
six individual colonies by colorometric /3-galactosidase assay. (A) After curing the bait plasmid, an L40 strain that retains the prey plasmid 
(that codes for GAL4TAD-L34 fusion protein) was mated with strain AMR70 that had already been transformed with pLEX-a/lamin or 
pLEX-a/Cdk5 (these plasmids express Lex-a-lamin and Lex-a-Cdk5 fusion proteins, respectively). The results show that L34 interacts with 
Cdk5 but not with the unspecific protein, lamin. (B) Left panel, plasmid pACT2/L34 (that expresses GAL4TAD-L34) was transformed in strain 
L40 that already contains pLEX-a/lamin, pLEX-a/MyoD, pLEX-a/Cdk5 or pLEX-a/p35. The results show that L34 interacts specifically with 
Cdk5. Right panel, plasmid pGAD424/p35 (expressing GAL4TAD-p35) was transformed in the same L40 yeast strains (see left panel), as a 
control. (C) Plasmids pGAD424/Cdk5 (left panel) and pGAD424/p35 (right panel, as negative control) were transformed into L40 strains that 
already harbor pLEX-a/L34 or pLEX-a/p35. Results show that Cdk5 and L34 can still interact with each other even after interchanging the 
two domains (GAL4TAD and Lex-aDBD) which has to be linked to two putative interacting proteins, in the two-hybrid assay. (D) Plasmids 
pACT2/L34 (left panel) and pACT2/p35 (right panel, as control), that express GAL4TAD-L34 and GAL4TMJ-p35 respectively, were transformed 
in L40 strains that already harbor pLEX-a/Cdk5, pLEX-a/Cdk4, pLEX-a/Cdk2 or pLEX-a/Cdkl. Results show that L34 interacts specifically 
with Cdk5 and Cdk4. 
lacked leucine; the prey plasmid contains LEU2). 
The resulting L40 strain (Mat a) that contains the 
prey plasmid, pGADGH/L34j was mated with strains 
of AMR70 (Mat a) that had been transformed either 
with pLEX-a/cdk5 or with pLEX-a/lamin. Beta-
galactosidase assays performed on mated diploid 
strains showed that L34 specifically interacts with 
Cdk5 but not with lamin (Fig. 1A). 
At this stage, the pGADGH/L34 plasmid was iso-
lated from yeast (via transformation of total yeast DNA 
in E. coli; see Materials and Methods). The insert was 
sequenced and it revealed that the cloned gene was 
full-length human L34. The ORF of the L34 gene was 
amplified by PCR from the vector pGADGH/L34 and 
was subcloned into pACT2, another yeast vector often 
used for two-hybrid assays. The plasmid pACT2/L34 
(which codes for GAL4TAD-L34 fusion protein) was 
transformed into the strain L40 that already contained 
pLEX-a/cdk5, pLEX-a/lamin, pLEX-a/MyoD or pLEX-
a/p35 (all plasmids code for LexaDBD fusion proteins). 
The results reiterate that, at least in the two-hybrid 
system, Cdk5 not only binds p35 (Cdk5's known acti-
vator) but also interacts with L34 (Fig. IB, left and 
right hand panels). It was also found that interaction of 
L34 with Cdk5 does not depend on the specific TAD to 
which L34 is linked. This was supported by the obser-
vation that a VP16T AD-L34 fusion protein binds as well 
as GAL4TAD-L34 to LexaDBD-Cdk5, in the two-hybrid 
assay (data not shown). Furthermore, the gene L34 
was cloned in pLEX-a and cdk5 in pGAD424. It was 
seen that interchanging the two domains, TAD and 
DBD, did not affect the interaction between L34 and 
Cdk5 (i.e., LexaDBD-L34 fusion protein bound strongly 
to GAL4TAD-Cdk5; Fig. 1C). All these observations 
proved beyond doubt that neither a TAD nor a DBD 
has any influence on the Cdk5-L34 interaction. 
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We also wanted to find out if Cdk5 was the only Cdk 
to which L34 has an affinity. In order to test this, yeast 
strain L40 was first transformed with pLEX-a/cdk5, 
pLEX-a/cdk4, pLEX-a/cdk2 or pLEX-a/cdkl. The plas-
mid pACT2/L34 (that codes for GAL4TAD-L34) was then 
transformed into L40 strains that already have the 
ability to express Lexa-Cdk5, Lexa-Cdk4, Lexa-Cdk2 
or Lexa-Cdkl fusion proteins. A 0-galactosidase assay 
(Fig. ID) depicts that, in the yeast-two-hybrid system, 
L34 can interact with Cdk5 and Cdk4 but not with 
Cdk2 and Cdkl. 
In order to confirm some of the yeast-two-hybrid 
data, a set of in vitro pull-down experiments were 
employed. We found that bacterially expressed GST-
L34 fusion protein was able to pull-down 36S-
methionine-labeled Cdk5 and Cdk4 but not Cdk2 and 
Cdkl (all proteins were transcribed/translated in 
vitro). We were sure that the GST moiety in GST-L34 
did not play a role in the precipitation of Cdk5 or Cdk4 
since GST protein alone is not able to pull-down Cdk5 
(Fig. 2A). 
As an alternative to the in vitro transcription/ 
translation procedure to obtain desired proteins, Cdk5, 
Cdk4 and Cdk2 were expressed in COS-1 cells. Lysates 
from transfectants were incubated with the E. coli 
expressed GST-L34 fusion protein. The bound proteins 
were detected by Western blotting, using antibodies 
specific to Cdk5, Cdk4 or Cdk2. Similar to our earlier 
observations with labeled proteins, we observed that 
GST-L34 was able to bind COS-1-expresssed Cdk5 
and Cdk4 whereas it was unable to pull-down Cdk2 
(Fig. 2B). 
The Cdk5/GST-p35 heterodimeric complex was ex-
pressed in insect cells using the baculovirus expression 
system. The enzyme was purified by binding to GSH-
Sepharose 4B. The bead-bound enzyme was tested for 
activity (see Materials and Methods) using histone HI 
as substrate. Fig. 3A (lane 1) portrays the phosphory-
lation of histone HI by GST-p35 activated Cdk5 ki-
nase. Kinase assays performed on GST-L34 demon-
strate that L34 is not phosphorylated by Cdk5 and 
therefore cannot be a Cdk5 substrate (Fig. 3A, lanes 2 
& 3). We then asked if L34 could be an inhibitor of 
Cdk5. Fig. 3B shows a dose dependent inhibition of 
Cdk5 by GST-L34. However, it should be noted that 10 
/i,g of GST did not have any affect on the kinase (Fig. 
3B, lane 8) whereas 0.4 /xg of GST-L34 distinctly in-
hibited the complex (>50%; Fig. 3B, lane 5). Stauro-
sporine (CGP 39360, Novartis), which strongly inhibits 
most Cdk-s including Cdk5, was used as a control 
inhibitor (21). 
It can be argued that the relatively large GST moiety 
causes a steric hindrance in the fusion protein so that 
it interferes with L34's ability to act as a substrate for 
Cdk5 or that the presence of GST causes an artifactual 
inhibition of Cdk5. Therefore, L34 was expressed in E. 
(A) 
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FIG. 2. L34 binds to Cdk5 and Cdk4 but not to Cdk2 and Cdkl 
in in vitro binding assays. L34 was expressed as a GST fusion in E. 
coli. (A) GST-L34 binds to s6S-labeled Cdk4 and Cdk5 and not to 
35S-labeled Cdkl and Cdk2. Lane 1, 10% of the MS-labeled Cdkl 
input used for the pull-down assay with GST-L34 (as in lane 2); lane 
3, 10% of the 35S-labeled Cdk2 input used for the pull-down assay 
with GST-L34 (as in lane 4); lane 5, 10% of the ^S-labeled Cdk4 
input used for the pull-down assay with GST-L34 (as in lane 6); lane 
7, 10% of the MS-labeled Cdk5 input used for the pull-down assay 
with GST-L34 (as in lane 8); lane 9, 100% of the ^S-labeled Cdk5 
input used for the pull-down assay with GST alone. (B) GST-L34 
binds to Cdk4 and Cdk5 and not to Cdk2 overexpressed in COS-1 
cells. Each lane shows a Western blot of proteins fractionated on a 
10% SDS-polyacrylamide gel. Polyclonal antibodies raised against 
Cdk2 and the N-terminii of Cdk4 and Cdk5 were used to detect the 
respective proteins. Lanes 1, 3 and 5, 15 /d of lysates from COS-1 
cells that express Cdk2, Cdk4 or Cdk5. Lanes 2, 4 and 6, 400 jd of 
same cell lysates, used in pull-down assays with GST-L34. 
coli as a His-tagged protein (six consecutive histidines 
attached to the protein at its N-terminus, as in pQE32; 
see Materials and Methods). His-L34 has been used to 
probe if it is a substrate or an inhibitor of the Cdk5/p35 
kinase. Like GST-L34, His-L34 is not phosphorylated 
by Cdk5/GST-p35 (Fig. 3D right panel, lane 4). Again 
similar to GST-L34, His-L34 inhibits the Cdk5/GST-
p35 complex in a dose dependent manner. His-L34 
completely abolishes the Cdk5-mediated phosphoryla-
tion of histone HI (Fig. 3C, left panel). The His-tagged 
protein can also completely inhibit the phosphorylation 
of GST-Rbl52 by the Cdk5/GST-p35 complex (Fig. 3C 
right panel, lane 5). 
Since D-type cyclins are reported to bind Cdk5 (5), 
we wanted to find if cyclin D would form a complex 
with Cdk5 when both proteins are expressed in insect 
cells, and if it did, whether the complex would form an 
active kinase by phosphorylating either histone HI or 
GST-Rbl52. One could speculate that an active cyclin 
D/Cdk5 enzyme, with no known cellular substrate, 
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FIG. 3. Kinase assays with histone HI and GST-Rbl52, as substrates, show that both GST-L34 and His-L34 proteins are not substrates 
for Cdk5 that is activated by p35 and cyclin D2. However, GST-L34 and His-L34 inhibit Cdk5-mediated phosphorylation of histone HI and 
GST-Rbl52 in a dose-responsive manner. (A) GST-L34 is not phosphorylated by p35 activated Cdk5 kinase. Lane i, Cdk5/GST-p35 + 10 fig 
histone HI as substrate; lane 2, Cdk57GST-p35 + 10 /xg GST as substrate; lane 3, Cdk5/GST-p35 + 0.4 /tg GST-L34 as substrate. (B) Dose 
response to GST-L34 in the inhibition of Cdk5-mediated phosphorylation of histone HI (1 /xg). Lane 1, Cdk57GST-p35 + no substrate; lane 
2, Cdk5/GST-p35 + substrate; lane 3, Cdk5/GST-p35 + substrate + 0.4 /xg GST-L34; lane 4, Cdk5/GST-p35 + substrate + 0.8 /xg GST-L34; 
lane 5, Cdk5/GST-p35 + substrate + 1.6 /xg GST-L34; lane 6, Cdk5/GST-p35 + substrate + 300 nM staurosporine; lane 7, Cdk5/GST-p35 + 
substrate + 40 nM staurosporine; lane 8, Cdk57GST-p35 + substrate + 10 /xg GST. (C) Left panel, dose response to His-L34 in the inhibition 
of Cdk5-mediated phosphorylation of histone HI (0.1 /xg). Lane 1, Cdk5/GST-p35 + no substrate; lane 2, Cdk5/GST-p35 + substrate; lane 
3, Cdk5/GST-p35 + substrate + 0.5 /xg His-L34; lane 4, Cdk5/GST-p35 + substrate + 1 /xg His-L34; lane 5, Cdk5/GST-p35 + substrate + 
3 /xg His-L34; lane 6, Cdk5/GST-p35 + substrate + 6 /xg His-L34. Right panel, dose response to His-L34 in the inhibition of Cdk5-mediated 
phosphorylation of GST-Rbl52 (0.25 /xg). Lane 1, Cdk5/GST-p35 + no substrate; lane 2, Cdk5/GST-p35 + substrate; lane 3, Cdk5/GST-p35 + 
substrate + 0.5 fig His-L34; lane 4, Cdk5/GST-p35 + substrate + 1 /xg His-L34; lane 5, Cdk5/GST-p35 + substrate + 6 /xg His-L34. (D) 
His-L34 is not a substrate for Cdk57GST-p35 and Cdk5/GST-cyclin D2 kinases. Left panel, GST-cyclin D2 activated kinases were prepared 
and were tested for their ability to phosphorylate 0.25 /xg GST-Rbl52. Lane 1, Cdk2/GST-cyclin D2 + no substrate; lane 2, Cdk2/GST-cyclin 
D2 + substrate; lane 3, Cdk4/GST-cyclin D2 + no substrate; lane 4, Cdk4/GST-cyclin D2 + substrate; lane 5, Cdk5/GST-cyclin D2 + no 
substrate; lane 6, Cdk5/GST-cyclin D2 + substrate. Right panel, both Cdk5/GST-p35 and Cdk5/GST-cyclin D2 were tested for their ability 
to phosphorylate histone HI, GST-Rbl52 and His-L34. Lane 1, Cdk5/GST-p35 + no substrate; lane 2, Cdk5/GST-p35 incubated with 1 tig 
histone HI; Lane 3, Cdk5/GST-p35 kinase incubated with 0.25 /xg GST-Rbl52; lane 4, Cdk5/GST-p35 incubated with 5 /xg His-L34; lane 5, 
Cdk5/GST-cyclin D2 + no substrate; lane 6, Cdk5/GST-cyclin D2 incubated with 1 /xg histone HI; lane 7, Cdk5/GST-cyclin D2 incubated with 
0.25 /xg GST-Rbl52; lane 8, Gdk5/GST-cyclin D2 incubated with 5 /xg His-L34. 
may phosphorylate the Cdk5-binding protein, L34. 
Hence, Sf9 insect cells were co-infected with baculovi-
ruses coding for Cdk5 and GST-cyclin Dl, GST-cyclin 
D2 or GST-cyclin D3. The cyclin D-bound Cdk5 pro-
teins obtained from insect cells were precipitated with 
GSH-Sepharose 4B and the bead-bound complexes (as 
confirmed by Western blotting using antibodies specific 
for Cdk5 and D-type cyclins; results not shown) were 
used directly for kinase assays. We observed that nei-
ther GST-cyclin Dl nor GST-cyclin D3 can activate 
Cdk5 (results not shown). Surprisingly, like cyclin D2-
activated Cdk2 (Fig. 3D left panel, lane 2) and Cdk4 
(Fig. 3D left panel, lane 4), kinases that are known to 
phosphorylate pRb, cyclin D2-activated Cdk5 also has 
the ability to phosphorylate the GST-Rbl52 (Fig. 3D 
left panel, lane 6). However, His-L34 is not phosphor-
ylated by cyclin D2 and p35 activated Cdk5 (Fig. 3D 
right panel, lanes 4 & 8). 
Since L34 interacts not only with Cdk5 but also with 
Cdk4 in both two-hybrid and in vitro binding assays, 
the affect of His-L34 on active Cdk4/cyclin Dl complex 
was investigated. We see that the His-tagged protein 
completely inhibits Cdk4/GST-cyclin Dl-mediated 
phosphorylation of GST-Rbl52 (Fig. 4A, lane 4). Fur-
thermore, L34 is definitely not a substrate for the 
Cdk4/GST-cyclin Dl enzyme (Fig. 4A, lane 5). 
Although His-L34 inhibits the Cdk5/GST-p35-
mediated phosphorylation of histone HI (there is at 
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FIG. 4. His-L34 is not a substrate for Cdk4/GST-cyclin Dl but 
; instead inhibits the kinase. Comparison of the inhibition of Cdk5/ 
i GST-p35 and Cdk2/GST-cyclin A kinases by His-L34. (A) His-L34 
; inhibits Cdk4/GST-cyclin Dl-mediated phosphorylation of GST-
i Rbl52 (0.5 /ig) and is not phosphorylated by the kinase. Lane 1, 
I Cdk4/GST-cyclin Dl + no substrate; lane 2, Cdk4/GST-cyclin Dl + 
i substrate (the lower band is a breakdown product of GST-Rbl52); 
I lane 3, Cdk4/GST-cyclin Dl + substrate + 1 jig His-L34; lane 4, 
Cdk4/GST-cyclin Dl + substrate + 6 jxg His-L34; lane 5, Cdk4/GST-
cyclin Dl + substrate + 6 jig His-L34. (B) Comparison of inhibition 
of the Cdk5/GST-p35 and Cdk2/GST-cyclin A-mediated phosphory-
lation of histone HI (1 /ig) by His-L34. Lane 1, Cdk2/GST-cyclin A + 
substrate; lane 2, Cdk2/GST-cyclin A + substrate + 0.5 ng His-L34; 
lane 3, Cdk5/GST-p35 + substrate; lane 4, Cdk5/GST-p35 + sub-
strate + 0.5 ng His-L34; lane 5, Cdk5/GST-p35 + substrate + 6 ycg 
His-FKBP12 (an unspecific protein). The results show that His-L34 
inhibits Cdk57GST-p35 but not the Cdk2/GST-cychn A kinase. 
least a 20-fold decrease in activity; compare lanes 3 & 
4 in Fig. 4B), it seems that phosphorylation of the same 
substrate by Cdk2/GST-cyclin A is not affected at all 
(Fig. 4B, compare lanes 1 & 2). This seems to corrobo-
rate our earlier two-hybrid data which indicated that 
L34 does not interact with Cdk2 but binds Cdk4 and 
Cdk5. 
Interestingly, the L34 gene lies within the BRCA1 
locus (22). BRCA1, a familial breast and ovarian cancer 
susceptibility gene encodes a nuclear phosphoprotein 
that functions as a tumor suppressor in human breast 
cancer cells. BRCA1 splice variants BRCAla and 
BRCAlb associate with E2F, cyclins and cyclin depen-
dent kinases (23). We have not found the consensus 
sequence (X-S/T-P-X-K/R-X-) (24), that is typical of a 
site phosphorylated by a Cdk, in L34 (PROSITE data-
base). However, the protein has a cAMP- and a cGMP-
dependent protein kinase phosphorylation site and five 
protein kinase C phosphorylation sites. 
Although Cdk5 is expressed in both proliferative and 
differentiated cells, its expression is relatively abun-
dant in nerve and muscle cells. Since L34 mRNA is 
present in HeLa cells, the L34 protein must be also 
present in proliferating cells. L34 may therefore play a 
role in inhibiting Cdk5 during the cell cycle. 
The p35 protein, the only known activator of Cdk5, is 
solely expressed in differentiated nerve cells. Cdk5 ki-
nase activity (with p35 as its activator) could therefore 
be responsible for the onset of differentiation of nerve 
cells and possibly of muscle cells (9-12). However, 
Cdk5 kinase activity should be blocked during termi-
nal differentiation. Since both Cdk5 and p35 are 
present in terminally differentiated cells, other pro-
teins should be involved in preventing this complex to 
be active in these cells. We would like to propose that 
L34 is probably one of the specific inhibitors of Cdk5. 
Since Cdk5 can phosphorylate neurofilament proteins 
and tau protein in vitro and neurofilament proteins are 
hyperphosphorylated in patients suffering from Lewy 
body pathologies, whereas the tau protein is hyper-
phosphorylated in patients suffering from Alzheimer's 
disease, it could be that L34 also plays a role in the 
aberrant phosphorylation of neurofilaments and tau. 
On the other hand, the Cdk4 kinase is responsible 
for the phosphorylation of pRb early in the Gl-phase of 
the cell cycle and has a very important function in 
cycling cells (25). One can speculate that binding of L34 
to the Cdk4 protein allows inhibition of its kinase ac-
tivity which thereby causes cell cycle arrest. Probably, 
this is what occurs in differentiated cells where it is 
essential that Cdk4 activity is inhibited. In cycling 
cells however, L34 should be bound to Cdk5 to prevent 
the premature onset of differentiation. When Cdk5 is 
activated during differentiation, L34 may switch its 
binding allegiance to Cdk4, resulting in the latter's 
inhibition and causing a cell cycle block. Later, termi-
nally differentiated cells may again have L34 bound to 
Cdk5 to maintain the kinase in its inactive form. 
Interaction of Cdk5 with the 60S ribosomal protein 
L34 may imply that Cdk5 activity is regulated at the 
translational level. It has been reported that L34 reg-
ulates polyamine biosynthesis by inhibiting ornithine 
decarboxylase (26). Polyamines are overexpressed in 
many cancers. The fact that L34 regulates polyamine 
biosynthesis by inhibiting ornithine decarboxylase 
may also suggest that L34 is expressed at the begin-
ning of the S phase of the cell cycle and may thus block 
Cdk4 activity at a point in the cell cycle where Cdk4 
activity is no longer needed. This assumption may be 
equally valid if Cdk5 were to be responsible for the 
onset of differentiation. However, the true role of L34 
in cycling and post-mitotic cells needs to be evaluated 
through further cellular analyses. 
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The cyclin-dependent kinase 5 (Cdk5) catalytic sub-
unit is expressed in both cycling and noncycling cells 
and is present in many tissues. Neuronal and muscle 
cells contain the highest amount of this protein. The 
p35 protein, which is expressed solely in the brain, 
activates Cdk5. CdkS activity is involved in terminal 
differentiation of neurons and muscle cells. We at-
tempted to clone cdkS by PCR from a human fetal 
brain cDNA library. Surprisingly, we amplified two 
forms of the cdk5 gene, the wild type and a cdk5 vari-
ant that lacks the complete kinase domain VI. The 
variant is also found in SH-SY-5Y neuroblastoma cells 
but not in T-cells, HeLa cells, the thymus, and placen-
tal tissue. The protein encoded by the cdk5 variant, 
the CdkS isoform (Cdk5i), purines with p35 when co-
expressed in insect cells. The activity associated with 
the heterodimer Cdk5i/p35 is found to be appreciably 
weaker than the wild-type Cdk5/p35 kinase. Moreover, 
Cdk5i/p35 cannot autophosphorylate its two subunits 
as with Cdk5/p35. Interestingly, kinase-defective Cdk5i 
can abolish the activity of wild-type Cdk5 when both 
are coexpressed with p35 in insect cells, suggesting 
that Cdk5i may have a function in regulating Cdk5 
activity in human Cells too. O 1998 Academic Press 
Key Words: p35; Cdk5; Cdk5 isoform; defective-
kinase. 
Cyclin dependent kinase 5 (Cdk5) was initially iden-
tified on the basis of its sequence similarity to the 
cyclin dependent kinases (Cdk-s), enzymes which play 
a key role in cell cycle progression (1, 2). However, 
1
 To whom correspondence should be addressed at Oncology Re-
search, Novartis Pharma AG, WKL-125.13.17, Basel, Switzerland. 
Fax: (41) (61) 696 38 35. E-mail: bob.chaudhuri@pharma.novartis.com. 
Abbreviations used: bp, base pair; Cdk5, human cyclin dependent 
kinase 5; Cdk5i, Cdk5 isoform; GSH-Sepharose, gluthathione-
Sepharose; GST, glutathione-S-transferase; p35, 35-kDa protein 
which activates Cdk5; PHF, paired helical filament; PCR, polymer-
ase chain reaction; RT-PCR, reverse-transcriptase PCR; pRb, human 
retinoblastoma protein; var, variant; wt, wild type. 
Cdk5 seems to have a function only in post-mitotic cells 
and is the first example of a cyclin dependent kinase 
with neuronal function (2, 3). Cdk5 is expressed a t 
basal levels in most human tissues (i.e.,in both cycling 
and non-cycling cells), with the exception of the central 
nervous system (CNS) and peripheral nervous system 
(PNS) where expression is several-fold greater (2, 3). It 
has been reported tha t cyclins D and E bind to Cdk5 
but these complexes have not been shown to be enzy-
matically active (3, 4). The protein p35, which is ex-
pressed exclusively in the CNS, is the only known 
activator of Cdk5 (3, 5), and has no influence on the 
activity of other Cdk-s. Moreover, p35 has no signifi-
cant homology to cyclins, with only eight out of a hun-
dred residues identical in the central conserved cyclin 
box (2, 3). The Cdk5 activator p35 was originally iso-
lated as p25, a smaller proteolytic product (2, 3). 
The Cdk5/p35 complex can phosphorylate both his-
tone H I and the retinoblastoma protein (pRb), two 
substrates which are commonly used to test Cdk activ-
ity in vitro (3, 6). Active Cdk5 also phosphorylates p35, 
its activating par tner (7). Furthermore, Cdk5 is known 
to phosphorylate in vitro a number of cytoskeletal pro-
teins including the neurofilament proteins NF-M, 
NF-H, the neuron-specific microtubule-associated pro-
tein tau and the actin-binding protein caldesmon (2,3). 
Phosphorylation of cytoskeletal proteins are thought to 
play an important role in the polymerization and as-
sembly of cytoskeletal elements which, in turn, may 
effect growth of neurites. Indeed, Cdk5 activity has 
been demonstrated to play a key role in neurite out-
growth (8) and neuronal migration during neuronal 
differentiation (9). Recently, Cdk5 has been shown to 
participate in the regulation of myogenesis in the early 
embryo (10, 11). These observations may provide 
new insight into the possible function of Cdk5 during 
differentiation. 
Cdk5 phosphorylates neurofilament proteins exclu-
sively at sites phosphorylated in Lewy body patholo-
gies, i.e., diffuse Lewy body disease (dementia), Par-
kinson's disease (12, 13) and amyothrophic lateral 
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FIG. 1. The primary sequence of wt-Cdk5 which consists of 293 amino acid residues. The gray shaded areas indicate the 11 conserved 
subdomains of protein-serine/threonine kinases (19). The sequence (amino acids 105-136) in wt-Cdk5 which is deleted in Cdk5i (consisting 
of 261 residues) is boxed. Cdk5i completely lacks subdomain VI. 
RESULTS AND DISCUSSION 
To clone the gene which codes for Cdk5, PCR was 
performed using a fetal brain cDNA library as tem-
plate. Unexpectedly, fragments of two distinct sizes 
were amplified using two oligonucleotide primers that 
should normally hybridize uniquely to cdkS (results 
not shown). Both fragments were subcloned and se-
quenced. DNA sequencing revealed that one of the 
products was a 879-base pair (bp) fragment which was 
identical to the wt-cdk5 gene. The second fragment was 
smaller (783 bp in length) and coded for a cdk5 variant 
(v«t-cdkS). One contiguous region (bases 313 to 409) in 
wt-cdk6 (1) was completely missing in vax-cdk5. 
Figure 1 shows a comparison of the polypeptide se-
quences translated from the genetic sequence of wt-cdk5 
and \ax-cdkS. The shaded areas indicate the eleven con-
served subdomains of protem-serine/threonine kinases. 
The subdomains are defined as regions never interrupted 
by large amino acid insertions and that contain charac-
teristic patterns of conserved residues (18). Cdk5i com-
pletely lacks subdomain VI. Subdomain VI is not only 
thought to act as a support structure, but the hydropho-
bic j3-strands with an intervening loop are considered to 
be the likely candidate for forming the catalytic base. 
This catalytic loop contains the consensus motif 
HRDLKxxN which is highly conserved within the protein 
kinase family. It has been predicted that, through an 
in-line phosphotransfer mechanism, the aspartic acid in 
this motif could accept the proton from the attacking 
hydroxyl group of the substrate. 
In Fig. 2, the 3-dimensional Cdk5 structure, modeled 
on the basis of the published Cdk2 structure (20) and 
known similarities between the primary sequences of 
FIG. 2. Structure of Cdk5 obtained through homology modeling (on the basis of the known structure of Cdk2; Ref. 20). The darker region 
is the peptidic region which is missing in Cdk5i. The right panel shows the same model, with ATP lying in the binding pocket of Cdk5. 
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sclerosis (2, 14), and tau protein at sites phosphory-
lated in Alzheimer's disease (2, 3, 15,16). Since the 
kinase activity of Cdk5 correlates with the extent of 
differentiation of neuronal cells (2, 3, 17) and colocal-
izes with neurofilament tracts in the axons of neuronal 
cells in culture, Cdk5 is a strong candidate for cata-
lyzing neurofilament and tau phosphorylation in vivo 
(2, 3). 
In this communication, we report the identification 
of a naturally-occuring variant of the cdk5 gene (var-
cdk5). This was fortuitously identified during cloning 
of the cdk5 gene (1) from a human fetal brain cDNA 
library. The protein encoded by this novel gene is re-
ferred to as the Cdk5 isoform (Cdk5i). The var-cdk5 
gene was not found in cDNA libraries constructed from 
human T-cells, HeLa cells, human thymus, human pla-
centa and human cerebellum but was present in a cell 
line (SH-SY-5Y) derived from a human neuroblastoma. 
Although the gene lacks one of the conserved domains 
present universally in all kinases (18), the Cdk5i pro-
tein still binds p35 when coexpressed in insect cells. 
The heterodimeric complex formed between Cdk5i and 
p35 (Cdk5i/p35) has the ability to phosphorylate his-
tone HI and the retinoblastoma protein (pRb), al-
though quite weakly compared to Cdk5/p35. However, 
the enzyme composed of Cdk5i and p35 can no longer 
phosphorylate Cdk5i or p35, its two subunits. Intrigu-
ingly, increasing amounts of Cdk5i can nullify the ac-
tivity of wild type Cdk5 protein when both wild type 
and mutant proteins are coexpressed with p35 in insect 
cells. The kinase-defective Cdk5i is reminiscent of the 
artificially constructed dominant-negative mutants of 
Cdk5 which are known to block the activity of wild-type 
protein (3, 8, 10, 11, 19). One could speculate that 
Cdk5i may have a physiological role in the biochemical 
events that lead to neuronal differentiation. 
MATERIALS AND METHODS 
PCR. To clone a BamHI-ffmdIII fragment of cdk5 (1), PCR was 
performed on the following cDNA libraries (all obtained from Clon-
tech): human fetal brain, human T-cells, HeLa cells, human thymus, 
human placenta and human cerebellum. The primers used were 
5'-TAGGATCCGATGCAGAAATACGAGAGAAACTGGAAAAG-
ATT-3' (5'-end primer) and 5'-ATAAGCTTCTAGGGCGGACAGA-
AGTCGGAGAAGTAGGG-3' (3'-end primer). 
Total RNA derived from SH-SY-5Y human neuroblastoma cells 
(using a kit from Qiagen) was first reverse transcribed using a cDNA 
synthesis kit (Boehringer) before PCR was performed using the 
above mentioned primers. 
Plasmid constructs. BamHl-Hindlll fragments of human wild 
type (wt)-cdA5 and var-cdk5, obtained from the fetal brain cDNA 
library (Clontech) and from SH-SY-5Y cells, were first subcloned in 
pBluescriptKS(+) (Stratagene). The cloned genes were sequenced 
using the Applied Bio-Systems 370A automated DNA sequencer 
(Microsynth, Switzerland). 
The gene isolated from SH-SY-5Y cells was used for construction of 
recombinant baculovirus encoding var-cdk5, whereas the vtt-cdk5 
containing baculovirus was constructed from the gene obtained from 
the fetal brain cDNA library. At first, BamHl-Sall fragments of wt-
and var-cdk5 were isolated from the corresponding pBlue-
scriptKS(+) plasmids. They were then cloned in pFastBacl (Gibco-
BRL) to facilitate generation of the recombinant baculoviruses. The 
vector pFastBacl carries a baculovirus-specific polyhedrin promoter 
from Autographa californica nuclear polyhedrosis virus (AcNPV) for 
heterologous expression of proteins in insect cells. 
A Bglll-EcoRI PCR fragment of GST (PCR template: pGEX4T-l, 
Pharmacia) was first subcloned in pBluescriptKS(+). The same frag-
ment from the resultant plasmid was then cloned in pFastBacl. The 
EcoRISall fragments of human p35, human cyclin A, and an EcoRI-
Xhol fragment of human cyclin Dl were then cloned in the pFast-
Bacl vector downstream of the Bglll-EcoRI fragment of GST. 
Transposition and transfection. pFastBacl constructs were 
transformed in DHlOBac competent cells (containing "bacmid" and 
helper; Gibco-BRL) in order to transpose the expression cassettes 
into the baculovirus genome. Recombinant bacmid DNA was isolated 
(according to the instructions from Gibco-BRL) and Sf9 cells were 
transfected with bacmid DNA using Cellfectin (Gibco-BRL). Recom-
binant baculoviruses were harvested and amplified until a desired 
titer was reached (viz. 1 X 108 pfu/ml). 
Coinfections. Baculoviruses carrying the wt-cdk5 and GST-p35 
genes, or the var-cdk5 and GST-p35 genes were used to coinfect 2 X 
107 Sf9 insect cells (multiplicity of infection, MOI, of 5) in 25 ml of 
SF900 II SFM medium (Gibco-BRL). After 72 h, the cells were 
harvested and lysed by sonication in NETN buffer [20 mM Tris/HCl, 
pH 8.0, 100 mM NaCl, 1 mM EDTA, 05% v/v NP-40, 5 mM NaF, 30 
mM p-nitrophenyl phosphate, 1 mM phenylmethylsulfonyl fluoride 
(PMSF), 1 ng/ml antipain; 50 ml of buffer contained 1 tablet of 
protease inhibitor cocktail Complete (Boehringer)]. The lysate was 
preincubated for 2 h at 4°C with 100 fil of Sepharose 4B (Amersham-
Pharmacia Biotech) to reduce non-specific binding of proteins to 
GSH-Sepharose beads, which were used in the next step. Finally the 
lysate was incubated with 100 /il of glutathione(GSH)-Sepharose 4B 
(Amersham-Pharmacia Biotech), overnight at 4°C. The beads were 
washed seven times with ice-cold NETN buffer and 3 times with 
ice-cold kinase buffer (20 mM Tris/HCl, pH 7.5, 10 mM MgCl2). The 
beads were resuspended in 100 /i.1 kinase buffer and kept on ice 
before performing a kinase assay. 
Kinase assays. The substrates used in the assays were either 100 
ng of histone HI (Type III-S from calf thymus, Sigma H-5505) or 250 
ng of GST-RM52 (i.e., C-terminal 152 amino acids of pRb covalently 
linked to GST; Santa Cruz Biotechnology, Cat. No. sc-4112, Lot. No. 
G287). The phosphorylation reaction was performed in kinase buffer 
for 40 min at 30°C using 2 jil of the GSH-Sepharose bead-bound 
enzyme, 10 JLM ATP and 3 nCi [y-33P]ATP (specific activity = 3000 
Ci/mmol, Amersham-Pharmacia Biotech) in a total volume of 10 /il. 
The reactions were boiled in Laemmli sample buffer containing 50 
mM DTT before loading on to a 12.5% SDS-polyacrylamide gel along 
with the prestained molecular weight markers (Kaleidoscope; Bio-
Rad). The gel was fixed (10% v/v glacial acetic acid, 30% v/v metha-
nol) and dried on Whatman paper. The phosphorylation was quan-
tified using a Phospholmager (Molecular Devices). 
Western blot analysis. Ten microliters of GSH-Sepharose beads, 
either bound to Cdk5wt/GST-p35 or Cdk5i/GST-p35 complex, was 
boiled in Laemmli sample buffer containing 50 mM DTT. The pro-
teins in the supernatants, along with the prestained molecular 
weight markers (Kaleidoscope; Bio-Rad), were fractionated by 12.5% 
SDS-PAGE. Proteins were transferred to PVDF membranes (Immo-
bilon; Millipore) using a semidry electroblotter (Pegasus, Germany). 
GST-p35 was detected using a monoclonal antibody against GST 
(Clonetech) whereas both Cdk5 and its isoform were detected with a 
monoclonal antibody against Cdk5 (Ab-1; Calbiochem) using the 
ECL kit, according to the manufacturer's instructions (Amersham-
Pharmacia Biotech). 
86 
Vol. 253, No. 2, 1998 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 
Cdk2 and Cdk5 (homology-modeling), is depicted. Like 
Cdk2, the Cdk5 kinase domain folds into a two-lobed 
structure. The smaller, NH2-terminal lobe, which in-
cludes subdomains I-IV, is primarily involved in an-
choring and orienting the nucleotide, ATP (Fig. 2, right 
panel). This lobe has a predominantly antiparallel 
/3-sheet structure tha t is unique among nucleotide 
binding proteins. The larger COOH-terminal lobe, 
which includes subdomains V7-XI, is largely responsi-
ble for binding the peptide substrate and initiating 
phosphotransfer. It is predominantly a-helical in con-
tent. Subdomain V residues span the two lobes. The 
deep cleft between the two lobes is recognized as the 
site of catalysis. The darker region in the COOH-
terminal lobe is the region (amino acid residues 105-
136) missing in Cdk5i. 
After having discovered the gene coding for Cdk5i in 
the fetal brain cDNA library, we asked if \ax-cdk5 was 
present in all cells (i.e., also in proliferating cells and 
tissues). Hence, PCR was performed on cDNA libraries 
derived from HeLa cells, human T-cells, thymus and 
placenta using the unique cdk5 primers. We isolated 
wt-cdk5 from all the libraries. However, it was surpris-
ing that repeated at tempts failed to amplify var-cdk5 
from any of these libraries (data not shown). The var-
cdk5 gene was also not obtained from a cDNA library 
constructed from the adult human cerebellum which 
should consist of post-mitotic, differentiated cells. It 
could be that \ax-cdk5 exists only in neuronal cells 
which have not yet undergone differentiation (i.e., cells 
similar to those present in the fetal brain). 
With this in mind, reverse transcriptase (RT)-PCR 
was performed on total RNA derived from dividing 
human neuroblastoma SH-SY-5Y cells. Like fetal brain 
cells, SH-SY-5Y cells in culture can readily undergo 
differentiation under specific conditions (21). It was 
indeed interesting to find that RT-PCR yielded two 
products similar to the ones obtained from the PCR 
amplification of the fetal brain cDNA library. Sequenc-
ing revealed that the two products were identical to 
wt-cdk5 and var-cdk5, the two genes identified in the 
fetal brain library. 
To find out if the mutan t gene could form an active 
kinase, we coexpressed wt-Cdk5 with GST-p35 and, in 
parallel, Cdk5i (the protein encoded by vai-cdk5) with 
GST-p35. Protein expression was obtained by identical 
means, tha t is, by coinfecting Sf9 insect cells with the 
respective baculoviruses (each with an MOI of 5; see 
Materials and Methods). Attempts were then made to 
precipitate the heterodimeric complexes from the cell 
lysates using equal amounts of GSH-Sepharose and 
also under exactly identical conditions. The precipi-
tates (10 /xl of GSH-Sepharose beads; see Materials 
and Methods) were analyzed by Western-blotting (Fig. 
3). It seems that both complexes are pulled down by 
GSH-Sepharose beads, which implies tha t not only 
wt-Cdk5 protein binds to GST-p35 but that also Cdk5i 
K5I K5wt 
Gp35 Gp35 
KSi K5wt 
Gp35 Gp35 
GST-p35*-
hCdkSwt 
GST-Ab Cdk5-Ab 
FIG. 3. Western blot analyses of Cdk5i/GST-p35 (K5i/Gp35) and 
the Cdk5/GST-p35 (K5wtfGp35) complexes bound to GSH-
Sepharose beads (10 /U each; see Materials and Methods). GST-p35 
was detected with a monoclonal antibody against GST (left panel), 
whereas both Cdk5 and its isoform were detected with a monoclonal 
antibody against Cdk5 (right panel) using the ECL kit (Amersham-
Pharmacia Biotech). 
forms a complex with the activator protein (Fig. 3). We 
observe that levels of the two subunits (catalytic and 
regulatory) are roughly the same in Cdk5i/GST-p35 
and Cdk5/GST-p35 (Fig. 3, compare left and right 
panels). 
Activities of the two complexes, Cdk5i/GST-p35 and 
Cdk5/GST-p35, were tested in kinase assays using 
histone H I and GST-Rbl52 as substrates. Figure 4A 
depicts that wt-Cdk5 kinase is able to phosphorylate 
itself and its activating par tner p35, even in the ab-
sence of any substrate (lane 2). In contrast, the Cdk5i 
kinase has totally lost the ability to autophosphorylate 
either of its two subunits (lane 5). However, the Cdk5i/ 
GST-p35 complex can still phosphorylate histone H I 
and GST-Rbl52 (lanes 4 and 6). It should be men-
tioned that , since the kinase activity of the isoform is 
much weaker than that obtained from the wild type 
(Fig. 5; compare lanes 1 and 6; and unpublished re-
sults), the concentration of Cdk5i kinase used in these 
experiments was a t least ten times more than tha t of 
the corresponding wt-Cdk5 kinase. This allowed us to 
make a clear distinction between the two purified ki-
nases (compare lanes 1 and 3 with 4 and 6). Figure 4B 
depicts tha t GST-p35 alone does not precipitate a re-
sidual kinase activity which could have phosphory-
lated histone H I or GST-Rbl52. To further confirm the 
validity of our Cdk5 assay, we tried to activate Cdk5i 
and Cdk5 using GST-cyclin A and GST-cyclin D l as 
regulatory partners. As known in the literature, nei-
ther cyclin A nor cyclin D l yielded active kinases in 
characteristic phosphorylation assays using histone 
H I and GST-Rbl52 as substrates (data not shown). 
We then questioned if Cdk5i could compete with 
wt-Cdk5 for binding to p35. Therefore, Sf9 insect cells 
were simultaneously infected with the three baculovi-
ruses encoding var-cdk5, wt-cdk5 and GST-p35. Dif-
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FIG. 4. (A) The Cdk5i/GST-p35 kinase has lost the ability to 
autophosphorylate its two subunits, Cdk5i and p35. Lane 1, Cdk5/ 
GST-p35 kinase incubated with 100 ng of histone HI; lane 2, Cdk5/ 
GST-p35 kinase without any substrate; lane 3, Cdk5/GST-p35 ki-
nase incubated with 250 ng of GST-Rbl52; lane 4, Cdk5i/GST-p35 
kinase incubated with 100 ng of histone HI; lane 5, Cdk5i/GST-p35 
kinase without any substrate; lane 6, Cdk5i/GST-p35 kinase incu-
bated with 250 ng of GST-Rb. (B) GSH-Sepharose was used to 
precipitate proteins from insect cells which had been infected only 
with GST-p35 encoding baculovirus. The precipitated proteins do 
not phosphorylate histone HI (HI) or GST-Rbl52 (Rb). 
ferent MOI-s of var-cdk5 virus were used in these 
triple infections whereas the MOI of the other two 
viruses was kept constant. The complexes were pulled 
down with GSH-Sepharose and their activities were 
: tested in kinase assays using histone HI and GST-
Rbl52 as substrates (Fig. 5; upper and lower panels). 
When the m.o.i. of wax-cdk5 in the triple infection as-
says was twice that of v/t-cdk5, phosphorylation on the 
catalytic subunit was not detectable anymore (lane 3, 
lower panel; in the upper panel, phosphorylated Cdk5 
!
 protein co-migrates with the multiple histone HI phos-
phorylation bands and, therefore, the disappearance of 
the Cdk5 band is not clearly perceived). When the MOI 
of \ax-cdkB virus in the triple infection assays was 4 
times the MOI of the wt-cdk5, phosphorylation of the 
activating partner p35 decreased considerably (lane 4). 
When MOI of \sr-cdk5 virus was 5 times greater than 
the vit-cdk5 virus, the kinase activity of the precipi-
tated complex was as if there was no wt-Cdk5 protein 
bound to GSH-Sepharose beads (i.e., activity was the 
: same as the Cdk5i kinase; compare lanes 5 and 6). 
The above results seem to suggest that Cdk5i is not 
really a "kinase-dead" protein (like the dominant neg-
ative mutants of the Cdk-s; Ref. 22) but can assemble 
with p35 as a defective kinase. This is indicated by the 
fact that Cdk5i has some activity when coexpressed 
with p35 in insect cells. We believe that absence of the 
kinase domain VI in Cdk5i does not prevent it to bind 
ATP. This has been proven by using staurosporine, a 
nonspecific ATP competitor for Cdk2, Cdk4 and Cdk5 
(23). We observe that staurosporine can inhibit Cdk5i, 
just like Cdk5 (data not shown). Gradual increase of 
ATP concentrations in the kinase assay prevent this 
inhibition to occur. Therefore, kinase domain VI seems 
to have no role in ATP binding. However, the deleted 
domain in Cdk5i must have a function in substrate 
recognition. Even though the affinity of Cdk5i for p35 
may be the same as wt-Cdk5, Cdk5i has lost the ability 
to autophosphorylate its two subunits. We also observe 
that, in insect cells, activity of Cdk5/p35 is abrogated 
by coinfecting increasing amounts of the \ax-cdk5 bac-
ulovirus. This can only mean that the catalytic subunit 
Cdk5i, defective in its kinase activity, can displace 
wt-Cdk5 from a Cdk5/p35 heterodimeric complex. Al-
though these conclusions are solely based on our ex-
periments with only two substrates (the retinoblas-
toma protein and histone HI), we believe that the 
defective kinase Cdk5i/p35 would behave identically if 
tested for its ability to phosphorylate neurofilament 
proteins and tau in vitro (24, 25). 
It has been widely suggested that misregulation of 
Cdk5 can cause a variety of neurodegenerative dis-
eases, from Alzheimer's and Parkinson's diseases to 
amyotrophic lateral sclerosis (ALS). It could be that 
MOI's(COK5wt virus) 
MOI's(COK5i virus) 
0.5 
0 
2 
10 
0 
10 
GST-p35H 
Histone H1 
> 
Cdk5 
GST-p35*-
GST-Rb152-»» 
C d k 5 * -
—85 
45 
—32.8 
kDa 
85 
45 
—32.8 
Lanes 6 
FIG. 5. Cdk5i competes with wt-Cdk5 for binding to GST-p35. 
Sf9 insect cells were infected with the 3 baculoviruses encoding 
wt-cdk5, var-cdk5 and GST-p35. The amount of var-cdkS virus in 
the triple infections was raised stepwise, whereas the wt-cdk5 and 
GST-p35 viruses were kept constant (MOI as indicated). The com-
plexes were purified via binding of Cdk57GST-p35 and Cdk5i/GST-
p35 to 100 pi GSH-Sepharose beads. 2 /il of beads were used for each 
kinase assay. Upper panel, phosphorylation of 100 ng of histone HI. 
Lower panel, phosphorylation of 250 ng GST-Rbl52. 
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Cdk5i is differentially expressed in patients suffering 
from such diseases. In Alzheimer's disease, paired he-
lical filaments (PHF) are composed of hyperphos-
phorylated tau (24). In the fetal brain, tau is also 
hyperphosphorylated and the phosphorylation sites 
identified in fetal tau are the same as for PHF-tau (26). 
This suggests that PHF-tau may arise from a loss of 
regulatory control of tau phosphorylation in degener-
ating neurons that results in the reappearance of a 
fetal phosphorylation pattern (26). Since the var-cdk5 
occurs specifically in the fetal brain and not in mature 
human cerebellum, it is possible that kinase-defective 
Cdk5i plays a specific role in the developing brain (27, 
28). There is a similar precedent in the recent litera-
ture. It has been proposed that another naturally oc-
curing defective kinase, the tyrosine kinase receptor 
ErbB-3, plays a specific role only in proliferating cells 
whereas the active kinase ErbB-4 correlates with only 
the differentiated phenotype (29). 
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6. Summary and conclusions 
Cell division (proliferation) is necessary for growth, maintenance and 
multiplication of living organisms, consisting of one or more cells. Different cells can 
fulfill specific functions within one multicellular organism. These cells which do not 
divide anymore and have taken up a certain specialized function are called 
differentiated cells. Cells which neither differentiate nor proliferate are in the 
quiescent state G0. Proliferating cells reside in different phases before they divide. 
After cell division a cell can enter the different phases again until another division 
takes place. This is what we call the cell cycle. 
Each phase transition is controlled by specific enzymes. These enzymes which 
are called cyclin dependent kinases, Cdk-s, have to bind a cyclin in order to be active. 
The Cdk catalytic subunits are present during each phase of the cell cycle. This is in 
contrast with the cyclins, the activating partners of the Cdk-s, which have a shorter 
half life then the Cdk-s catalytic subunits and are expressed only at certain time points 
during the cell cycle. The temporal activation of individual Cdk-s is dictated in part by 
the timing of expression of their cognate cyclins together with both activating and 
inhibitory phosphorylation. Different cyclins can bind different Cdk-s giving rise to a 
whole set of Cdk-cyclin complexes each with a specific function. Cdk-s belong to the 
protein kinase family and their function is to phosphorylate protein substrates which 
play defined roles during the cell cycle. Cdk-s in turn are also inhibited by specific 
inhibitors. 
During the first phase of the cell cycle which is called Gi (first gap), certain 
conditions must be met before DNA can be replicated in the S (synthesis) phase. A 
few Cdk-s check the G,/S phase transition which is called the 'restriction point' in 
mammals. At this point of no return the retinoblastoma protein, (pRb), plays a key 
role. Hypophosphorylated pRb binds to certain transcription factors amongst which 
E2F is the most known. When pRb is hyperphosphorylated by Cdk-s, the E2F 
transcription factor is released and activates the transcription of a range of genes 
driving the cell into the S phase. pRb phosphorylating Cdk-s acting at the G,/S 
transition are Cdk6-cyclin D, Cdk4-cyclin D, Cdk2-cyclin E and Cdk2-cyclin A. 
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After the S phase the cell resides in G2 (second gap). If the DNA is replicated 
correctly the cell can divide. The division phase is called M (mitosis). The G2/M 
phase transition is controlled by Cdkl-cyclin B. 
The exact passage through the eukaryotic cell cycle is therefore regulated by 
the progressive activation and inactivation of a family Cdk-s. Cell cycle diseases like 
for instance cancer have a genetic basis. Cancer cells evolve from normal cells when 
some essential processes in a dividing cell malfunction. This causes inappropriate 
replication, segregation and repair of the genome during progression of the cell cycle. 
Increased Cdk4 activity due to overexpression of Cdk4 and/or cyclin D, or because 
pl6INK4A, the Cdk4 specific inhibitor is missing from the cell, will cause the cell to 
cycle without a functional restriction point. The duration of the cell cycle shortens 
giving rise to mistakes in DNA replication. These malignant cells will grow out to 
form tumours sapping all life from the host. 
Potential antineoplastic drugs against certain forms of cancer could be 
synthetic chemicals which would inhibit for instance Cdk4 activity. This chemical 
should of course not be lethal to the patient. Screening of compounds on their Cdk 
inhibitory effect is one example of how pharmaceutical industries are performing 
cancer research. In chapter 2 of this thesis a method is presented to facilitate Cdk4 
compound screening. Human Cdk4 is expressed in the yeast Saccharomyces 
cerevisiae under the control of the GAL1-GAL10 promoter and inhibits cell growth 
when the yeast is grown on galactose. Coexpression of pi6mKAA restores yeast cell 
growth. Moreover flavopiridol, the Cdk inhibitor which has already entered phase 3 
clinical trials, is also restoring growth when it is added to the growth medium of the 
yeast. Simple OD readings of this yeast transformation when grown on galactose 
could give useful information upon whether a compound added to the growth medium 
could be a Cdk4 inhibitor or not. This Cdk4 inhibition will be of certain specificity 
since the yeast Cdc28 has high homology with human Cdkl and Cdk2. 
Components, which normally would reside in the cell cycle, have recently been 
found to function atypically in non-proliferating neuronal cells. The cyclin dependent 
kinase Cdk5 for instance is identified via its homology with other Cdk-s and has not 
been shown to play a role in the cell cycle. Cdk5 has a ubiquitous tissue distribution 
in mammals with brains containing the highest amount of the transcript. On the other 
hand, the expression of p35, the only known activator of Cdk5, which has no 
homology to cyclins, is strictly confined to brains. Cyclin D and cyclin E have been 
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found to bind to Cdk5 but no activity of these complexes has been shown. The 
Cdk5/p35 complex can phosphorylate histone HI and pRb, two proteins which are 
commonly used to test Cdk activity in vitro. Activated Cdk5 kinase phosphorylates a 
number of cytoskeletal proteins including neurofilaments and the neuron-specific 
microtubule associated protein tau in vitro, which are assumed to be the natural 
substrates. Phosphorylation of cytoskeletal proteins may play an important role in the 
polymerization and assembly of cytoskeletal elements which, in turn, may effect the 
growing neurites suggesting that Cdk5 is involved in the growth and maintenance of 
neurites. Recently Cdk5 has been shown to play a role in differentiation of muscles as 
well. 
Nerve cells are terminally differentiated before the onset of birth. This is in 
contrast with other tissues where differentiated cells still are able to divide after tissue 
damage. Since nerves do not have any regeneration capacity, damaged or malignant 
cells will automatically undergo apoptosis. In the neurodegenerative diseases 
dementia (diffuse Lewy body disease), Parkinson's and amyotrophic lateral sclerosis 
neurofilament proteins are hyperphosphorylated whereas in Alzheimer's disease the 
tau protein is hyperphosphorylated. These malignant nerve cells undergo apoptosis 
leading to a certain death of the patient suffering from these diseases. 
Neurodegeneration possibly occurs as a result of inappropriate activation/deactivation 
of tissue-specific components of the cell cycle. It is very likely that Cdk5 is overactive 
in these malignant nerve cells. 
Since Cdk5 has been found in both proliferative and differentiated cells it is 
interesting to search for protein interactions with Cdk5 and the effect of these proteins 
on the Cdk5 kinase. During these investigations attempts were made to search for 
protein interactions with Cdk5 in proliferative cells and the possible roles of these 
proteins towards the Cdk5 kinase. 
In chapter 3 a C-terminal fragment of DNA binding protein, dbpA is described 
which can bind to Cdk5. This protein-protein interaction is shown via the yeast-two-
hybrid system. Several in vitro experiments have confirmed that the C-terminal 
fragment of dbpA indeed specifically binds to Cdk5. Kinase assays have shown that 
this protein fragment inhibits the phosphorylation of both histone HI and pRb by the 
Cdk5 kinase. DbpA is expressed in skeletal muscle and the heart. Since Cdk5 has 
been found to play a role in differentiation of muscles it is possible that dbpA plays a 
role in this phenomenon as well. 
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Chapter 4 depicts another Cdk5 binding protein, a 60S ribosomal protein, L34. 
This protein interaction is discovered via the yeast-two-hybrid system as well. L34 
like dbpA blocks the phosphorylation of histone HI and pRb by Cdk5. 
Cloning of the cdk5 gene has been done via PCR on cDNA libraries. PCR on 
cDNA from a fetal brain library revealed two PCR products. One of the PCR products 
had the size of the cdk5 open reading frame whereas the other product was much 
smaller. Sequencing of both products showed the larger fragment coded indeed for the 
cdkS gene whereas the other product was identical with the cdk5 open reading frame 
with bases 313 to 409 missing in the middle of the gene. In fetal brain this Cdk5 
isoform could be expressed which lacks amino acids 105-136, which are thought to be 
responsible for catalyzing the phosphorylation reaction. Although this Cdk5 isoform 
(Cdk5i) can bind to p35, little kinase activity has been shown. Since this cdk5 variant 
has been found in total RNA of SH-SY-5Y neuroblastoma cells as well, but not in 
cDNA libraries of T-cells, HeLa cells, thymus, placenta and cerebellum, this protein 
could play a specific role in the differentiation of human nerve cells too. Binding of 
Cdk5i in these respective cells to p35 could prevent the wildtype Cdk5 from being 
activated. In this way Cdk5i could modulate the activity of the Cdk5 wildtype kinase. 
Chapter 5 depicts the results of this research. 
In this thesis a screen is presented to search for Cdk4 antagonists. Furthermore 
the Cdk5 interacting proteins presented and the Cdk5 isoform could be tested for their 
ability to regulate the Cdk5 kinase in vivo. The role of these Cdk5 regulating proteins 
in cycling and post-mitotic cells needs to be evaluated through further cellular 
analyses. 
With these findings which have been revealed during my doctoral research I 
hope to have contributed in a positive manner to the elucidation of both cancer and 
neurodegenerative diseases. 
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Samenvatting 
(Summary in Dutch) 
Het delen van cellen (proliferatie) is nodig voor groei, instandhouding en 
vermeerdering van levende organismen, die uit een of meer cellen bestaan. Daamaast 
kunnen cellen binnen een meercellig organisme specifieke functies vervullen, zonder 
zich voortdurend te delen. Deze cellen met specifieke functie, die zich niet meer 
delen, noemt men gedifferentienteerde cellen. Een eel, die zich niet deelt, maar ook 
niet is gedifferentieerd bevindt zich in een rustfase genaamd G0 (quiescent state). Een 
zich delende eel doorloopt verschillende fasen voordat zij zich heeft gedeeld. Na 
celdeling kan een eel de verschillende fasen opnieuw volledig doorlopen, totdat een 
volgende celdeling kan plaatsvinden. Een delende, niet gedifferentieerde, eel cycleert 
dus. Men spreekt over de celcyclus (cell cycle). 
Elke fase overgang van de eel (phase transition) wordt gecontroleerd door een 
aantal enzymen. Deze enzymen worden cyclin dependent kinases, Cdk's, genoemd, 
omdat ze voor hun activiteit aan een cyclin moeten binden. Meestal zijn verschillende 
Cdk's tijdens elke fase aanwezig. De cyclins, de activerende partners voor de Cdk's 
echter niet. Zij worden tot expressie gebracht als hun functie tijdens de celcyclus 
gewenst is en worden ook afgebroken als hun aanwezigheid niet meer noodzakelijk is. 
Sommige cyclins kunnen verschillende Cdk's binden, zodat een heel scala aan Cdk-
cyclin complexen gevormd kan worden, elk met hun eigen specifieke functie. Deze 
functie bestaat uit het fosforyleren van bepaalde eiwitten (Cdk's behoren tot de eiwit 
kinasen), zodat dat eiwit (het substraat) andere eigenschappen verkrijgt en daardoor 
een andere rol in de celcyclus zal gaan spelen. De geactiveerde Cdk's kunnen geremd 
worden door bepaalde andere eiwitten (Cdk inhibitors). 
Voordat het erfelijk materiaal (DNA) tijdens de celcyclus wordt verdubbeld, 
moet aan een bepaald aantal voorwaarden worden voldaan. De eel bevindt zich nu in 
fase G, (first gap). Een aantal Cdk's controleren de overgang naar de DNA replicatie 
fase S (synthesis). Deze G,/S overgang wordt bij zoogdieren 'restriction point' 
genoemd. Deze deur naar de DNA replicatie fase wordt geblokkeerd door een eiwit, 
genaamd pRb (retinoblastoma protein). Dit eiwit bindt onder andere aan E2F, een 
eiwit wat een aantal genen kan activeren (transcriptie factor) indien E2F niet aan pRb 
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gebonden is. Deze genen dienen geactiveerd te worden ten behoeve van de DNA 
replicatie. De Cdk-cyclin kinasen die de G,/S fase overgang controleren kunnen pRb 
fosforyleren, waardoor het niet meer aan E2F bindt. E2F kan vervolgens zijn functie 
vervullen en de DNA replicatie op gang brengen. De Cdk-cyclin complexen die pRb 
kunnen fosforyleren zijn: Cdk6-cyclin D, Cdk4-cyclin D en Cdk2-cyclin E. 
Na de S fase bevindt de eel zich in G2 (second gap). Hier wordt gecontroleerd 
of het DNA juist gedupliceerd is, voordat de eel zich in tweeen deelt. Het uiteindelijke 
delen vindt plaats in de M fase (mitosis). De G2/M fase overgang wordt gecontroleerd 
door Cdkl-cyclin B. 
Het juiste verloop van de celcyclus wordt dus gereguleerd door Cdk's. Het is 
erg belangrijk dat deze enzymen op het juiste tijdstip de juiste activiteit vertonen. 
Helaas komt het in de natuur wel eens voor dat deze enzymen een te hoge activiteit 
vertonen, bijvoorbeeld doordat teveel Cdk4 of cyclin D tot expressie wordt gebracht of 
doordat het eiwit pi6, wat het Cdk4-cyclin D kinase zou kunnen remmen, ontbreekt. 
Sommige cellen gaan zich hierdoor vaker delen dan gewenst is. De celcyclus wordt 
sneller doorlopen en sommige fouten in DNA replicatie worden niet meer hersteld. De 
zo ontstane cellen woekeren in het lichaam van het organisme zonder dat het lichaam 
er enige controle over heeft. De cellen parasiteren in de gastheer en zorgen er 
uiteindelijk voor dat het organisme aan deze genetisch bepaalde afwijking overlijdt. 
Deze ziekte is bij ons bekend onder de naam kanker. 
Een medicijn tegen bepaalde soorten kanker zou dus een bepaalde stof kunnen 
zijn, dat in staat is om bijvoorbeeld Cdk4 activiteit te remmen. Vanzelfsprekend mag 
deze verbinding niet te giftig (toxisch) zijn voor de patient. Bij de farmaceutische 
industrie verricht men ondere andere op deze wijze onderzoek naar kanker. Men zoekt 
Cdk remmende verbindingen (compounds). In hoofdstuk 2 van dit proefschrift wordt 
een methode beschreven om het zoeken naar specifieke Cdk4 remmende compounds 
(compound screening) te vergemakkelijken. Humaan Cdk4 wordt tot expressie 
gebracht in bakkersgist. Daar deze Cdk voor de gist een vreemd eiwit is wat allerlei 
readies in de gist zou kunnen veroorzaken, vermeerdert de gist zich niet meer. Als 
tezamen met Cdk4 ook pi6 in de gist tot expressie wordt gebracht kan de gist zich 
weer normaal delen. Ook flavopiridol, een chemische verbinding die als 
kankermedicijn in overweging wordt genomen, heeft hetzelfde effect op de gist, die 
door Cdk4 wordt gekweld. De gist vermeerdert zich weer als flavopiridol aan het 
groeimedium van de gist wordt toegevoegd. De zieke gist met humaan Cdk4 als 
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ballast zou derhalve gebruikt kunnen worden bij het testen van verbindingen op nun 
Cdk4 kinase remmende activiteit. Zodra de gist zich weer gaat venneerderen is dit een 
indicatie dat de stof een Cdk4 remmer zou kunnen zijn. 
Er bestaat een Cdk, Cdk5 genaamd, waarvan geen rol binnen de celcyclus is 
aangetoond. Cdk5 komt in vele weefsels voor, maar wordt in grotere hoeveelheden tot 
expressie gebracht in zenuwcellen. Cyclin D en cyclin E kunnen met Cdk5 binden, 
maar er is nog geen activiteit van deze enzymcomplexen aangetoond. Het eiwit p35, 
wat geen homologie met cyclins heeft kan Cdk5 echter activeren. Er zijn 
verschillende substraten aangetoond. Zo kan de Cdk5 kinase histone HI en pRb 
fosforyleren. Deze twee eiwitten worden vaak gebruikt tijdens onderzoek naar Cdk5 
activiteit. De natuurlijke substraten van Cdk5 moeten echter gezocht worden onder de 
eiwitten die het skelet van de zenuwcel vormen. Cdk5 fosforyleert bijvoorbeeld 
neurofilamenten en tau. Van Cdk5 wordt gedacht dat het geen functie vervult tijdens 
de celcyclus, maar dat het betrokken is bij de differentiatie van zenuwcellen. 
Recentelijk is aangetoond dat Cdk5 ook een rol speelt bij de differentiatie van 
spiercellen. 
Zenuwcellen differentieren zich reeds voor de geboorte, totdat ze een bepaalde 
fase bereikt hebben (terminale differentiatie), waarbij ze zich nooit meer kunnen delen. 
Dit is in tegenstelling tot vele andere celtypen, die na beschadiging van een bepaald 
weefsel, hun gedifferentieerde toestand verlaten om zich weer te gaan delen. De 
zenuwcellen vervullen dus een bepaalde functie in het lichaam en behouden deze 
functie een leven lang. Beschadigde of zieke cellen kunnen niet vervangen worden, 
zodat het individu deze functie verliest. Er zijn een aantal zenuwziekten bekend 
waarbij zenuwcellen afsterven. Dit afsterven is een actief proces wat door de eel zelf 
wordt gestuurd. Zieke cellen plegen als het ware zelfmoord (apoptosis) om zo het 
individu tot dienst te zijn. Dementie (difuse Lewy body disease), Parkinson, 
amyothrophic lateral sclerosis en Alzheimer zijn voorbeelden van ziekten waarbij 
zenuwcellen afsterven. Bij zenuwonderzoek vraagt men zich af waarom dit het geval 
is. Bij restanten van zenuwcellen, die men gevonden heeft bij patienten, die aan 
dementie, Parkinson of amyothrophic lateral sclerosis lijden, heeft men ontdekt dat de 
neurofilamenten te veel gefosforyleerd zijn (gehyperfosforyleerd). Bij Alzheimer 
patienten heeft men juist ontdekt dat tau gehyperfosforyleerd is. Net als bij kanker 
waar door een genetische afwijking Cdk4 te actief zou kunnen zijn, zou bij deze 
zenuwziekten door een genetische afwijking Cdk5 overactief kunnen zijn. Ook bij 
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deze ziekten zou dus weer de mogelijkheid kunnen bestaan dat een natuurlijk eiwit, 
wat aan het eind van de differentiatie van zenuwcellen Cdk5 zou moeten remmen 
(Cdk5 inhibitor), ontbreekt. 
Omdat Cdk5 in zo vele verschillende cellen van verschillende weefsels 
voorkomt in zowel prolifererende als gedifferentieerde cellen is het interessant te 
onderzoeken welke eiwitten met Cdk5 kunnen binden in zowel prolifererende als 
gedifferentieerde cellen en wat nun invloed zou kunnen zijn op de activiteit van dit 
enzym. Tijdens dit promotie onderzoek is getracht eiwitinteracties met Cdk5 aan te 
tonen in prolifererende cellen. 
In hoofdstuk 3 wordt een DNA bindend eiwit, dbpA beschreven wat met 
humaan Cdk5 kan binden. Deze eiwitinteractie is aangetoond met behulp van een 
bepaald systeem in gist het zogenaamde yeast-two-hybrid systeem. Meerdere 
bindingsexperimenten hebben aangetoond dat dit eiwit, dbpA, inderdaad met Cdk5 
associeert. DbpA schijnt met name in skeletspieren en de hartspier voor te komen. 
Daar Cdk5 ook een rol speelt bij de differentiatie van spiercellen is het zeer wel 
mogelijk dat dbpA ook een functie vervult tijdens de differentiatie van spiercellen. 
Kinase experimenten hebben aangetoond dat dbpA de activiteit van Cdk5 kan 
remmen. Door bepaalde hoeveelheden dbpA aan de Cdk5 kinase toe te voegen was dit 
enzym niet meer in staat histone HI of pRb te fosforyleren. 
Hoofdstuk 4 gaat over een 60S ribosomaal eiwit, L34. Dit eiwit kan ook een 
binding aangaan met Cdk5 en is op dezelfde wijze als dbpA aangetoond namelijk met 
behulp van het yeast-two-hybrid systeem. L34 kan net als dbpA fosforylering van 
histone HI en pRb door Cdk5 remmen. 
Om het gen coderend voor humaan Cdk5 in gist te kunnen inbrengen 
(transformatie) dient het vermeerderd te worden. Deze methode heet PCR. Na een 
PCR reactie verricht aan cDNA van fetale hersenen was niet alleen het Cdk5 gen 
vermeerderd, maar er ontstond ook een kleiner PCR produkt. Na sequencing van het 
DNA bleek dat dit PCR produkt identiek was aan het Cdk5 gen. Echter er ontbrak een 
deel van de DNA sequentie in het midden van het PCR produkt. In fetale hersenen 
zou dus een eiwit kunnen worden geproduceerd wat identiek is aan Cdk5 maar wat 
juist dat deel van het enzym ontbreekt, waarvan gedacht wordt dat het een belangrijke 
rol vervult bij de katalyse van de fosforyleringsreactie. Deze Cdk5 isoform (Cdk5i) 
kan met p35 binden, maar heeft vrijwel nauwelijks kinase activiteit. Omdat dit 
gentranscript ook in neuroblastoma cellen, maar niet in T-cellen, HeLa cellen, thymus, 
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placenta en cerebellum wordt gevonden, zou dit eiwit ook een specifieke rol kunnen 
spelen bij de differentiatie van humane zenuwcellen. Doordat dit kinase-defectieve 
eiwit met p35 kan binden, wordt verhinderd dat p35 met het normale Cdk5 (Cdk5 
wildtype) bindt. Op deze wijze zou Cdk5i de activiteit van Cdk5 wildtype kunnen 
reguleren. In hoofdstuk 5 staan de resultaten van dit onderzoek vermeld. 
Met deze resultaten, die naar voren zijn gekomen tijdens mijn promotie 
onderzoek, hoop ik een positieve bijdrage te hebben geleverd op het gebied van zowel 
kanker- als zenuwonderzoek. 
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